0000320017-17-000093.txt : 20171109 0000320017-17-000093.hdr.sgml : 20171109 20171109160732 ACCESSION NUMBER: 0000320017-17-000093 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171109 DATE AS OF CHANGE: 20171109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CALADRIUS BIOSCIENCES, INC. CENTRAL INDEX KEY: 0000320017 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 222343568 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33650 FILM NUMBER: 171190846 BUSINESS ADDRESS: STREET 1: 110 ALLEN ROAD STREET 2: SECOND FLOOR CITY: BASKING RIDGE STATE: NJ ZIP: 07920 BUSINESS PHONE: 908-842-0100 MAIL ADDRESS: STREET 1: 110 ALLEN ROAD STREET 2: SECOND FLOOR CITY: BASKING RIDGE STATE: NJ ZIP: 07920 FORMER COMPANY: FORMER CONFORMED NAME: Caladrius Biosciences, Inc. DATE OF NAME CHANGE: 20150608 FORMER COMPANY: FORMER CONFORMED NAME: NeoStem, Inc. DATE OF NAME CHANGE: 20060906 FORMER COMPANY: FORMER CONFORMED NAME: PHASE III MEDICAL INC/DE DATE OF NAME CHANGE: 20030819 10-Q 1 clbs-10qx20170930.htm 10-Q Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2017
 
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the Transition Period from __________________   to _________________________
 
Commission File Number 001-33650
 
CALADRIUS BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
22-2343568
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
 
 
110 Allen Road, 2nd Floor, Basking Ridge, New Jersey
07920
(Address of principal executive offices)
(zip code)
 
Registrant’s telephone number, including area code: 908-842-0100

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes     x         No     o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes  x        No     o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer     o
Accelerated filer     o
Non-accelerated filer   o     (Do not check if a smaller reporting company)
Smaller reporting company     x
 
Emerging growth      o

If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes  o     No  x
9,470,860 Shares, $0.001 Par Value, as of November 6, 2017
 
(Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date)


EXPLANATORY NOTE

Unless stated otherwise, the information contained in these consolidated financial statements gives retroactive effect to a one-for-ten reverse stock split of Caladrius Biosciences, Inc.'s (the "Company’s") common stock effected on July 28, 2016. See Note 1 of the consolidated financial statements for further information.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This quarterly report (this "Quarterly Report") contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this Quarterly Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “plan,” “intend,” “may,” “will,” “expect,” “believe,” “could,” “anticipate,” “estimate,” “continue” or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:

•
potential adverse reactions or changes to business relationships resulting from the announcement or completion of the sale of PCT, LLC to Hitachi Chemical Co., America, Ltd. (as described more fully below, the “Sale”);
•
unexpected costs, charges or expenses relating to or resulting from the Sale;
•
litigation or adverse judgments relating to the Sale;
•
our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology;
•
our ability to build and maintain the management and human resources infrastructure necessary to support the growth of our business;
•
whether a market is established for our cell-based products and services and our ability to capture a meaningful share of this market;
•
scientific, regulatory and medical developments beyond our control;
•
our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;
•
whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business; and our ability to commercialize products without infringing the claims of third party patents;
•
whether any potential strategic or financial benefits of various licensing agreements will be realized;
•
the results of our development activities;
•
our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population and the need of patients to meet the inclusion criteria of the trial or otherwise; and
•
other factors discussed in "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 16, 2017 (our "2016 Form 10-K").

The factors discussed herein, including those risks described in "Item 1A. Risk Factors" and elsewhere in our 2016 Form 10-K and in our other periodic filings with the SEC, which are available for review at www.sec.gov, could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.


2

TABLE OF CONTENTS
 
Page No.
 
 
 
Financial Statements:
 
 
 
 
Consolidated Balance Sheets at September 30, 2017 (unaudited) and December 31, 2016
 
 
 
 
Consolidated Statements of Operations for the three and nine months ended September 30, 2017 and 2016 (unaudited)
 
 
 
 
Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2017 and 2016 (unaudited)
 
 
 
 
Consolidated Statements of Equity for the nine months ended September 30, 2017 and 2016 (unaudited)
 
 
 
 
Consolidated Statements of Cash Flows for the nine months ended September 30, 2017 and 2016 (unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

3

PART I. FINANCIAL INFORMATION

ITEM I. FINANCIAL STATEMENTS
Item 1. Consolidated Financial Statements

CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

 
September 30,
2017
 
December 31,
2016
ASSETS
(Unaudited)
 
 
Current Assets
 

 
 

Cash and cash equivalents
$
15,077,872

 
$
7,076,651

Restricted cash
5,002,649

 
—

Marketable securities
44,371,615

 
—

Accounts receivable, net of allowances of $0 at September 30, 2017 and December 31, 2016, respectively
401,558

 
138,774

Prepaid and other current assets
920,008

 
1,900,493

Current assets related to discontinued operations
—

 
15,533,043

Total current assets
65,773,702

 
24,648,961

Property, plant and equipment, net
364,118

 
705,438

Other assets
1,417,439

 
1,582,209

Other assets related to discontinued operations
—

 
26,577,834

Total assets
$
67,555,259

 
$
53,514,442

LIABILITIES, REDEEMABLE SECURITIES - NON-CONTROLLING INTERESTS AND EQUITY
 

 
 

Current Liabilities
 

 
 

Accounts payable
$
879,625

 
$
2,226,580

Accrued liabilities
10,135,600

 
2,659,433

Long-term debt, current
—

 
3,126,457

Notes payable, current
359,553

 
563,777

Due to PCT
—

 
1,681,594

Current liabilities related to discontinued operations
—

 
10,925,052

Total current liabilities
11,374,778

 
21,182,893

Notes payable
—

 
159,180

Long-term debt
—

 
2,524,897

Other long-term liabilities
3,200,154

 
389,858

Liabilities related to discontinued operations
—

 
5,791,134

Total liabilities
$
14,574,932

 
$
30,047,962

Commitments and Contingencies


 


Redeemable Securities - Non-Controlling Interests
—

 
19,400,000

EQUITY
 

 
 

Stockholders' Equity
 
 
 

Preferred stock, authorized, 20,000,000 shares
Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2017 and December 31, 2016
100

 
100

Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 9,427,001 and 8,205,790 shares, at September 30, 2017 and December 31, 2016, respectively
9,427

 
8,206

Additional paid-in capital
433,006,780

 
410,372,049

Treasury stock, at cost; 11,080 shares at September 30, 2017 and December 31, 2016, respectively
(707,637
)
 
(707,637
)
Accumulated deficit
(378,947,243
)
 
(404,788,809
)
Accumulated other comprehensive loss
(28,717
)
 
—

Total Caladrius Biosciences, Inc. stockholders' equity
53,332,710

 
4,883,909

Noncontrolling interests
(352,383
)
 
(817,429
)
Total equity
52,980,327

 
4,066,480

Total liabilities, redeemable securities - non-controlling interests, and equity
$
67,555,259

 
$
53,514,442

See accompanying notes to consolidated financial statements.

4

CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
 (Unaudited)

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Operating Expenses:
 
 
 
 
 
 
 
Research and development
$
3,187,024

 
$
2,958,593

 
$
11,190,939

 
$
13,496,045

General and administrative
2,942,877

 
2,768,927

 
9,081,806

 
10,513,570

Total operating expenses
6,129,901

 
5,727,520

 
20,272,745

 
24,009,615

 
 
 
 
 
 
 
 
Operating loss
(6,129,901
)
 
(5,727,520
)
 
(20,272,745
)
 
(24,009,615
)
 
 
 
 
 
 
 
 
Other income (expense):
 
 
 
 
 
 
 
Other income (expense), net
176,855

 
5,117

 
137,288

 
19,559

Interest expense
(8,687
)
 
(368,364
)
 
(372,099
)
 
(1,601,421
)
 
168,168

 
(363,247
)
 
(234,811
)
 
(1,581,862
)
 
 
 
 
 
 
 
 
Loss from continuing operations before benefit from income taxes and noncontrolling interests
(5,961,733
)
 
(6,090,767
)
 
(20,507,556
)
 
(25,591,477
)
Benefit from income taxes
(2,413,951
)
 
—

 
(8,301,494
)
 
—

Net loss from continuing operations
(3,547,782
)
 
(6,090,767
)
 
(12,206,062
)
 
(25,591,477
)
Discontinued operations - net of taxes
—

 
(1,196,838
)
 
37,329,963

 
(1,628,694
)
Net (loss) income
$
(3,547,782
)
 
$
(7,287,605
)
 
$
25,123,901

 
$
(27,220,171
)
 
 
 
 
 
 
 
 
Less - net loss from continuing operations attributable to noncontrolling interests
(119,342
)
 
(59,423
)
 
(149,509
)
 
(187,126
)
Less - net loss from discontinued operations attributable to noncontrolling interests
—

 
(345,649
)
 
(568,156
)
 
(334,879
)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders
$
(3,428,440
)
 
$
(6,882,533
)
 
$
25,841,566

 
$
(26,698,166
)
 
 
 
 
 
 
 
 
Amounts Attributable to Caladrius Inc. common stockholders:
 
 
 
 
 
 
 
Loss from continuing operations
(3,428,440
)
 
(6,031,344
)
 
(12,056,553
)
 
(25,404,351
)
Income (loss) from discontinued operations - net of taxes
—

 
(851,189
)
 
37,898,119

 
(1,293,815
)
Net income (loss) attributable to Caladrius Inc. common stockholders
$
(3,428,440
)
 
$
(6,882,533
)
 
$
25,841,566

 
$
(26,698,166
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted income (loss) per share
 
 
 
 
 
 
 
Continuing operations
$
(0.38
)
 
$
(0.95
)
 
$
(1.37
)
 
$
(4.23
)
Discontinued operations
$
—

 
$
(0.13
)
 
$
4.30

 
$
(0.22
)
Caladrius Biosciences, Inc. common stockholders
$
(0.38
)
 
$
(1.09
)
 
$
2.94

 
$
(4.45
)
 
 
 
 
 
 
 
 
Weighted average common shares outstanding:
 
 
 
 
 
 
 
Basic and diluted shares
9,093,880

 
6,323,427

 
8,803,784

 
6,001,572


See accompanying notes to consolidated financial statements.

5

CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited) 

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Net (loss) income
$
(3,547,782
)
 
$
(7,287,605
)
 
$
25,123,901

 
$
(27,220,171
)
 
 
 
 
 
 
 
 
Other comprehensive loss:
 
 
 
 
 
 
 
Available for sale securities - net unrealized loss
(28,717
)
 
(486
)
 
(28,717
)
 
(486
)
Total other comprehensive loss
(28,717
)
 
(486
)
 
(28,717
)
 
(486
)
 
 
 
 
 
 
 
 
Comprehensive (loss) income
(3,576,499
)
 
(7,288,091
)
 
25,095,184

 
(27,220,657
)
 
 
 
 
 
 
 
 
Comprehensive loss attributable to noncontrolling interests
(119,342
)
 
(405,072
)
 
(717,665
)
 
(522,005
)
 
 
 
 
 
 
 
 
Comprehensive (loss) income attributable to Caladrius Biosciences, Inc. common stockholders
$
(3,457,157
)
 
$
(6,883,019
)
 
$
25,812,849

 
$
(26,698,652
)
 
See accompanying notes to consolidated financial statements.

6

CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited) 

 
Series B Convertible
Preferred Stock
 
Common Stock
 
Additional
Paid in
Capital
 
Accumulated
Other
Comprehensive
Income
 
Accumulated
Deficit
 
Treasury
Stock
 
Total
Caladrius Biosciences,
Inc.
Stockholders'
Equity
 
Non-
Controlling
Interest in
Subsidiary
 
Total
Equity
 
Shares
 
Amount
 
Shares
 
Amount
 
 
 
 
 
 
 
Balance at December 31, 2015
10,000

 
$
100

 
5,673,302

 
$
5,673

 
$
396,547,401

 
$
486

 
$
(372,132,490
)
 
$
(707,637
)
 
$
23,713,533

 
$
(429,709
)
 
$
23,283,824

Net loss
—

 
—

 
—

 
—

 
—

 
—

 
(26,698,166
)
 
—

 
(26,698,166
)
 
(522,005
)
 
(27,220,171
)
Unrealized gain/loss on marketable securities
—

 
—

 
—

 
—

 
—

 
(486
)
 
—

 
—

 
(486
)
 
—

 
(486
)
Share-based compensation
—

 
—

 
104,754

 
105

 
2,275,511

 
—

 
—

 
—

 
2,275,616

 
—

 
2,275,616

Net proceeds from issuance of common stock
—

 
—

 
2,403,865

 
2,404

 
11,648,308

 
—

 
—

 
—

 
11,650,712

 
—

 
11,650,712

Change in Ownership in Subsidiary
—

 
—

 
—

 
—

 
(195,219
)
 
—

 
—

 
—

 
(195,219
)
 
195,219

 
—

Balance at September 30, 2016
10,000

 
$
100

 
8,181,921

 
$
8,182

 
$
410,276,001

 
$
—

 
$
(398,830,656
)
 
$
(707,637
)
 
$
10,745,990

 
$
(756,495
)
 
$
9,989,495

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Series B Convertible
Preferred Stock
 
Common Stock
 
Additional
Paid in
Capital
 
Accumulated
Other
Comprehensive
Income
 
Accumulated
Deficit
 
Treasury
Stock
 
Total
Caladrius Biosciences,
Inc.
Stockholders'
Equity
 
Non-
Controlling
Interest in
Subsidiary
 
Total
Equity
 
Shares
 
Amount
 
Shares
 
Amount
 
 
 
 
 
 
 
Balance at December 31, 2016
10,000

 
$
100

 
8,205,790

 
$
8,206

 
$
410,372,049

 
$
—

 
$
(404,788,809
)
 
$
(707,637
)
 
$
4,883,909

 
$
(817,429
)
 
$
4,066,480

Net income
—

 
—

 
—

 
—

 
—

 
—

 
25,841,566

 
—

 
25,841,566

 
(717,665
)
 
25,123,901

Unrealized gain/loss on marketable securities
—

 
—

 
—

 
—

 
—

 
(28,717
)
 
—

 
—

 
(28,717
)
 
—

 
(28,717
)
Share-based compensation
—

 
—

 
54,545

 
55

 
2,412,926

 
—

 
—

 
—

 
2,412,981

 
—

 
2,412,981

Net proceeds from issuance of common stock
—

 
—

 
1,162,831

 
1,162

 
5,677,470

 
—

 
—

 
—

 
5,678,632

 
—

 
5,678,632

Proceeds from option exercises
—

 
—

 
3,835

 
4

 
13,572

 
—

 
—

 
—

 
13,576

 
—

 
13,576

Elimination of non-controlling interests associated with PCT sale
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
(3,686,526
)
 
(3,686,526
)
Reclassification of redeemable securities
—

 
—

 
—

 
—

 
14,733,908

 
—

 
—

 
—

 
14,733,908

 
4,666,092

 
19,400,000

Change in Ownership in Subsidiary
—

 
—

 
—

 
—


(203,145
)
 
—

 
—

 
—

 
(203,145
)
 
203,145

 
—

Balance at September 30, 2017
10,000

 
$
100

 
9,427,001

 
$
9,427

 
$
433,006,780

 
$
(28,717
)
 
$
(378,947,243
)
 
$
(707,637
)
 
$
53,332,710

 
$
(352,383
)
 
$
52,980,327

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See accompanying notes to consolidated financial statements.
 

7

CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 
 
Nine Months Ended September 30,
 
2017
 
2016
Cash flows from operating activities:
 

 
 

Net income (loss)
$
25,123,901

 
$
(27,220,171
)
(Income) loss from discontinued operations
(37,329,963
)
 
1,628,694

Share-based compensation
1,881,712

 
2,275,616

Depreciation and amortization
284,005

 
351,226

Loss on disposal of assets
175,793

 
591,307

Accretion on marketable securities
218,755

 
—

Changes in operating assets and liabilities:
 

 
 

Prepaid and other current assets
980,495

 
871,417

Accounts receivable
(262,784
)
 
14,424

Other assets
164,788

 
191,717

Due to/from PCT
(1,681,593
)
 
1,605,550

Accounts payable, accrued liabilities and other liabilities
(5,823,272
)
 
(3,210,626
)
Net cash used in operating activities - continuing operations
(16,268,163
)
 
(22,900,846
)
Net cash (used in) provided by operating activities - discontinued operations
(638,069
)
 
2,608,615

Net cash used in operating activities
(16,906,232
)
 
(20,292,231
)
Cash flows from investing activities:
 

 
 

Purchase of marketable securities
(51,724,691
)
 
—

Sale of marketable securities
7,105,603

 
—

Net proceeds from PCT sale
74,689,814

 
—

Net cash sold in PCT sale
(6,727,263
)
 
—

Acquisition of property, plant and equipment
(118,478
)
 
(1,068,130
)
Net cash provided by (used in) investing activities - continuing operations
23,224,985

 
(1,068,130
)
Net cash used in investing activities - discontinued operations
(188,794
)
 
(1,247,623
)
Net cash provided by (used in) investing activities
23,036,191

 
(2,315,753
)
Cash flows from financing activities:
 

 
 

Proceeds from exercise of options
13,576

 
—

Tax withholding payments on net share settlement equity awards
(357,665
)
 
—

Net proceeds from issuance of common stock
5,678,632

 
11,650,712

Repayment of long-term debt
(5,651,354
)
 
(9,348,646
)
Proceeds from notes payable
400,998

 
368,615

Repayment of notes payable
(764,402
)
 
(715,610
)
PCT dividend to Caladrius
—

 
15,000,000

Net cash (used in) provided by financing activities - continuing operations
(680,215
)
 
16,955,071

Net cash (used in) provided by financing activities - discontinued operations
(74,231
)
 
3,941,244

Net cash (used in) provided by financing activities
(754,446
)
 
20,896,315

Net increase (decrease) in cash, cash equivalents and restricted cash
5,375,513

 
(1,711,669
)
Cash, cash equivalents and restricted cash at beginning of period - continuing operations
7,076,651

 
18,657,971

Cash and cash equivalents at beginning of period - discontinued operations
7,628,357

 
1,660,440

Cash, cash equivalents and restricted cash at end of period
$
20,080,521

 
$
18,606,742

    Less cash and cash equivalents of discontinued operations at end of period
—

 
6,962,677

Cash, cash equivalents and restricted cash of continuing operations at end of period
20,080,521

 
11,644,065

 
 
 
 
Supplemental Disclosure of Cash Flow Information:
 
 
 
Cash paid during the period for:
 
 
 
Interest
$
706,231

 
$
973,729

See accompanying notes to consolidated financial statements.

8

CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES
 
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
Note 1 – The Business
 
Overview
 
Caladrius Biosciences, Inc. (“we,” “us,” "our," “Caladrius” or the “Company”), is a company developing cellular therapeutics to treat certain diseases. We leverage specialized clinical development expertise to select and develop early-stage cell therapy candidates with the intention of developing such candidates to their next significant clinical milestone and, if appropriate, partnering such candidates. Our current lead product candidate, CLBS03, is an autologous polyclonal regulatory T cell ("Treg") clinical phase 2 therapy targeting children aged 8-17 with recent-onset type 1 diabetes mellitus ("T1D").

Immunomodulation (Treg Technology)

We are developing strategically, through the utilization of our core clinical development expertise, a product candidate (CLBS03) that has the potential to be an innovative therapy for T1D. This therapy is based on a proprietary platform technology for immunomodulation. We have selected as an initial target the unmet medical need of patients who are newly diagnosed with T1D, most of whom will be under the age of 18. This program is based on the use of Tregs to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg number and function. Tregs are a natural part of the human immune system and regulate the activity of effector T cells, the cells that are responsible for protecting the body from pathogens and foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by effector T cells. In autoimmune disease, however, it is thought that deficient Treg activity and numbers permit the effector T cells to attack the body's own beneficial cells. In the case of T1D, the beta cells in the pancreas are attacked thereby reducing and/or eliminating over time the patient's ability to produce insulin. Insulin is necessary to regulate sugar metabolism and maintain proper sugar levels in the blood. Inconsistent or unnatural insulin levels can lead to many complications, including blindness, vascular disease and, if no insulin supplement is provided, even death. There are currently no curative treatments for TID, only lifelong insulin therapy, which often does not prevent serious co-morbidities. Two Phase 1 clinical trials of Treg technology in T1D demonstrated safety and tolerance, feasibility of manufacturing, an implied durability of effect as well as an early indication of potential therapeutic effect through the preservation of beta cell function. In the first quarter of 2016, we commenced patient enrollment in the first of two cohorts in The Sanford Project: T-Rex Study, a Phase 2 prospective, randomized, placebo-controlled, double-blind clinical trial (the "TRex Study") to evaluate the safety and efficacy of CLBS03 in adolescents with recent onset TID. In October 2016, we received a satisfactory safety evaluation by our independent Data Safety Monitoring Board based on safety data then available from the first 19 patients enrolled in the trial. A subsequent interim analysis is planned after approximately 50% of patients reach the six-month follow-up milestone, the results of which are expected to be publicly available by the mid to late first quarter of 2018. We entered into a strategic collaboration with Sanford Research to support the execution of this trial. Sanford Research is a U.S.-based non-profit research organization that supports an emerging translational research center focused on finding a cure for T1D. On February 23, 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received $5.7 million in initial funding on May 4, 2017. CLBS03 has been granted Fast Track and orphan drug designations from the U.S. Food and Drug Administration ("FDA") as well as Advanced Therapeutic Medicinal Product ("ATMP") classification from the European Medicines Agency ("EMA").

Ischemic Repair (CD34 Cell Technology)
Our CD34 cell technology has led to the development of therapeutic candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Through the administration of CD34 cells, we seek to promote the development and formation of new blood vessels and thereby increase blood flow to the impacted area. We believe that conditions caused by underlying ischemic injury can be improved through our CD34 cell technology, including critical limb ischemia ("CLI"). Published reports in Circulation Cardiovascular Interventions, Atherosclerosis, Stem Cells and Circulation Journal, provide preliminary evidence that CD34 cell therapy is safe and can exert significant therapeutic effects in patients with CLI, a condition in which blood flow to the legs is severely impaired, causing pain and non-healing ulcers and, ultimately, potentially resulting in the need for amputation. Our Clinical Trial Notification for a pivotal Phase 2 trial investigating our product candidate in CLI CLBS12 was submitted to the Japanese Pharmaceutical and Medical Device Agency ("PMDA") and was cleared to proceed. The protocol design was agreed to with PMDA and, we intend to begin enrolling patients in late 2017 or early 2018. Under our agreement with the PMDA, a successful outcome of this trial would make CLBS12 eligible for early conditional approval in Japan. We are seeking to collaborate on CLBS12 with development and/or manufacturing partners. Furthermore, we submitted grant applications in an effort to seek non-dilutive financing to investigate the CD34 technology for

9

additional clinical indications in the United States and on October 2, 2017 we announced the award of a $1.9 million grant from the National Institutes of Health to support a clinical study of CD34 cells in patients with coronary microvascular dysfunction.
We intend to develop this platform if capital becomes available through grants, partnerships or licensing, as well as potentially using reasonable amounts of our own capital.
Additional Out-licensing Opportunities
    
Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. These include additional indications for our Treg product, additional indications for our CD34 cell technology and a platform using tumor cell/dendritic cell technology for immuno-oncology application. The immuno-oncology program has the benefit of promising Phase 2 clinical data and applicability to multiple indications. In 2016, we completed multiple out-licensing agreements for this and other technology platforms in an effort to monetize non-core assets.

Our current long-term strategy focuses on advancing our therapies through development toward the market and assisting patients suffering from life-threatening medical conditions. We believe that we are positioned to realize potentially meaningful value increases within our own proprietary pipeline based on the realization of advancing our product candidates to their next significant development milestone.

Discontinued Operations
On May 18, 2017 (the "Closing Date"), we completed the previously announced sale of our remaining 80.1% membership interest in PCT, LLC, a Caladrius company ("PCT") to Hitachi Chemical Co. America, Ltd. ("Hitachi"), pursuant to the Interest Purchase Agreement (the "Purchase Agreement"), dated as of March 16, 2017, by and among us, PCT and Hitachi (the "2017 Hitachi Transaction"), for $75.0 million in cash, plus an additional cash adjustment based on PCT’s cash and outstanding indebtedness as of the Closing Date ("Additional Consideration") and a potential future milestone payment (see Note 3). The sale of PCT represents a strategic shift that has a major effect on our operations, and therefore, PCT is accounted for as discontinued operations. All periods presented were adjusted to reflect PCT as discontinued operations.

Basis of Presentation

The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of September 30, 2017 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2016 and 2015 included in our 2016 Form 10-K. Operating results for the nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.
    
Use of Estimates
 
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining useful lives of our long-lived assets, allowances for doubtful accounts, and stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.

An accounting policy is considered to be critical if it is important to the Company’s financial condition and results of operations and if it requires management’s most difficult, subjective and complex judgments in its application.
 
Principles of Consolidation
 
The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly-owned and partially-owned subsidiaries and affiliates, as well as the operations of our former subsidiaries PCT, LLC, a Caladrius company, NeoStem

10

Family Storage, LLC, and PCT Allendale, LLC entities (collectively the "PCT Segment") through May 18, 2017, representing the date which these entities were sold to Hitachi (see Note 3). The PCT Segment is reported in discontinued operations. All intercompany activities have been eliminated in consolidation, except for intercompany activities between Caladrius and the PCT Segment, which are reported without intercompany eliminations in continuing operations and discontinued operations, respectively.

Note 2 – Summary of Significant Accounting Policies
 
In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our 2016 Form 10-K. There were no changes to these policies during the three and nine months ended September 30, 2017.

Concentration of Risks
We are subject to credit risk from our portfolio of cash, cash equivalents, restricted cash, and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.

Share-Based Compensation  

The Company expenses all share-based payment awards to employees, directors, consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.


Recently Issued Accounting Pronouncement

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires that a lessee recognize lease assets and lease liabilities for those leases classified as operating leases. The guidance is effective for interim and annual periods beginning after December 15, 2018, and will be applied at the beginning of the earliest period presented using a modified retrospective approach. This ASU may have a material impact on the Company’s financial statements. The impact on the Company’s results of operations is currently being evaluated. The impact of the ASU is non-cash in nature and will not affect the Company’s cash position.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting for forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance was effective for interim and annual periods beginning after December 15, 2016. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU 2016-15 is effective in first quarter of fiscal 2018 and earlier adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.

In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized as current period income tax expense or benefit at the transaction date and removes the option to defer and amortize the consolidated tax consequences of intra-entity transfers. The new standard will be effective on January 1, 2018 and will be adopted using a modified retrospective approach which requires a cumulative effect adjustment to retained earnings as of the beginning of the period of adoption. Early adoption

11

is permitted at the beginning of a fiscal year. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard will be effective on January 1, 2018 and the Company has been early adopted, with all adjustments reflected as of the beginning of the fiscal years reported.

In May 2017, the FASB issued ASU 2017-09, "Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU 2017-09 also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. For all entities, including emerging growth companies, the standard is effective for annual periods beginning after December 15, 2017, and for interim periods therein. Early adoption is permitted. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.


Note 3 – Collaboration and License Agreement

2016 Hitachi Transaction

On March 11, 2016, PCT entered into a global collaboration with Hitachi. This collaboration consists of an equity investment in and a license agreement with PCT.

Under the equity investment agreement, Hitachi purchased a 19.9% membership interest in PCT for $19.4 million of which $15.0 million of proceeds was distributed to Caladrius from PCT and $4.4 million remained at PCT to be used for the continued expansion and improvements at PCT in support of commercial product launch readiness as well as for general corporate purposes.

PCT and Hitachi also entered into an exclusive license agreement for the acceleration of the creation of a global commercial cell therapy development and manufacturing expertise in Asia pursuant to which PCT received $5.6 million from Hitachi in 2016. PCT licensed certain cell therapy technology and know-how (including an exclusive license in Asia) and agreed to provide Hitachi Chemical with certain training and support.  As additional consideration, Hitachi Chemical agreed to pay PCT royalties on contract revenue generated in Asia for a minimum of ten years.

2017 Hitachi Transaction

On May 18, 2017, the Company sold its remaining 80.1% membership interest in PCT to Hitachi pursuant to the Purchase Agreement, dated as of March 16, 2017, by and among Caladrius PCT and Hitachi (the "2017 Hitachi Transaction"). The aggregate purchase price to the Company consisted of (i) $75.0 million in cash, (ii) $4.4 million, representing Additional Consideration based on PCT’s cash and outstanding indebtedness as of the Closing Date, and (iii) a potential future milestone payment of $5.0 million if PCT achieves $125 million in Cumulative Revenue (excluding clinical service reimbursables) (the “Milestone”) for the period from January 1, 2017 through December 31, 2018 (the “Milestone Period”).
Hitachi paid the Company $5.0 million in March 2017 as an advance payment pending shareholder approval of the transaction and other closing conditions. On the Closing Date, the Company received $65.0 million, with an additional $5.0 million of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against Caladrius. The Escrow Amount is classified as restricted cash on the balance sheet as of September 30, 2017. In June 2018, the escrow agent will disburse to the Company the Escrow Amount less (i) that portion of the Escrow Amount previously paid in satisfaction of claims for indemnification pursuant to the terms of the Purchase Agreement and (ii) that portion of the Escrow Amount that is determined, in the reasonable judgment of Hitachi, to be necessary to satisfy all unsatisfied or disputed claims for indemnification specified in any claim notice delivered to the Company. The Company also received the $4.4 million Additional Consideration payment in July 2017. The Company incurred approximately $6.9 million in transaction costs related to the 2017 Hitachi Transaction, including $4.3 million in retention payments to PCT employees, of which 50% was paid in June 2017, and the other 50% payable on the one year anniversary of the Closing Date.

Concurrent with the signing of the Purchase Agreement, on March 16, 2017, Caladrius entered into a Retention and Incentive Agreement with Robert A. Preti, a former Caladrius director and a co-founder and the President of PCT, (the “Retention Agreement”). The Retention Agreement superseded all prior agreements and understandings between Dr. Preti and Caladrius regarding the subject matter of the Retention Agreement. Among other things, the Retention Agreement provided for:

12


•
Simultaneously with the closing of the 2017 Hitachi Transaction, Caladrius paid to Dr. Preti $1.9 million (the “First Retention Payment”).
•
As an incentive to remain employed with PCT and to use commercially reasonable efforts to cause PCT to maximize its overall performance and in particular to achieve the Milestone (but not contingent upon achieving the Milestone), Dr. Preti will receive a lump-sum cash retention and incentive payment equal to $1.9 million for the period from the Closing Date until the date one year after the date of the Closing Date (the “Anniversary Date”), subject to Dr. Preti’s continued employment with PCT through the Anniversary Date (the “Second Retention Payment”).
•
Dr. Preti will be entitled to 5% of the Milestone Payment if it is successfully earned.

Note 4 – Available-for-Sale-Securities
 
The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):

 
September 30, 2017
 
December 31, 2016
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
Certificate of deposits
$
249.0

 
$
—

 
$
—

 
$
249.0

 
$
—

 
$
—

 
$
—

 
$
—

Corporate debt securities
49,345.6

 
—

 
(28.8
)
 
49,316.8

 
—

 
—

 
—

 
—

Money market funds
6,678.6

 
0.1

 
—

 
6,678.7

 
4,426.8

 
—

 
—

 
4,426.8

Total
$
56,273.2

 
$
0.1

 
$
(28.8
)
 
$
56,244.5

 
$
4,426.8

 
$
—

 
$
—

 
$
4,426.8


Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):

 
September 30, 2017
 
December 31, 2016
Cash and cash equivalents
$
11,872.9

 
$
4,426.8

Marketable securities
44,371.6

 
—

Total
$
56,244.5

 
$
4,426.8


The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):
 
 
September 30, 2017
 
Amortized Cost
 
Estimated Fair Value
Less than one year
$
56,273.2

 
$
56,244.5

Greater than one year
—

 
—

Total
$
56,273.2

 
$
56,244.5



Note 5 – Loss Per Share
 

13

For the three and nine months ended September 30, 2017 and 2016, the Company incurred net losses from continuing operations and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At September 30, 2017 and 2016, the Company excluded the following potentially dilutive securities:
 
September 30,
 
2017
 
2016
Stock Options
1,105,790

 
942,129

Warrants
218,978

 
362,650

Restricted Stock Awards
8,000

 
61,456

Restricted Stock Units
10,260

 
—

 
Note 6 – Fair Value Measurements
 
The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:
 
Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
 
Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.
 
Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
 
The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of September 30, 2017, and December 31, 2016 (in thousands).

 
 
September 30, 2017
 
December 31, 2016
 
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketable securities - available for sale
 
$
—

 
$
44,371.6

 
$
—

 
$
44,371.6

 
$
—

 
$
—

 
$
—

 
$
—

 
 
$
—

 
$
44,371.6

 
$
—

 
$
44,371.6

 
$
—

 
$
—

 
$
—

 
$
—


Note 7 – Accrued Liabilities

Accrued liabilities as of September 30, 2017 and December 31, 2016 were as follows (in thousands):
 
September 30, 2017
 
December 31, 2016
Salaries, employee benefits and related taxes
$
1,169.6

 
$
1,406.3

Retention payments
2,233.0

 
—

Professional fees
367.3

 
224.5

Income tax liability
4,075.6

 
—

CIRM upfront funding - current
1,745.5

 
—

Other
544.7

 
1,028.6

Total
$
10,135.7

 
$
2,659.4


Note 8 – Debt
 

14

Notes Payable
 
As of September 30, 2017 and December 31, 2016, the Company had notes payable of approximately $0.4 million and $0.7 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years.
 
Long-Term Debt

On September 26, 2014, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (together with its successors and assigns, the “Lender”) pursuant to which the Lender disbursed $15.0 million (the “Loan”). The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and will be amortized to interest expense throughout the life of the Loan using the effective interest rate method.

In March 2016, concurrent with the 2016 Hitachi Transaction (see Note 3), the Company and the Lender entered into an amendment to the Loan and Security Agreement whereby (i) the Company paid $7.0 million to Lender, comprising principal, interest and early termination fees, (ii) the Company's subsidiaries PCT, PCT Allendale, LLC, and NeoStem Family Storage, LLC (collectively the "Removed Borrowers") were removed as borrowers under the Loan, (iii) Lender's security interests in any and all assets of the Removed Borrowers were released, (iv) the interest only period on the remaining outstanding Loan balance was extended until January 1, 2017, and (v) in the event the Company received gross proceeds from the sale or issuance of any equity securities or subordinated debt, or any partnership, licenses, collaboration, dividend, grant or asset sale through March 31, 2017, 20% of such proceeds will be paid to Lender, up to a $3.0 million maximum as additional partial repayment of Loan. On September 14, 2016, concurrent with the Company's September 2016 Registered Direct Offering and Concurrent Private Placement (see Note 10), the Company repaid $3.0 million of such proceeds to the Lender. The outstanding balance was approximately $5.7 million at December 31, 2016.

In May 2017, concurrent with the 2017 Hitachi Transaction (see Note 3), the Company retired the Loan in full, and paid $4.9 million to Lender, comprising principal, interest and early termination fees. The Company was making interest-only payments on the outstanding amount of the Loan on a monthly basis at a rate of 8.50% per annum. During the nine months ended September 30, 2017, the Company recognized $0.4 million of interest expense related to the Loan and Security Agreement. During the three and nine months ended September 30, 2016, the Company recognized $0.2 million and $0.7 million of interest expense, respectively, related to the Loan and Security Agreement.

Note 9 – Redeemable Securities

Under the 2016 Hitachi Transaction (see Note 3), Hitachi had the right, at any time following the tenth anniversary of the 2016 Hitachi Transaction to require Caladrius or PCT to purchase all or some of the equity securities in PCT then held by Hitachi ("Hitachi Put Right") for an amount equal to the lesser of (i) the fair market value of the Hitachi equity holdings and (ii) the original purchase price paid of $19.4 million on March 11, 2016 for its 19.9% ownership interest, plus interest at a rate of 2.0% per annum compounded annually; provided, however, that if Hitachi ownership interests increased subsequent to its initial ownership interest, and it offers to sell its equity holdings in excess of 21% of PCT’s outstanding equity securities, then the Company would be required to purchase all such equity holdings of Hitachi but in no event would the aggregate purchase price of such Hitachi equity holdings exceed $20.5 million plus interest at the rate of 2.0% per annum compounded annually.

As of December 31, 2016, since Hitachi had the right to deliver the equity interests in PCT it held in exchange for cash from Caladrius or PCT, the initial $19.4 million value of the non-controlling interest was considered redeemable equity, requiring it to be treated as mezzanine equity. Redeemable non-controlling interest is required to be initially measured at the initial carrying amount. If the non-controlling interest is not currently redeemable and also not probable of becoming redeemable (e.g., it is not probable a contingency that triggers redemption will be met), the non-controlling interest should be classified in mezzanine equity.

Concurrent with 2017 Hitachi Transaction (see Note 3), the Hitachi Put Right was eliminated, and $14.7 million previously classified as Redeemable Securities was classified to Additional Paid in Capital. In addition, the remaining portion classified as Redeemable Securities of $4.7 million was classified to Non-Controlling Interests, representing Hitachi's ownership interest in PCT at the time of the 2016 Hitachi Transaction, which was subsequently eliminated upon the 2017 Hitachi transaction and included the PCT gain on sale.

Note 10 – Shareholders' Equity

Reverse Stock Split


15

On July 28, 2016, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on June 22, 2016 and unanimously approved by the Company’s board of directors on July 22, 2016. The Reverse Stock Split became effective on July 27, 2016 at 5:00 pm and the common stock of the Company began trading on The NASDAQ Capital Market on a post-split basis at the open of business on July 28, 2016. As of July 28, 2016, every ten shares of the Company’s issued and outstanding common stock were combined into one share of its common stock, except to the extent that the Reverse Stock Split resulted in any of the Company’s stockholders owning a fractional share, which was rounded up to the next highest whole share. In connection with the Reverse Stock Split, there was no change in the nominal par value per share of $0.001.

All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “Additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.

Equity Issuances

September 2016 Registered Direct Offering and Concurrent Private Placement

On September 14, 2016, the Company entered into a securities purchase agreement (the “RD Purchase Agreement”) with a single institutional investor (the “Purchaser”), pursuant to which the Company issued and sold to the Purchaser, in a registered direct offering, an aggregate of 847,458 shares of the Company’s common stock at a purchase price of $4.72 per share. The gross proceeds to the Company from the registered direct offering of the shares of common stock were $4.0 million.

In concurrent private placements, on September 14, 2016, the Company entered into Securities Purchase Agreements (each a “Private Placement Purchase Agreement” and, collectively, the “Private Placement Purchase Agreements”) with certain accredited investors (the “Investors”) with whom it had a substantive, pre-existing relationship, including certain existing stockholders, for the sale by the Company of an aggregate of 4,449,153 shares of Common Stock, at a purchase price of $4.72 per share. The investments were placed in two tranches: (i) $12.6 million upon an initial closing (the “Initial Closing”), and (ii) $8.4 million, subject to certain conditions, including the enrollment of 70 subjects in the Company’s Phase 2 CLBS03 clinical trial, in a second closing (the “Second Closing”). As of March 31, 2017, $6.0 million of the Initial Closing tranche had not been received from a single investor, who was in breach of his obligations under the Private Placement Purchase Agreement. This investor had also committed to fund $4.0 million in the Second Closing. As a result, the Company terminated the Private Placement Purchase Agreement with this investor in the first quarter of 2017. In 2017, the Company met the conditions of the Second Closing, and received the remaining $4.4 million in proceeds in accordance with the terms of the Second Closing tranche and issued 932,204 shares of common stock.

Aspire Purchase Agreements

In November 2015, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30 million of shares (limited to a maximum of approximately 1.1 million shares, unless stockholder approval is obtained or certain minimum sale price levels are reached) of the Company's common stock over a 24-month term. As consideration for entering into the Purchase Agreement, the Company issued 84,270 shares of its common stock to Aspire Capital. During the nine months ended September 30, 2017, the Company issued 210,506 shares of common stock under the Purchase Agreement for gross proceeds of $1.2 million. Overall, as of September 30, 2017, the Company has issued 319,776 shares under the Purchase Agreement for gross proceeds of $1.5 million.

Under the Purchase Agreement, at the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price, trading volume and conditions, including NASDAQ's trading requirements, are met. The purchase price for the shares of common stock is based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreements. We have filed a registration statement with the SEC and a related prospectus supplement that covers the offering of shares of our common stock subject to the Purchase Agreement, and therefore can initiate sales to Aspire Capital at any time, subject to the limitation discussed above.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2017:

16


 
 
Stock Options
 
Warrants
 
 
Shares
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term (Years)
 
Aggregate Intrinsic Value (In Thousands)
 
Shares
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term (Years)
 
Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2016
 
952,790

 
$
39.90

 
7.60
 
$
—

 
388,062

 
$
76.50

 
1.24
 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Changes during the period:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Granted
 
447,757

 
11.70

 
 
 
 
 
—

 
—

 
 
 
 
Exercised
 
(3,835
)
 
4.70

 
 
 
 
 
—

 
—

 
 
 
 
Forfeited
 
(244,413
)
 
18.70

 
 
 
 
 
(1,691
)
 
700.00

 
 
 
 
Expired
 
(46,509
)
 
41.20

 
 
 
 
 
(167,393
)
 
104.50

 
 
 
 
Outstanding at September 30, 2017
 
1,105,790

 
$
33.30

 
5.11
 
$
8.2

 
218,978

 
$
54.80

 
1.15
 
$
—

Vested at September 30, 2017
or expected to vest in the future
 
1,105,336

 
$
33.30

 
5.11
 
$
8.2

 
218,978

 
$
54.80

 
1.15
 
$
—

Vested at September 30, 2017
 
1,097,350

 
$
32.70

 
5.12
 
$
8.2

 
218,978

 
$
54.80

 
1.15
 
$
—



Restricted Stock

During the nine months ended September 30, 2017 and 2016, the Company issued restricted stock for services as follows (in thousands, except share data):

 
 
Nine Months Ended September 30,
  
 
2017
 
2016
Number of restricted stock issued
 
132,726

 
107,719

Value of restricted stock issued
 
$
469.9

 
$
651.7



Note 11 – Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants, restricted stock, and restricted stock units.  The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2017 and 2016 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Research and development
$
—

 
$
154.0

 
$
208.2

 
$
225.0

General and administrative
62.4

 
485.6

 
1,673.6

 
1,297.6

Discontinued operations
—

 
401.0

 
888.9

 
753.0

Total share-based compensation expense
$
62.4

 
$
1,040.6

 
$
2,770.7

 
$
2,275.6

 
 
 
 
 
 
 
 

The approval of the 2017 Hitachi Transaction (see Note 3) by our stockholders resulted in a change in control under our equity compensation plans (as defined in the 2009 Plan and the 2015 Equity Plan, and, together with the 2009 Plan, the “Equity Compensation Plans”). Accordingly, all outstanding unvested equity awards were accelerated upon the Closing Date, resulting in an acceleration of $1.9 million of equity compensation in the second quarter of 2017. In addition, in connection with the 2017 Hitachi Transaction, the Company agreed to extend the post-termination option exercise period for all PCT employees transitioning to Hitachi from 90 days to the earlier of (i) two years (May 18, 2019) or (ii) the date of the employees' termination from PCT. The post-termination option exercise period modification resulted in an additional expense of $0.3 million, which was recorded entirely during the three months ended June 30, 2017 and recorded in discontinued operations, since there were no future service requirements to receive the extended benefit.

17

 
Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2017 were as follows (in thousands):
 
Stock Options
 
Restricted Stock
Unrecognized compensation cost
$
39.7

 
$
4.2

Expected weighted-average period in years of compensation cost to be recognized
0.67

 
0.13


Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2017 and 2016 were as follows (in thousands):
 
Stock Options
 
Nine Months Ended September 30,
 
2017
 
2016
Total fair value of shares vested
$
5,001.7

 
$
2,189.4

Weighted average estimated fair value of shares granted
$
1.72

 
$
3.25


Valuation Assumptions

The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

Note 12 – Research Funding

California Institute of Regenerative Medicine Grant Award
In February 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received $5.7 million in initial funding in May 2017, which will be amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses. As of September 30, 2017, $1.7 million of the funding received is recorded in Accrued Liabilities, representing the amount expected to be recognized over the next 12 months, and $3.2 million of the funding received is recorded in Other Long-Term Liabilities. During the three and nine months ended September 30, 2017, the Company amortized and recognized a $0.4 million and $0.7 million credit to research and development related to CIRM funds received.

Note 13 – Income Taxes
 
As of December 31, 2016, the Company had approximately $232.7 million of federal net operating loss carryforwards ("NOLs") available to offset future taxable income expiring from 2027 through 2036. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  If a change of ownership did occur, there would be an annual limitation on the usage of the Company’s losses, which are available through 2036.

In assessing the ability to realize deferred tax assets, including the NOLs, the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  During the quarter ended June 30, 2017, the Company generated a gain from the sale of 80.1% of their ownership in PCT. The gain from the sale of PCT is included in discontinued operations. The Company for the nine months ended September 30, 2017 has generated losses from continuing operations and has forecasted losses for the remainder of the year. Based on generating taxable income for the 2017 year, the Company will utilize net operating losses which were offset by a full valuation allowance. The Company anticipates that they will maintain a valuation allowance on the remaining deferred tax assets at the end of the year.

Deferred tax liabilities were $0 and $1.1 million as of September 30, 2017 and December 31, 2016, respectively, and relate to the taxable temporary differences on the goodwill recognized in the PCT acquisition in 2011. The taxable temporary differences,

18

which were tax deductible and were to be amortized over 15 years. The deferred tax liability was reversed during the three months ended June 30, 2017, as a result of the divestiture of PCT.

The Company applies ASC 740-10 for uncertain tax positions. The Company utilizes the two step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.

As of September 30, 2017, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

During the nine months ended September 30, 2017, the Company has both continuing and discontinued operations. ASC 740-20-45-7 addresses the income tax accounting treatment when there is a loss from continuing operations and income from discontinuing operations. The Company must consider the gain from discontinued operations for purposes of allocating a tax benefit to the current year loss from continuing operations. The Company has adopted a method in which the income from discontinued operations are recognized as a discrete item in the period in which it occurs and apply the concepts of the annual effective tax rate (AETR) during each period in computing the income tax provision from continuing operations. This method results in a tax expense for discontinued operations and an income tax benefit for the loss generated from continuing operations. The Company is forecasting losses from continuing operations for the remainder of 2017 against which an income tax benefit will be recorded.

The Company completed the audit of its federal tax returns for the years 2012 and 2013 during the fourth quarter of 2016. The audit resulted in an adjustment to the Company's NOL carryforward. For years prior to 2014, the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from date of filing. The Company ceased doing business in China in 2012.  After 2012, the Company had no foreign tax filing obligations.  The foreign returns filed for 2012 and prior are subject to examination for five years.


Note 14 – Discontinued Operations
 
PCT Segment

On May 18, 2017, the Company completed the previously announced Sale of its remaining 80.1% membership interest in PCT to Hitachi. Pursuant to the Purchase Agreement, by and among Caladrius, PCT and Hitachi, the aggregate purchase price to the Company consisted of (i) $75.0 million in cash, (ii) a $4.4 million cash adjustment, based on PCT’s cash and outstanding indebtedness as of the Closing Date, and (iii) a potential future milestone payment of $5.0 million if PCT achieves $125 million in Cumulative Revenue (excluding clinical service reimbursables) (the “Milestone”) for the period from January 1, 2017 through December 31, 2018 (the “Milestone Period”). The Company has determined that the fair value of the milestone payment as of the closing date was valued at zero. 
Pursuant to the terms of the Purchase Agreement, Hitachi paid the Company $5.0 million in March 2017 as an advance payment pending shareholder approval of the transaction and other closing conditions included in the Purchase Agreement. On the Closing Date, the Company received $65.0 million, with an additional $5.0 million of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against Caladrius. In June 2018, the escrow agent will disburse to the Company the Escrow Amount less (i) that portion of the Escrow Amount previously paid in satisfaction of claims for indemnification pursuant to the terms of the Purchase Agreement and (ii) that portion of the Escrow Amount that is determined, in the reasonable judgment of Hitachi, to be necessary to satisfy all unsatisfied or disputed claims for indemnification specified in any claim notice delivered to the Company. The Company also received the additional $4.4 million cash adjustment payment in July 2017. The Company incurred approximately $6.9 million in transaction costs related to the Sale, including $4.3 million in retention payments to PCT employees, of which 50% was paid in June 2017, and the other 50% payable on the one year anniversary of the Closing Date.

The Company recognized the following gain on the date of sale of its 80.1% interest in PCT (in thousands):

19

Fair value of consideration received
$
79,425

Transaction and retention costs
(6,919
)
Carrying value of segment non-controlling interest
3,687

 
$
76,193

Less carrying amount of assets and liabilities sold:
 
Cash
$
6,727

Accounts receivable
3,702

Deferred costs
4,685

Prepaid expenses and other current assets
743

Property, plant and equipment, net
14,900

Goodwill
7,013

Intangibles, net
2,090

Other assets
215

Accounts payable
(2,278
)
Accrued liabilities
(2,927
)
Due from Caladrius
450

Unearned revenues
(10,529
)
Notes payable
(342
)
 
$
24,449

 
 
Gain on sale of PCT
$
51,744


The operations and cash flows of the PCT Segment were eliminated from ongoing operations with the sale of the Company's PCT Interest. The operating results of the PCT Segment for the nine months ended September 30, 2017 and three and nine months ended September 30, 2016 were as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2017
 
2016
Revenue
$
10,794

 
$
16,039

 
$
29,910

Cost of revenues
(9,482
)
 
(15,321
)
 
(25,122
)
Research and development
(277
)
 
(257
)
 
(610
)
Selling, general, and administrative
(2,168
)
 
(3,251
)
 
(5,587
)
Other expense
(17
)
 
(16
)
 
(72
)
Provision for income taxes
(47
)
 
(11,608
)
 
(147
)
Gain on sale of segment
—

 
51,744

 
—

Income (loss) from discontinued operations
$
(1,197
)
 
$
37,330

 
$
(1,629
)


Note 15 – Commitments and Contingencies
 
Lease Commitments
 
We lease facilities under various operating lease agreements in Basking Ridge, NJ, New York, NY, and Irvine, CA, of which certain leases have escalation clauses and renewal options. We also lease equipment under certain noncancelable operating leases. Our leases expire from time to time through 2021.
A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2017 are as follows (in thousands):  
Years ended
 
Operating Leases
2017
 
$
327.5

2018
 
817.4

2019
 
786.2

2020
 
801.6

2021 and thereafter
 
603.0

Total minimum lease payments
 
$
3,335.7

 
Expense incurred under operating leases was approximately $0.3 million and $1.1 million for the three and nine months ended September 30, 2017, respectively. Expense incurred under operating leases was approximately $0.3 million and $1.0 million for the three and nine months ended September 30, 2016, respectively.
 
Contingencies
 
We have entered into a strategic collaboration with Sanford Research with the goal of developing a therapy for the treatment of T1D. The initial focus of the collaboration will be the execution of a prospective, randomized, placebo-controlled, double-blind clinical trial (The Sanford Project: T-Rex Study) to evaluate the safety and efficacy of the Company’s T regulatory cell product candidate, CLBS03, in adolescents with recent onset T1D. The Phase 2 study has an open and active IND in place and subject enrollment commenced in the first quarter of 2016. We were initially responsible for the supply of all study drug to the first 19 enrolled patients while Sanford assumed all patient and clinical site costs for subjects enrolled in their two centers as well as the expense associated with general clinical monitoring services. For the remaining 92 patients in the study, we will continue to be responsible for the supply of all study drug and the costs of study enrollment for sites outside of the Sanford centers.

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not

20

believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
 
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Cautionary Note Regarding Forward-Looking Statements” herein and under “Risk Factors” in our 2016 Form 10-K. The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report and in our 2016 Form 10-K.
 
Overview
 
Caladrius Biosciences, Inc. (“we,” “us,” "our," “Caladrius” or the “Company”), is a company developing cellular therapeutics to treat certain diseases. We leverage specialized clinical development expertise to select and develop early-stage candidates with the intention of developing such candidates to their next significant clinical milestone and,if appropriate, partnering such candidates. Our current lead product candidate, CLBS03, is an autologous polyclonal regulatory T cell ("Treg") clinical phase 2 therapy targeting children aged 8-17 with recent-onset type 1 diabetes mellitus ("T1D").

Immunomodulation (Treg Technology)

We are developing strategically, through the utilization of our core clinical development expertise, a product candidate (CLBS03) that has the potential to be an innovative therapy for T1D. This therapy is based on a proprietary platform technology for immunomodulation. We have selected as an initial target the unmet medical need of patients who are newly diagnosed with T1D, most of whom will be below the age of 18. This program is based on the use of Tregs to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg number and function. Tregs are a natural part of the human immune system and regulate the activity of effector T cells; the cells that are responsible for protecting the body from pathogens and foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by effector T cells. In autoimmune disease, however, it is thought that deficient Treg activity and numbers permit the effector T cells to attack the body's own beneficial cells. In the case of T1D, the beta cells in the pancreas are attacked thereby reducing and/or eliminating over time the patient's ability to produce insulin. Insulin is necessary to regulate sugar metabolism and maintain proper sugar levels in the blood. Inconsistent or unnatural insulin levels can lead to many complications, including blindness, vascular disease and, if no insulin supplement is provided, even death. There are currently no curative treatments for T1D, only lifelong insulin therapy, which often does not prevent serious co-morbidities. Two Phase 1 clinical trials of Treg technology in T1D demonstrated safety and tolerance, feasibility of manufacturing, an implied durability of effect as well as an early indication of potential therapeutic effect through the preservation of beta cell function. In the first quarter of 2016, we commenced patient enrollment in the first of two cohorts in The Sanford Project: T-Rex Study, a Phase 2 prospective, randomized, placebo-controlled, double-blind clinical trial (the "TRex Study") to evaluate the safety and efficacy of CLBS03 in adolescents with recent onset TID. In October 2016, we received a satisfactory safety evaluation by our independent Data Safety Monitoring Board based on safety data then available from the first 19 patients enrolled in the trial. A subsequent interim analysis is planned after approximately 50% of patients reach the six-month follow-up milestone, the results of which are expected to be publicly available by the mid to late first quarter 2018. We entered into a strategic collaboration with Sanford Research to support the execution of this trial. Sanford Research is a U.S.-based non-profit research organization that supports an emerging translational research center focused on finding a cure for T1D. On February 23, 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received $5.7 million in initial funding on May 4, 2017. CLBS03 has been granted Fast Track and orphan drug designations from the U.S. Food and Drug Administration ("FDA") as well as Advanced Therapeutic Medicinal Product ("ATMP") classification from the European Medicines Agency ("EMA").

Ischemic Repair (CD34 Cell Technology)
Our CD34 cell technology has led to the development of therapeutic candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Through the administration of CD34 cells, we seek to promote the development and formation of new blood vessels and thereby increase blood flow to the impacted area. We believe that conditions caused by underlying ischemic injury can be improved through our CD34 cell technology, including critical limb ischemia ("CLI"). Published reports in Circulation Cardiovascular Interventions, Atherosclerosis, Stem

21

Cells and Circulation Journal, provide preliminary evidence that CD34 cell therapy is safe and can exert significant therapeutic effects in patients with CLI, a condition in which blood flow to the legs is severely impaired, causing pain and non-healing ulcers and, ultimately, potentially resulting in the need for amputation. Our Clinical Trial Notification for a pivotal Phase 2 trial investigating our product candidate in CLI CLBS12, was submitted to the Japanese Pharmaceutical and Medical Device Agency ("PMDA") and was cleared to proceed. The protocol design was agreed to with PMDA and we hope to begin enrolling patients in late 2017 or early 2018. Under our agreement with PMDA, a successful outcome of this trial would make CLBS12 eligible for early conditional approval in Japan. We are seeking to collaborate on CLBS12 with development and/or manufacturing partners. Furthermore, we submitted grant applications in an effort to seek non-dilutive financing to investigate the CD34 technology for additional clinical indications in the United States and on October 2, 2017 we announced the award of a $1.9 million grant from the National Institutes of Health to support a clinical study of CD34 cells in patients with coronary microvascular dysfunction.
 
Additional Out-licensing Opportunities
    
Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. These include additional indications for our Treg product, additional indications for our CD34 cell technology and a platform using tumor cell/dendritic cell technology for immuno-oncology application. The immuno-oncology program has the benefit of promising Phase 2 clinical data and applicability to multiple indications. This platform is based on our extensive intellectual property portfolio. In 2016, we completed multiple out-licensing agreements for this and other technology platforms in an effort to monetize non-core assets.

Our long-term strategy focuses on advancing our therapies through development toward the market and assisting patients suffering from life-threatening medical conditions. We believe that we are positioned to realize potentially meaningful value increases within our own proprietary pipeline based on the realization of advancing our product candidates to their next significant development milestone.

Discontinued Operations
On May 18, 2017 (the "Closing Date"), the Company completed the previously announced sale of its remaining 80.1% membership interest in PCT, LLC, a Caladrius company ("PCT") to Hitachi Chemical Co. America, Ltd. ("Hitachi"), pursuant to the Interest Purchase Agreement (the "Purchase Agreement"), dated as of March 16, 2017, by and among Caladrius, PCT and Hitachi (the "2017 Hitachi Transaction"), for $75.0 million in cash, plus an additional cash adjustment based on PCT’s cash and outstanding indebtedness as of the Closing Date ("Additional Consideration") and a potential future milestone payment. The sale of PCT represents a strategic shift that has a major effect on the Company’s operations, and therefore, PCT is accounted for as discontinued operations. All periods presented were adjusted to reflect PCT as discontinued operations.

Results of Operations
 
Three and Nine Months Ended September 30, 2017 Compared to Three and Nine Months Ended September 30, 2016
 
Net loss from continuing operations was $3.5 million for the three months ended September 30, 2017, compared to net loss from continuing operations of $6.1 million for the three months ended September 30, 2016. Overall net loss for the three months ended September 30, 2017 was approximately $3.5 million, compared to overall net loss of $7.3 million for the three months ended September 30, 2016. The overall net loss during the three months ended September 30, 2016 included losses from discontinued operations of $1.2 million.

Net loss from continuing operations was $12.2 million for the nine months ended September 30, 2017, compared to net loss from continuing operations of $25.6 million for the nine months ended September 30, 2016. Overall net income for the nine months ended September 30, 2017 was approximately $25.1 million, which included income from discontinued operations of $37.3 million. Overall net loss for the nine months ended September 30, 2016 was approximately $27.2 million, which included losses from discontinued operations of $1.6 million.

Operating Expenses

 For the three months ended September 30, 2017, operating expenses totaled $6.1 million compared to $5.7 million for the three months ended September 30, 2016, representing an increase of $0.4 million, or 7%. Operating expenses were comprised of the following:
 

22

•
Research and development expenses were approximately $3.2 million for the three months ended September 30, 2017, compared to $3.0 million for the three months ended September 30, 2016, representing an increase of approximately $0.2 million, or 8%.

◦
Immune Modulation - Immune modulation expenses, primarily related to expenses associated with our Phase 2 study of CLBS03 in T1D, were $2.5 million for the three months ended September 30, 2017, compared to $2.8 million for the three months ended September 30, 2016. The lower expenses are due to lower clinical trial and manufacturing costs in the current year period compared to the prior year period.

◦
Ischemic Repair - Ischemic repair expenses were $0.7 million for the three months ended September 30, 2017, compared to $0.1 million for the three months ended September 30, 2016. The increase is primarily related to initiation-related program expenses associated with our critical limb ischemia development program in Japan.

•
General and administrative expenses were approximately $2.9 million for the three months ended September 30, 2017, compared to $2.8 million for the three months ended September 30, 2016, representing an increase of approximately $0.2 million, or 6%. The increase was due to higher overall corporate development activity expenses, which were partially offset by lower overall equity-based compensation expenses.

 For the nine months ended September 30, 2017, operating expenses totaled $20.3 million compared to $24.0 million for the nine months ended September 30, 2016, representing a decrease of $3.7 million or 16%. Operating expenses were comprised of the following:
 
•
Research and development expenses were approximately $11.2 million for the nine months ended September 30, 2017, compared to $13.5 million for the nine months ended September 30, 2016, representing a decrease of approximately $2.3 million, or 17%.

◦
Immune Modulation - Immune modulation expenses, including expenses associated with our Phase 2 study of CLBS03 in T1D, were $10.4 million for the nine months ended September 30, 2017, compared to $7.5 million for the nine months ended September 30, 2016. The higher expenses are due to higher clinical trial and manufacturing costs in the current year period compared to the prior year period.

◦
Ischemic Repair - Ischemic repair expenses were $1.0 million for the nine months ended September 30, 2017, compared to $2.0 million for the nine months ended September 30, 2016. The decrease is primarily due to wind down expenses associated with the close-out activities of the PreSERVE-AMI Phase 2 study for CLBS10 during the nine months ended September 30, 2016, which were partially offset by initiation-related program expenses associated our critical limb ischemia development program in Japan.

◦
Other - Other research and development expenses during the nine months ended September 30, 2016 included $2.6 million of close-out activities for the Intus Phase 3 clinical trial for the immunotherapy product candidate CLBS20, announced in January 2016, along with $1.2 million of associated one-time restructuring costs for severance and asset impairments.

•
General and administrative expenses were approximately $9.1 million for the nine months ended September 30, 2017 compared to $10.5 million for the nine months ended September 30, 2016, representing a decrease of approximately $1.4 million, or 14%. The decrease was primarily related to operational and compensation-related cost reductions compared to the prior year period, but offset by higher transaction-related expenses associated with the PCT Sale. Equity-based compensation of $1.7 million was also higher during the nine months ended September 30, 2017, compared with $1.3 million for the nine months ended September 30, 2016, reflecting the acceleration of vesting of all options and restricted stock outstanding as of May 18, 2017 (the PCT Closing Date), as the transaction was determined to qualify as a change in control under our employee compensation plan which triggered the vesting.

Historically, to minimize our use of cash, we have used a variety of equity and equity-linked instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.

Interest Expense

Interest expense was $0.01 million for the three months ended September 30, 2017, compared with $0.4 million for the three months ended September 30, 2016, and $0.4 million for the nine months ended September 30, 2017, compared with $1.6 million

23

for the nine months ended September 30, 2016. Interest expense is primarily related to interest expense on the loan from Oxford Finance LLC ("Oxford Finance"). Concurrent with the PCT Sale on May 18, 2017, the Oxford loan was fully repaid and retired.
 
Benefit from Income Taxes
 
The benefit from income taxes was $2.4 million and $8.3 million for the three and nine months ended September 30, 2017, respectively. The Company reports both continuing and discontinued operations. ASC 740-20-45-7 addresses the income tax accounting treatment when there is a loss from continuing operations and income from discontinuing operations. The Company must consider the gain from discontinued operations for purposes of allocating a tax benefit to the current year loss from continuing operations. There are three acceptable methods on how a company can record its tax provision in interim periods. The Company has adopted a method in which the income from discontinued operations are recognized as a discrete item in the period in which it occurs and applies the concepts of the annual effective tax rate (AETR) during each period in computing the income tax provision from continuing operations. This method results in tax expense for discontinued operations and an income tax benefit for the loss generated from continuing operations. The Company is forecasting losses from continuing operations for the remainder of 2017 against which an income tax benefit will be recorded.

Discontinued Operations
 
On May 18, 2017, the Company completed the Sale of its remaining 80.1% membership interest in PCT to Hitachi. Pursuant to the Purchase Agreement, by and among Caladrius, PCT and Hitachi, the aggregate purchase price to the Company consisted of (i) $75.0 million in cash, (ii) a $4.4 million cash adjustment, based on PCT’s cash and outstanding indebtedness as of the Closing Date, and (iii) a potential future milestone payment of $5.0 million, if PCT achieves $125 million in Cumulative Revenue (excluding clinical service reimbursables) (the “Milestone”) for the period from January 1, 2017 through December 31, 2018 (the “Milestone Period”). The Company has determined that the fair value of the milestone payment as of the closing date was valued at zero. 

Pursuant to the terms of the Purchase Agreement, Hitachi paid the Company $5.0 million in March 2017, as an advance payment pending shareholder approval of the transaction and other closing conditions included in the Purchase Agreement. On the Closing Date, the Company received $65.0 million, with an additional $5.0 million of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against the Company. In June 2018, the escrow agent will disburse to the Company the Escrow Amount less (i) that portion of the Escrow Amount previously paid in satisfaction of claims for indemnification pursuant to the terms of the Purchase Agreement and (ii) that portion of the Escrow Amount that is determined, in the reasonable judgment of Hitachi, to be necessary to satisfy all unsatisfied or disputed claims for indemnification specified in any claim notice delivered to the Company. The Company also received the additional $4.4 million cash adjustment payment in July 2017. The Company incurred approximately $6.9 million in transaction costs related to the Sale, including $4.3 million in retention payments to PCT employees, of which 50% was paid in June 2017, and the other 50% payable on the one year anniversary of the Closing Date.

The Company recognized the following gain on the date of sale of its 80.1% interest in PCT (in thousands):

24

Fair value of consideration received
$
79,425

Transaction and retention costs
(6,919
)
Carrying value of segment non-controlling interest
3,687

 
$
76,193

Less carrying amount of assets and liabilities sold:
 
Cash
$
6,727

Accounts receivable
3,702

Deferred costs
4,685

Prepaid expenses and other current assets
743

Property, plant and equipment, net
14,900

Goodwill
7,013

Intangibles, net
2,090

Other assets
215

Accounts payable
(2,278
)
Accrued liabilities
(2,927
)
Due from Caladrius
450

Unearned revenues
(10,529
)
Notes payable
(342
)
 
$
24,449

 
 
Gain on sale of PCT
$
51,744


The operations and cash flows of the PCT Segment were eliminated from ongoing operations with the sale of the Company's PCT Interest. The operating results of the PCT Segment for the nine months ended September 30, 2017 and three and nine months ended September 30, 2016 were as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2017
 
2016
Revenue
$
10,794

 
$
16,039

 
$
29,910

Cost of revenues
(9,482
)
 
(15,321
)
 
(25,122
)
Research and development
(277
)
 
(257
)
 
(610
)
Selling, general, and administrative
(2,168
)
 
(3,251
)
 
(5,587
)
Other expense
(17
)
 
(16
)
 
(72
)
Provision for income taxes
(47
)
 
(11,608
)
 
(147
)
Gain on sale of segment
—

 
51,744

 
—

Income (loss) from discontinued operations
$
(1,197
)
 
$
37,330

 
$
(1,629
)



25

Analysis of Liquidity and Capital Resources
 
At September 30, 2017, we had cash, cash equivalents, restricted cash, and marketable securities of approximately $64.5 million, working capital of approximately $54.4 million, and stockholders’ equity of approximately $53.3 million.
 
During the nine months ended September 30, 2017, we met our immediate cash requirements through cash received from the transaction with Hitachi, proceeds from the issuances of our common stock, and existing cash balances. Additionally, we used equity and equity-linked instruments to pay for services and compensation.
 
Net cash provided by or used in operating, investing and financing activities from continuing operations were as follows (in thousands): 
 
Nine Months Ended September 30,
 
2017
 
2016
Net cash used in operating activities - continuing operations
$
(16,268.2
)
 
$
(22,900.8
)
Net cash provided by (used in) investing activities - continuing operations
23,225.0

 
(1,068.1
)
Net cash (used in) provided by financing activities - continuing operations
(680.2
)
 
16,955.1

 
Operating Activities - Continuing Operations
 
Our cash used in operating activities in the nine months ended September 30, 2017 totaled approximately $16.3 million, which is the sum of (i) our net income of $25.1 million, less income from discontinued operations of $37.3 million, adjusted for non-cash expenses totaling $2.6 million (which includes adjustments for equity-based compensation, depreciation and amortization, loss on disposal of assets, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities using approximately $6.6 million.

Our cash used in operating activities in the nine months ended September 30, 2016 totaled approximately $22.9 million, which is the sum of (i) our net loss of $27.2 million, less loss from discontinued operations of $1.6 million, adjusted for non-cash expenses totaling $3.2 million (which includes adjustments for equity-based compensation, depreciation and amortization, and loss on disposal of assets), and (ii) changes in operating assets and liabilities using approximately $0.5 million.

 Investing Activities - Continuing Operations
 
Our cash provided by investing activities in the nine months ended September 30, 2017 totaled approximately $23.2 million. In 2017, we received $74.7 million in net proceeds in connection with the sale of our 80.1% ownership interest in PCT to Hitachi, less $6.7 million of cash held by our PCT subsidiary on the date of the acquisition. We also invested $44.6 million in marketable securities (net), spent approximately $0.1 million for property and equipment.

Our cash used in investing activities in the nine months ended September 30, 2016 totaled approximately $1.1 million, representing property and equipment purchases.
 
Financing Activities - Continuing Operations

During the nine months ended September 30, 2017, our financing activities consisted of the following: 
•
We paid $5.7 million in principal payments on our long-term debt to Oxford Finance.
•
We raised gross proceeds of approximately $4.4 million through the issuance of approximately 932,204 shares of our common stock under the conditions of the Second Closing (achievement of the enrollment of 70 subjects in our Phase 2 CLBS03 clinical trial), relating to the September 2016 private placement offering.
•
We raised gross proceeds of approximately $1.2 million through the issuance of approximately 210,506 shares of our common stock under the provisions of our Common Stock Purchase Agreement with Aspire.
During the nine months ended September 30, 2016, our financing activities consisted of the following: 
•
Hitachi purchased a 19.9% membership interest in PCT for $19.4 million, of which $15.0 million of proceeds was distributed to Caladrius from PCT and $4.4 million remained at PCT.

26

•
We raised $4.0 million in a registered direct offering through the issuance of 0.8 million shares of common stock, and $6.6 million in concurrent private placement offerings through the issuance of 1.4 million shares of common stock.
•
We raised $1.0 million in a private placement through the issuance of 0.1 million shares of common stock and two-year warrants to purchase up to an aggregate of 0.1 million shares our common stock, at an exercise price of $10.00 per share.
•
Upon execution of the March 2016 Hitachi Transaction, we paid $6.3 million in principal payments on our long term debt to Oxford Finance, and in September 2016, we paid an additional $3.0 million in principal payments on our long term debt to Oxford Finance LLC.

Liquidity and Capital Requirements Outlook

To meet our short and long term liquidity needs, we expect to use existing cash balances and a variety of other means. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets. Our history of operating losses and liquidity challenges may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of biopharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations. We will also continue to seek, as appropriate, grants for scientific and clinical studies from various governmental agencies and foundations. We believe that our cash on hand will enable us to fund the development of CLBS03 and other operating expenses for at least the next 12 months following the issuance of our financial statements.
In 2016, Hitachi purchased a 19.9% membership interest in PCT for $19.4 million, of which $15.0 million of proceeds was distributed to Caladrius from PCT and $4.4 million remained at PCT. In 2017, we received $74.7 million (net) in connection with the sale of our remaining 80.1% ownership interest in PCT to Hitachi, less $6.7 million of cash held by our PCT subsidiary on the date of the acquisition.
In September 2016, we entered into a securities purchase agreement with a single institutional investor pursuant to which we issued in a registered direct offering, an aggregate of 0.8 million shares of our common stock at a purchase price of $4.72 per share. The gross proceeds to us from the registered direct offering of the shares of common stock were $4.0 million. In concurrent private placements, in September 2016, we entered into Private Placement Purchase Agreements with certain accredited investors for the sale of common stock, at a purchase price of $4.72 per share. The investments were placed in two tranches: (i) $6.6 million upon an initial closing (the “Initial Closing”), and (ii) $4.4 million, subject to certain conditions, including the enrollment of 70 subjects in our Phase 2 CLBS03 clinical trial, in a second closing (the “Second Closing”). We received the Initial Closing tranche in 2016 and issued 1.4 million shares of common stock. In 2017, we received $4.4 million in accordance with the terms of the Second Closing tranche and issued 0.9 million shares of common stock.
In March 2016, we entered into a securities purchase agreement with certain investors, pursuant to which we issued and sold in a private placement an aggregate of 141,844 shares of common stock and two-year warrants to purchase up to an aggregate of 141,844 shares of our common stock, at an exercise price of $10.00 per share. The unit purchase price for a share of our common stock and warrants to purchase one share of our common stock was $7.05 per unit, with $1.0 million of gross proceeds received by us.
In November 2015, we entered into a common stock purchase agreement with Aspire Capital (the "Aspire Agreement"), whereby we can sell to Aspire Capital, subject to terms and conditions under the Aspire Agreement as well as NASDAQ rules, the lesser of (i) $30 million of common stock or (ii) the dollar value of approximately 1.1 million shares of common stock based on the market price of the common stock at the time of such sale as determined under the Purchase Agreement. We have issued 319,776 shares under the Aspire Agreement for gross proceeds of $1.5 million.
In September 2014, we entered into a Loan and Security Agreement with Oxford Finance LLC and received $15.0 million in gross proceeds. We had been making interest-only payments on the outstanding amount of the loan on a monthly basis at a rate of 8.50% per annum. In March 2016, upon execution of the March 2016 Hitachi Transaction, we and Oxford Finance LLC entered into an amendment to the Loan and Security Agreement whereby (i) we paid $7.0 million to Oxford Finance LLC, comprised of principal, interest and early termination fees, (ii) our subsidiaries PCT, PCT Allendale, LLC, and NeoStem Family Storage, LLC (collectively the "Removed Borrowers") were removed as borrowers under the Loan, (iii) Oxford Finance LLC's security interests in any and all assets of the Removed Borrowers were released, (iv) the interest only period on the remaining outstanding Loan balance was extended until January 1, 2017. In September 2016, we paid $3.0 million to repay a portion of the outstanding loan with Oxford Finance. In May 2017, upon execution of the May 2017 Hitachi Transaction, we and Oxford Finance LLC entered into an amendment to the Loan and Security Agreement whereby we paid the remaining $5.7 million long-term debt balance to Oxford Finance LLC.

27

While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; our stock price may not reach levels necessary to induce option or warrant exercises; and asset sales may not be possible on terms we consider acceptable. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay the expansion of our business or raise funds on terms that we currently consider unfavorable.

Seasonality
 
We do not believe that our operations are seasonal in nature.
 
Off-Balance Sheet Arrangements
 
We do not have any off-balance sheet arrangements.
 
Critical Accounting Policies and Estimates

There have been no material changes in our critical accounting policies and estimates during the three months ended September 30, 2017, compared to those reported in our 2016 Form 10-K.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4.  CONTROLS AND PROCEDURES.  

(a)  Disclosure Controls and Procedures

Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.

As of September 30, 2017, we carried out an evaluation, with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

(b)  Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15, that occurred during our last quarter to which this Quarterly Report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

28

PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.
There are no material changes to the disclosures previously reported in our 2016 Form 10-K.

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors previously reported in our 2016 Form 10-K. See the risk factors set forth in our 2016 Annual Report on Form 10-K under the caption "Item 1 A - Risk Factors."

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

Effective September 18, 2017, the Board amended the Company’s Amended and Restated Bylaws (the “Bylaws”) by amending Article I, Sections 1.10 and 1.11.

As amended, Article I, Section 1.10 governs the introduction of business at annual and special meetings of the Company’s stockholders. Article I, Section 1.10(a) sets forth the procedure by which a stockholder may nominate persons for election to the Board and propose business to be considered and acted upon at an annual meeting of the stockholders. The procedure outlines the timeline for providing notice and the information to be contained in such notice, which includes certain details with respect to the proposed director nomination or other business, certain information about the stockholder making the proposal (including such stockholder’s equity interest in the Company and agreements entered into by such stockholder pertaining to the proposed director nomination or other business), and certain representations and certifications made by the proposing stockholder, among other required disclosures. Article I, Section 1.10(b) provides that director nominations and proposals of other business to be considered and acted upon by the stockholders shall not be brought before a special meeting of stockholders unless such special meeting is held in lieu of an annual meeting of stockholders.

As amended, Article I, Section 1.11 governs stockholder action without a meeting. Article I, Section 1.11(a) sets forth the procedure by which a stockholder may request that the Board fix a record date for the purpose of determining the stockholders entitled to take action by written consent.

Pursuant to the Bylaws and Rule 14a-8 under the Exchange Act, to be included in the Company’s proxy statement and proxy card for its 2018 annual meeting of stockholders, stockholder proposals must be submitted to the Company’s Secretary at 420 Lexington Avenue, Suite 350, New York, NY 10170 no later than January 16, 2018. Any such proposal must meet the requirements set forth in the rules and regulations of the SEC and comply with the requirements set forth in the Bylaws in order to be eligible for inclusion in the proxy statement for the 2018 annual meeting.

In addition, stockholders who desire to bring business or nominate an individual for election or re-election as a director outside of Rule 14a-8 under the Exchange Act before the Company’s 2018 annual meeting must comply with the Bylaws, which currently require that such stockholder have provided written notice of such business or nominee to the Company’s Secretary at 420 Lexington Avenue, Suite 350, New York, NY 10170 no earlier than 5:00 pm, December 17, 2017 and no later than 5:00 pm, January 16, 2018, and otherwise comply with the advance notice and other provisions set forth in the Bylaws, which contain additional requirements regarding advance notice of stockholder proposals and director nominations.


29



None.
ITEM 6. EXHIBITS
The Exhibit Index appearing immediately after the signature page to this Form 10-Q is incorporated herein by reference.



30

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
CALADRIUS BIOSCIENCES, INC.
November 9, 2017
 
By:  /s/ David J. Mazzo, PhD
Name: David J. Mazzo, PhD
Title: President and Chief Executive Officer
(Principal Executive Officer)
November 9, 2017
 
By: /s/ Joseph Talamo
Name: Joseph Talamo
Title: Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)






31

CALADRIUS BIOSCIENCES, INC.
FORM 10Q

Exhibit Index


Amendment to Amended and Restated By-Laws (filed with the Company's Current Report on Form 8-K filed on September 21, 2017 (File No. 001-33650) and incorporated by reference).
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
XBRL Instance Document
101.SCH
XBRL Taxonomy Extension Schema
101.CAL
XBRL Taxonomy Extension Calculation Linkbase
101.DEF
XBRL Taxonomy Extension Definition Linkbase
101.LAB
XBRL Taxonomy Extension Label Linkbase
101.PRE
XBRL Taxonomy Extension Presentation Linkbase
_______________

*
Filed herewith.
**
Furnished herewith.
             

32
 EX-31.1 2 clbs-ex311_20170930xq3.htm EXHIBIT 31.1 Exhibit
Exhibit 31.1
 
CERTIFICATION
 
I, David J. Mazzo,PhD, certify that:
 
1.  I have reviewed this Quarterly Report on Form 10-Q of Caladrius Biosciences, Inc.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by  this report based on such evaluation; and
 
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.  The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: November 9, 2017

/s/ David J. Mazzo, PhD
Name: David J. Mazzo, PhD
Title: Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 clbs-ex312_20170930xq3.htm EXHIBIT 31.2 Exhibit
Exhibit 31.2
 
CERTIFICATION
 
I, Joseph Talamo, certify that:
 
1.  I have reviewed this Quarterly Report on Form 10-Q of Caladrius Biosciences, Inc.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by  this report based on such evaluation; and
 
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.  The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date: November 9, 2017

 
/s/ Joseph Talamo
Name: Joseph Talamo
Title: Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)


 EX-32.1 4 clbs-ex321_20170930xq3.htm EXHIBIT 32.1 Exhibit
Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Caladrius Biosciences, Inc. (the “Company”) for the quarter ended September 30, 2017 filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David J. Mazzo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:
 

1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and

2.
The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.
 
Dated:  November 9, 2017
 

 
/s/ David J. Mazzo, PhD
 
David J. Mazzo, PhD
 
Chief Executive Officer (Principal Executive Officer)
 
The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.
 



 EX-32.2 5 clbs-ex322_20170930xq3.htm EXHIBIT 32.2 Exhibit
Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Caladrius Biosciences, Inc. (the “Company”) for the quarter ended September 30, 2017 filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Talamo, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:
 

1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and

2.
The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.
 
Dated:  November 9, 2017

 
 
/s/ Joseph Talamo
 
Joseph Talamo
 
Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)
 
The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.
 


 EX-101.INS 6 clbs-20170930.xml XBRL INSTANCE DOCUMENT 0000320017 2017-01-01 2017-09-30 0000320017 2017-11-09 0000320017 2016-12-31 0000320017 2017-09-30 0000320017 2017-07-01 2017-09-30 0000320017 2016-07-01 2016-09-30 0000320017 2016-01-01 2016-09-30 0000320017 us-gaap:ParentMember 2016-09-30 0000320017 us-gaap:ParentMember 2016-01-01 2016-09-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0000320017 us-gaap:NoncontrollingInterestMember 2017-09-30 0000320017 2016-09-30 0000320017 us-gaap:ParentMember 2017-01-01 2017-09-30 0000320017 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-09-30 0000320017 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000320017 us-gaap:TreasuryStockMember 2016-12-31 0000320017 us-gaap:ParentMember 2016-12-31 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0000320017 us-gaap:NoncontrollingInterestMember 2016-12-31 0000320017 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-09-30 0000320017 us-gaap:CommonStockMember 2015-12-31 0000320017 us-gaap:RetainedEarningsMember 2016-12-31 0000320017 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2015-12-31 0000320017 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0000320017 us-gaap:CommonStockMember 2017-09-30 0000320017 us-gaap:CommonStockMember 2016-12-31 0000320017 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2016-12-31 0000320017 us-gaap:ParentMember 2015-12-31 0000320017 us-gaap:RetainedEarningsMember 2017-09-30 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-09-30 0000320017 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2017-09-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0000320017 us-gaap:NoncontrollingInterestMember 2016-09-30 0000320017 us-gaap:TreasuryStockMember 2017-09-30 0000320017 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2016-09-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000320017 us-gaap:RetainedEarningsMember 2016-09-30 0000320017 us-gaap:CommonStockMember 2016-09-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0000320017 us-gaap:TreasuryStockMember 2016-09-30 0000320017 us-gaap:TreasuryStockMember 2015-12-31 0000320017 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0000320017 us-gaap:RetainedEarningsMember 2015-12-31 0000320017 us-gaap:ParentMember 2017-09-30 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0000320017 us-gaap:NoncontrollingInterestMember 2015-12-31 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-09-30 0000320017 2015-12-31 0000320017 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000320017 2017-05-04 0000320017 2016-01-01 2016-03-31 0000320017 clbs:PctAllendaleLlcMember clbs:HitachiChemicalCo.LTDMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember clbs:PCTSegmentMember 2017-05-18 2017-05-18 0000320017 clbs:TheSanfordProjectTRexStudyMember 2016-01-01 2016-03-31 0000320017 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember clbs:PCTSegmentMember 2017-05-18 0000320017 2017-02-23 0000320017 clbs:HitachiChemicalCo.LTDMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember clbs:PCTSegmentMember 2017-03-01 2017-03-31 0000320017 clbs:PctAllendaleLlcMember 2016-03-11 0000320017 clbs:HitachiChemicalCo.LTDMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember clbs:PCTSegmentMember 2017-07-01 2017-07-31 0000320017 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember clbs:PCTSegmentMember 2017-07-01 2017-09-30 0000320017 clbs:HitachiChemicalCo.LTDMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember clbs:PCTSegmentMember 2017-05-18 2017-05-18 0000320017 clbs:HitachiChemicalCo.LTDMember 2016-03-11 0000320017 clbs:PctAllendaleLlcMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0000320017 clbs:RobertA.PretiMember us-gaap:DirectorMember us-gaap:ScenarioForecastMember 2017-05-18 2018-05-18 0000320017 clbs:RobertA.PretiMember us-gaap:DirectorMember 2017-05-18 2017-05-18 0000320017 clbs:PctAllendaleLlcMember 2016-03-11 0000320017 2016-03-11 0000320017 us-gaap:CorporateDebtSecuritiesMember 2017-09-30 0000320017 us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000320017 us-gaap:CertificatesOfDepositMember 2017-09-30 0000320017 us-gaap:MoneyMarketFundsMember 2016-12-31 0000320017 us-gaap:MoneyMarketFundsMember 2017-09-30 0000320017 us-gaap:CertificatesOfDepositMember 2016-12-31 0000320017 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0000320017 us-gaap:WarrantMember 2016-01-01 2016-09-30 0000320017 us-gaap:WarrantMember 2017-01-01 2017-09-30 0000320017 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0000320017 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-09-30 0000320017 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0000320017 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000320017 us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000320017 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000320017 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000320017 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000320017 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000320017 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000320017 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000320017 clbs:LoanandSecurityAgreementMember clbs:OxfordFinanceLLCMember 2016-03-01 2016-03-31 0000320017 clbs:LoanandSecurityAgreementMember clbs:OxfordFinanceLLCMember us-gaap:MaximumMember 2016-03-01 2016-03-31 0000320017 clbs:LoanandSecurityAgreementMember clbs:OxfordFinanceLLCMember us-gaap:LoansPayableMember 2016-12-31 0000320017 clbs:LoanandSecurityAgreementMember clbs:OxfordFinanceLLCMember us-gaap:LoansPayableMember 2016-09-14 2016-09-14 0000320017 us-gaap:NotesPayableOtherPayablesMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0000320017 us-gaap:NotesPayableOtherPayablesMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0000320017 clbs:LoanandSecurityAgreementMember clbs:OxfordFinanceLLCMember us-gaap:LoansPayableMember 2017-09-30 0000320017 clbs:LoanandSecurityAgreementMember clbs:OxfordFinanceLLCMember 2014-09-26 0000320017 clbs:LoanandSecurityAgreementMember clbs:OxfordFinanceLLCMember us-gaap:LoansPayableMember 2016-03-01 2016-03-31 0000320017 clbs:LoanandSecurityAgreementMember clbs:OxfordFinanceLLCMember us-gaap:LoansPayableMember 2017-05-18 2017-05-18 0000320017 clbs:HitachiChemicalCo.LTDMember 2017-05-18 2017-05-18 0000320017 clbs:HitachiChemicalCo.LTDMember 2016-03-11 2016-03-11 0000320017 clbs:UsEquityPlanMember 2016-12-31 0000320017 clbs:UsEquityPlanMember 2017-01-01 2017-09-30 0000320017 clbs:UsEquityPlanMember 2017-09-30 0000320017 clbs:UsEquityPlanMember 2016-01-01 2016-12-31 0000320017 2016-01-01 2016-12-31 0000320017 clbs:PrivatePurchaseAgreementMember 2016-09-14 2016-09-14 0000320017 clbs:AspireCapitalPurchaseAgreementMember 2015-11-30 0000320017 clbs:RDPurchaseAgreementMember 2016-09-14 2016-09-14 0000320017 clbs:AspireCapitalPurchaseAgreementMember 2017-09-30 0000320017 2016-09-14 0000320017 clbs:PrivatePurchaseAgreementMember 2016-09-14 0000320017 clbs:AspireCapitalPurchaseAgreementMember 2015-11-01 2015-11-30 0000320017 clbs:AspireCapitalPurchaseAgreementMember 2017-01-01 2017-09-30 0000320017 2016-07-28 0000320017 clbs:PrivatePurchaseAgreementMember 2017-01-01 2017-03-31 0000320017 clbs:PrivatePurchaseAgreementMember 2017-03-31 0000320017 2016-07-28 2016-07-28 0000320017 clbs:DiscontinuedOperations1Member 2016-01-01 2016-09-30 0000320017 clbs:DiscontinuedOperations1Member 2016-07-01 2016-09-30 0000320017 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0000320017 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0000320017 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-07-01 2016-09-30 0000320017 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0000320017 clbs:DiscontinuedOperations1Member 2017-07-01 2017-09-30 0000320017 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0000320017 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0000320017 clbs:DiscontinuedOperations1Member 2017-01-01 2017-09-30 0000320017 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-09-30 0000320017 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2017-09-30 0000320017 us-gaap:EmployeeStockOptionMember 2017-09-30 0000320017 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0000320017 us-gaap:EmployeeStockOptionMember 2016-06-30 0000320017 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0000320017 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0000320017 us-gaap:RestrictedStockMember 2017-09-30 0000320017 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2017-09-30 0000320017 us-gaap:OtherNoncurrentLiabilitiesMember 2017-09-30 0000320017 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember clbs:PCTSegmentMember 2017-05-18 2017-05-18 0000320017 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember clbs:PCTSegmentMember 2017-01-01 2017-09-30 0000320017 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember clbs:PCTSegmentMember 2016-07-01 2016-09-30 0000320017 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember clbs:PCTSegmentMember 2016-01-01 2016-09-30 iso4217:USD xbrli:shares clbs:clinical_trial_subject xbrli:shares iso4217:USD clbs:warrant xbrli:pure clbs:cohort iso4217:USD 0 0 0 0 0.02 0 -195219 195219 -195219 0 -203145 203145 -203145 388062 218978 125000000 3000000 0.2 1700000 3200000 0.05 4685000 24449000 342000 450000 277000 610000 257000 76193000 6919000 3687000 -3210626 -5823272 P6Y 0.50 P10Y 2 70 P5Y1M13D 0.50 0.50 825000 825000 65000000 4400000 5000000 5000000 12600000 8400000 4000000 4400000 75000000 5000000 1101927.6 4449153 20500000 14700000 4700000 1900000 1900000 0.05 218978 0.801 P24M 1691 0 167393 0 218978 700.00 54.80 0.00 104.50 0.00 76.50 54.80 54.80 P1Y1M24D P1Y2M27D P1Y1M24D P1Y1M24D false --12-31 Q3 2017 2017-09-30 10-Q 0000320017 9470860 Smaller Reporting Company Caladrius Biosciences, Inc. 2226580 879625 5600000 138774 401558 0 -218755 2659433 10135600 2659400 10135700 224500 367300 0 -28717 410372049 433006780 2189400 5001700 1040600 401000 154000 485600 2275600 753000 225000 1297600 62400 0 0 62400 2770700 888900 208200 1673600 0 0 942129 61456 0 362650 1105790 8000 10260 218978 53514442 67555259 24648961 65773702 0 0 0 0 0 44371600 0 44371600 15533043 0 56273200 0 0 0 0 100 0 0 100 0 0 0 0 28800 0 28800 0 4426800 0 0 4426800 56273200 249000 49345600 6678600 56273200 56244500 0 0 4426800 0 0 4426800 56244500 249000 49316800 6678700 4426800 11872900 7076651 15077872 4426800 56244500 18657971 11644065 7076651 20080521 1660440 6962677 7628357 0 18606742 20080521 -1711669 5375513 0 6727263 3941244 -74231 -1247623 -188794 2608615 -638069 0.001 0.001 0.001 500000000 500000000 8205791 9427001 8205791 9427001 8206 9427 -6883019 -26698652 -3457157 25812849 -405072 -522005 -119342 -717665 -7288091 -27220657 -3576499 25095184 1 1 0 1745500 19400000 14733908 4666092 14733908 15000000 0.0850 P3Y P1Y 700000 1100000 0 351226 284005 51744000 0 0 51744000 47000 147000 11608000 3702000 2278000 2927000 26577834 0 6727000 79425000 9482000 25122000 15321000 10529000 2168000 5587000 3251000 7013000 2090000 215000 17000 72000 16000 743000 14900000 10794000 29910000 16039000 1681594 0 -1.09 -4.45 -0.38 2.94 1406300 1169600 39700 4200 0.199 0.21 12200000 5700000 591307 175793 -6031344 -25404351 -3428440 -12056553 -59423 -187126 -119342 -149509 -6090767 -25591477 -5961733 -20507556 -6090767 -25591477 -3547782 -12206062 -0.95 -4.23 -0.38 -1.37 -1196838 -1197000 -1628694 -1629000 0 37329963 37330000 -345649 -334879 0 -568156 -851189 -1293815 0 37898119 -0.13 -0.22 0.00 4.30 0 0 -2413951 -8301494 -14424 262784 -1605550 1681593 -191717 -164788 -871417 -980495 368364 1601421 8687 372099 973729 706231 0 0 0 0 0 44371600 0 44371600 2275616 1881712 300000 1000000 300000 1100000 30047962 14574932 53514442 67555259 21182893 11374778 10925052 0 5791134 0 5700000 3126457 0 2524897 0 159180 0 0 0 44372000 44371615 -817429 -352383 20896315 -754446 16955071 -680215 -2315753 23036191 -1068130 23224985 -20292231 -16906232 -22900846 -16268163 -6882533 -26698166 -3428440 25841566 -363247 -1581862 168168 -234811 700000 400000 563777 359553 5727520 24009615 6129901 20272745 -5727520 -24009615 -6129901 -20272745 3335700 603000 801600 786200 817400 327500 232700000 1028600 544700 1582209 1417439 -486 -486 -486 -28717 -28717 -28717 -486 -486 -28717 -28717 -486 -486 -28717 -28717 389858 3200154 5117 19559 176855 137288 0 357665 0 51724691 1068130 118478 4300000 0.01 0.01 20000000 20000000 10000 10000 10000 10000 100 100 1900493 920008 0 74689814 15000000 0 4000000 6000000 1200000 11650712 5678632 368615 400998 0 7105603 0 13576 -7287605 -27220171 -522005 -26698166 -26698166 -3547782 25123901 -717665 25841566 25841566 705438 364118 30000000 4400000 19400000 19400000 0 7000000 3000000 4900000 9348646 5651354 715610 764402 2958593 13496045 3187024 11190939 0 5002649 -404788809 -378947243 0 2233000 2768927 10513570 2942877 9081806 1900000 1900000 46509 244413 447757 0 8200 952790 1105790 39.90 33.30 8200 1097350 3.25 32.70 1.72 8200 1105336 33.30 300000 4.70 41.20 18.70 11.70 P0Y8M1D P0Y1M17D P7Y7M6D P5Y1M10D P5Y1M10D 319776 4.72 10000 5673302 10000 8181921 10000 8205790 10000 9427001 1500000 847458 2403865 1162831 84269.6 210506 107719 132726 104754 54545 3835 3835 11650712 11648308 2404 11650712 5678632 5677470 1162 5678632 651700 469900 2275616 2275511 105 2275616 2412981 2412926 55 2412981 13576 13572 4 13576 4883909 53332710 23283824 100 486 396547401 5673 -429709 23713533 -372132490 -707637 9989495 100 0 410276001 8182 -756495 10745990 -398830656 -707637 4066480 100 0 410372049 8206 -817429 4883909 -404788809 -707637 52980327 100 -28717 433006780 9427 -352383 53332710 -378947243 -707637 0.1 0 4075600 3686526 3686526 11080 11080 707637 707637 15000000 6323427 6001572 9093880 8803784 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Accrued Liabilities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:675px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:420px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:118px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:106px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Salaries, employee benefits and related taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,169.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,406.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retention payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,233.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">367.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,075.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CIRM upfront funding - current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,745.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">544.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,028.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,135.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,659.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">The Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius Biosciences, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; "our," &#8220;Caladrius&#8221; or the &#8220;Company&#8221;), is a company developing cellular therapeutics to treat certain diseases. We leverage specialized clinical development expertise to select and develop early-stage cell therapy candidates with the intention of developing such candidates to their next significant clinical milestone and, if appropriate, partnering such candidates. Our current lead product candidate, CLBS03, is an autologous polyclonal regulatory T cell ("Treg") clinical phase 2 therapy targeting children aged 8-17 with recent-onset type 1 diabetes mellitus ("T1D"). </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Immunomodulation (Treg Technology)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing strategically, through the utilization of our core clinical development expertise, a product candidate (CLBS03) that has the potential to be an innovative therapy for T1D. This therapy is based on a proprietary platform technology for immunomodulation. We have selected as an initial target the unmet medical need of patients who are newly diagnosed with T1D, most of whom will be under the age of 18. This program is based on the use of Tregs to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg number and function. Tregs are a natural part of the human immune system and regulate the activity of effector T cells, the cells that are responsible for protecting the body from pathogens and foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by effector T cells. In autoimmune disease, however, it is thought that deficient Treg activity and numbers permit the effector T cells to attack the body's own beneficial cells. In the case of T1D, the beta cells in the pancreas are attacked thereby reducing and/or eliminating over time the patient's ability to produce insulin. Insulin is necessary to regulate sugar metabolism and maintain proper sugar levels in the blood. Inconsistent or unnatural insulin levels can lead to many complications, including blindness, vascular disease and, if no insulin supplement is provided, even death. There are currently no curative treatments for TID, only lifelong insulin therapy, which often does not prevent serious co-morbidities. Two Phase 1 clinical trials of Treg technology in T1D demonstrated safety and tolerance, feasibility of manufacturing, an implied durability of effect as well as an early indication of potential therapeutic effect through the preservation of beta cell function. In the first quarter of 2016, we commenced patient enrollment in the first of </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> cohorts in The Sanford Project: T-Rex Study, a Phase 2 prospective, randomized, placebo-controlled, double-blind clinical trial (the "TRex Study") to evaluate the safety and efficacy of CLBS03 in adolescents with recent onset TID. In October 2016, we received a satisfactory safety evaluation by our independent Data Safety Monitoring Board based on safety data then available from the first 19 patients enrolled in the trial. A subsequent interim analysis is planned after approximately </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of patients reach the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">-month follow-up milestone, the results of which are expected to be publicly available by the mid to late first quarter of 2018. We entered into a strategic collaboration with Sanford Research to support the execution of this trial. Sanford Research is a U.S.-based non-profit research organization that supports an emerging translational research center focused on finding a cure for T1D. On February 23, 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to </font><font style="font-family:inherit;font-size:10pt;">$12.2 million</font><font style="font-family:inherit;font-size:10pt;"> to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;"> in initial funding on May 4, 2017. CLBS03 has been granted Fast Track and orphan drug designations from the U.S. Food and Drug Administration ("FDA") as well as Advanced Therapeutic Medicinal Product ("ATMP") classification from the European Medicines Agency ("EMA").</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Ischemic Repair (CD34 Cell Technology)</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our CD34 cell technology has led to the development of therapeutic candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Through the administration of CD34 cells, we seek to promote the development and formation of new blood vessels and thereby increase blood flow to the impacted area. We believe that conditions caused by underlying ischemic injury can be improved through our CD34 cell technology, including critical limb ischemia ("CLI"). Published reports in Circulation Cardiovascular Interventions, Atherosclerosis, Stem Cells and Circulation Journal, provide preliminary evidence that CD34 cell therapy is safe and can exert significant therapeutic effects in patients with CLI, a condition in which blood flow to the legs is severely impaired, causing pain and non-healing ulcers and, ultimately, potentially resulting in the need for amputation. Our Clinical Trial Notification for a pivotal Phase 2 trial investigating our product candidate in CLI CLBS12 was submitted to the Japanese Pharmaceutical and Medical Device Agency ("PMDA") and was cleared to proceed. The protocol design was agreed to with PMDA and, we intend to begin enrolling patients in late 2017 or early 2018. Under our agreement with the PMDA, a successful outcome of this trial would make CLBS12 eligible for early conditional approval in Japan. We are seeking to collaborate on CLBS12 with development and/or manufacturing partners. Furthermore, we submitted grant applications in an effort to seek non-dilutive financing to investigate the CD34 technology for additional clinical indications in the United States and on October 2, 2017 we announced receipt of a $1.9M grant award from the National Institutes of Health to support a clinical study of CD34 cells in patients with coronary microvascular dysfunction.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to develop this platform if capital becomes available through grants, partnerships or licensing, as well as potentially using reasonable amounts of our own capital.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Additional Out-licensing Opportunities</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. These include additional indications for our Treg product, additional indications for our CD34 cell technology and a platform using tumor cell/dendritic cell technology for immuno-oncology application. The immuno-oncology program has the benefit of promising Phase 2 clinical data and applicability to multiple indications. In 2016, we completed multiple out-licensing agreements for this and other technology platforms in an effort to monetize non-core assets. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current long-term strategy focuses on advancing our therapies through development toward the market and assisting patients suffering from life-threatening medical conditions. We believe that we are positioned to realize potentially meaningful value increases within our own proprietary pipeline based on the realization of advancing our product candidates to their next significant development milestone. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Discontinued Operations</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">May&#160;18, 2017</font><font style="font-family:inherit;font-size:10pt;"> (the "Closing Date"), we completed the previously announced sale of our remaining </font><font style="font-family:inherit;font-size:10pt;">80.1%</font><font style="font-family:inherit;font-size:10pt;"> membership interest in PCT, LLC, a Caladrius company ("PCT") to Hitachi Chemical Co. America, Ltd. ("Hitachi"), pursuant to the Interest Purchase Agreement (the "Purchase Agreement"), dated as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;16, 2017</font><font style="font-family:inherit;font-size:10pt;">, by and among us, PCT and Hitachi (the "2017 Hitachi Transaction"), for </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, plus an additional cash adjustment based on PCT&#8217;s cash and outstanding indebtedness as of the Closing Date ("Additional Consideration") and a potential future milestone payment (see Note 3). The sale of PCT represents a strategic shift that has a major effect on our operations, and therefore, PCT is accounted for as discontinued operations. All periods presented were adjusted to reflect PCT as discontinued operations. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> included in our 2016 Form 10-K. Operating results for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining useful lives of our long-lived assets, allowances for doubtful accounts, and stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An accounting policy is considered to be critical if it is important to the Company&#8217;s financial condition and results of operations and if it requires management&#8217;s most difficult, subjective and complex judgments in its application. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly-owned and partially-owned subsidiaries and affiliates, as well as the operations of our former subsidiaries PCT, LLC, a Caladrius company, NeoStem Family Storage, LLC, and PCT Allendale, LLC entities (collectively the "PCT Segment") through May 18, 2017, representing the date which these entities were sold to Hitachi (see Note 3). The PCT Segment is reported in discontinued operations. All intercompany activities have been eliminated in consolidation, except for intercompany activities between Caladrius and the PCT Segment, which are reported without intercompany eliminations in continuing operations and discontinued operations, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Redeemable Securities</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the 2016 Hitachi Transaction (see Note 3), Hitachi had the right, at any time following the tenth anniversary of the 2016 Hitachi Transaction to require Caladrius or PCT to purchase all or some of the equity securities in PCT then held by Hitachi ("Hitachi Put Right") for an amount equal to the lesser of (i) the fair market value of the Hitachi equity holdings and (ii) the original purchase price paid of </font><font style="font-family:inherit;font-size:10pt;">$19.4 million</font><font style="font-family:inherit;font-size:10pt;"> on March 11, 2016 for its </font><font style="font-family:inherit;font-size:10pt;">19.9%</font><font style="font-family:inherit;font-size:10pt;"> ownership interest, plus interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum compounded annually; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:10pt;">, that if Hitachi ownership interests increased subsequent to its initial ownership interest, and it offers to sell its equity holdings in excess of </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;"> of PCT&#8217;s outstanding equity securities, then the Company would be required to purchase all such equity holdings of Hitachi but in no event would the aggregate purchase price of such Hitachi equity holdings exceed </font><font style="font-family:inherit;font-size:10pt;">$20.5 million</font><font style="font-family:inherit;font-size:10pt;"> plus interest at the rate of </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum compounded annually.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, since Hitachi had the right to deliver the equity interests in PCT it held in exchange for cash from Caladrius or PCT, the initial </font><font style="font-family:inherit;font-size:10pt;">$19.4 million</font><font style="font-family:inherit;font-size:10pt;"> value of the non-controlling interest was considered redeemable equity, requiring it to be treated as mezzanine equity. Redeemable non-controlling interest is required to be initially measured at the initial carrying amount. If the non-controlling interest is not currently redeemable and also not probable of becoming redeemable (e.g., it is not probable a contingency that triggers redemption will be met), the non-controlling interest should be classified in mezzanine equity.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concurrent with 2017 Hitachi Transaction (see Note 3), the Hitachi Put Right was eliminated, and </font><font style="font-family:inherit;font-size:10pt;">$14.7 million</font><font style="font-family:inherit;font-size:10pt;"> previously classified as Redeemable Securities was classified to Additional Paid in Capital. In addition, the remaining portion classified as Redeemable Securities of </font><font style="font-family:inherit;font-size:10pt;">$4.7 million</font><font style="font-family:inherit;font-size:10pt;"> was classified to Non-Controlling Interests, representing Hitachi's ownership interest in PCT at the time of the 2016 Hitachi Transaction, which was subsequently eliminated upon the 2017 Hitachi transaction and included the PCT gain on sale.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Available-for-Sale-Securities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td style="width:170px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:17px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Estimated Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certificate of deposits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">249.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">249.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49,345.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49,316.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,678.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,678.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,426.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,426.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,273.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,244.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,426.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,426.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:482px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:83px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:83px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,872.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,426.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,371.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,244.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,426.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:485px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less than one year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,273.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,244.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Greater than one year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,273.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,244.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Commitments and Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lease Commitments</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We lease facilities under various operating lease agreements in Basking Ridge, NJ, New York, NY, and Irvine, CA, of which certain leases have escalation clauses and renewal options. We also lease equipment under certain noncancelable operating leases. Our leases expire from time to time through 2021. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">327.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">817.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">801.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021 and thereafter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">603.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,335.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expense incurred under operating leases was approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. Expense incurred under operating leases was approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into a strategic collaboration with Sanford Research with the goal of developing a therapy for the treatment of T1D. The initial focus of the collaboration will be the execution of a prospective, randomized, placebo-controlled, double-blind clinical trial (The Sanford Project: T-Rex Study) to evaluate the safety and efficacy of the Company&#8217;s T regulatory cell product candidate, CLBS03, in adolescents with recent onset T1D. The Phase 2 study has an open and active IND in place and subject enrollment commenced in the first quarter of 2016. We were initially responsible for the supply of all study drug to the first </font><font style="font-family:inherit;font-size:10pt;">19</font><font style="font-family:inherit;font-size:10pt;"> enrolled patients while Sanford assumed all patient and clinical site costs for subjects enrolled in their two centers as well as the expense associated with general clinical monitoring services. For the remaining </font><font style="font-family:inherit;font-size:10pt;">92</font><font style="font-family:inherit;font-size:10pt;"> patients in the study, we will continue to be responsible for the supply of all study drug and the costs of study enrollment for sites outside of the Sanford centers.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risks</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to credit risk from our portfolio of cash, cash equivalents, restricted cash, and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Debt</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Notes Payable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had notes payable of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Long-Term Debt</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 26, 2014, the Company entered into a loan and security agreement (the &#8220;Loan and Security Agreement&#8221;) with Oxford Finance LLC (together with its successors and assigns, the &#8220;Lender&#8221;) pursuant to which the Lender disbursed </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Loan&#8221;). The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and will be amortized to interest expense throughout the life of the Loan using the effective interest rate method. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, concurrent with the 2016 Hitachi Transaction (see Note 3), the Company and the Lender entered into an amendment to the Loan and Security Agreement whereby (i) the Company paid </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;"> to Lender, comprising principal, interest and early termination fees, (ii) the Company's subsidiaries PCT, PCT Allendale, LLC, and NeoStem Family Storage, LLC (collectively the "Removed Borrowers") were removed as borrowers under the Loan, (iii) Lender's security interests in any and all assets of the Removed Borrowers were released, (iv) the interest only period on the remaining outstanding Loan balance was extended until January 1, 2017, and (v) in the event the Company received gross proceeds from the sale or issuance of any equity securities or subordinated debt, or any partnership, licenses, collaboration, dividend, grant or asset sale through March&#160;31, 2017, </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> of such proceeds will be paid to Lender, up to a </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> maximum as additional partial repayment of Loan. On September 14, 2016, concurrent with the Company's September 2016 Registered Direct Offering and Concurrent Private Placement (see Note 10), the Company repaid </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> of such proceeds to the Lender. The outstanding balance was approximately </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, concurrent with the 2017 Hitachi Transaction (see Note 3), the Company retired the Loan in full, and paid </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> to Lender, comprising principal, interest and early termination fees. The Company was making interest-only payments on the outstanding amount of the Loan on a monthly basis at a rate of </font><font style="font-family:inherit;font-size:10pt;">8.50%</font><font style="font-family:inherit;font-size:10pt;"> per annum. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> of interest expense related to the Loan and Security Agreement. During the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> of interest expense, respectively, related to the Loan and Security Agreement.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Share-Based Compensation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-based Compensation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We utilize share-based compensation in the form of stock options, warrants, restricted stock, and restricted stock units.&#160; The following table summarizes the components of share-based compensation expense for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,673.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,297.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">401.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">888.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">753.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,040.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,770.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,275.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The approval of the 2017 Hitachi Transaction (see Note 3) by our stockholders resulted in a change in control under our equity compensation plans (as defined in the 2009 Plan and the 2015 Equity Plan, and, together with the 2009 Plan, the &#8220;Equity Compensation Plans&#8221;). Accordingly, all outstanding unvested equity awards were accelerated upon the Closing Date, resulting in an acceleration of </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;"> of equity compensation in the second quarter of 2017. In addition, in connection with the 2017 Hitachi Transaction, the Company agreed to extend the post-termination option exercise period for all PCT employees transitioning to Hitachi from 90 days to the earlier of (i) two years (May 18, 2019) or (ii) the date of the employees' termination from PCT. The post-termination option exercise period modification resulted in an additional expense of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, which was recorded entirely during the three months ended June 30, 2017 and recorded in discontinued operations, since there were no future service requirements to receive the extended benefit.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Restricted Stock</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized compensation cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected weighted-average period in years of compensation cost to be recognized</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:505px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:71px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:71px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Options</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of shares vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,001.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,189.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average estimated fair value of shares granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Valuation Assumptions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Restricted Stock</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized compensation cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected weighted-average period in years of compensation cost to be recognized</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Discontinued Operations</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PCT Segment</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">May&#160;18, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company completed the previously announced Sale of its remaining </font><font style="font-family:inherit;font-size:10pt;">80.1%</font><font style="font-family:inherit;font-size:10pt;"> membership interest in PCT to Hitachi. Pursuant to the Purchase Agreement, by and among Caladrius, PCT and Hitachi, the aggregate purchase price to the Company consisted of (i) </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, (ii) a </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> cash adjustment, based on PCT&#8217;s cash and outstanding indebtedness as of the Closing Date, and (iii) a potential future milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> if PCT achieves </font><font style="font-family:inherit;font-size:10pt;">$125 million</font><font style="font-family:inherit;font-size:10pt;"> in Cumulative Revenue (excluding clinical service reimbursables) (the &#8220;Milestone&#8221;) for the period from January 1, 2017 through December 31, 2018 (the &#8220;Milestone Period&#8221;). The Company has determined that the fair value of the milestone payment as of the closing date was valued at zero.&#160; </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of the Purchase Agreement, Hitachi paid the Company </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> in March 2017 as an advance payment pending shareholder approval of the transaction and other closing conditions included in the Purchase Agreement. On the Closing Date, the Company received </font><font style="font-family:inherit;font-size:10pt;">$65.0 million</font><font style="font-family:inherit;font-size:10pt;">, with an additional </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against Caladrius. In June 2018, the escrow agent will disburse to the Company the Escrow Amount less (i) that portion of the Escrow Amount previously paid in satisfaction of claims for indemnification pursuant to the terms of the Purchase Agreement and (ii) that portion of the Escrow Amount that is determined, in the reasonable judgment of Hitachi, to be necessary to satisfy all unsatisfied or disputed claims for indemnification specified in any claim notice delivered to the Company. The Company also received the additional </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> cash adjustment payment in July 2017. The Company incurred approximately </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> in transaction costs related to the Sale, including </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> in retention payments to PCT employees, of which </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> was paid in June 2017, and the other </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> payable on the one year anniversary of the Closing Date.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized the following gain on the date of sale of its </font><font style="font-family:inherit;font-size:10pt;">80.1%</font><font style="font-family:inherit;font-size:10pt;"> interest in PCT (in thousands):</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of consideration received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction and retention costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,919</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Carrying value of segment non-controlling interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,193</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less carrying amount of assets and liabilities sold:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,727</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,090</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,278</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due from Caladrius</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unearned revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(342</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,449</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of PCT</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The operations and cash flows of the PCT Segment were eliminated from ongoing operations with the sale of the Company's PCT Interest. The operating results of the PCT Segment for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:678px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:400px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:95px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:67px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:67px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,482</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,321</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,168</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,251</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,587</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,608</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(147</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of segment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,330</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Loss Per Share</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred net losses from continuing operations and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company excluded the following potentially dilutive securities:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,105,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">942,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">218,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,260</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands).</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="33" rowspan="1"></td></tr><tr><td style="width:157px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:18px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities - available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,371.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,371.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,371.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,371.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Fair Value Measurements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands).</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="33" rowspan="1"></td></tr><tr><td style="width:157px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:18px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:47px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities - available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,371.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,371.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,371.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,371.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Income Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$232.7 million</font><font style="font-family:inherit;font-size:10pt;"> of federal net operating loss carryforwards ("NOLs") available to offset future taxable income expiring from 2027 through 2036.&#160;In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.&#160; If a change of ownership did occur, there would be an annual limitation on the usage of the Company&#8217;s losses, which are available through 2036.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In assessing the ability to realize deferred tax assets, including the NOLs, the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.&#160; During the quarter ended June 30, 2017, the Company generated a gain from the sale of </font><font style="font-family:inherit;font-size:10pt;">80.1%</font><font style="font-family:inherit;font-size:10pt;"> of their ownership in PCT. The gain from the sale of PCT is included in discontinued operations. The Company for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> has generated losses from continuing operations and has forecasted losses for the remainder of the year. Based on generating taxable income for the 2017 year, the Company will utilize net operating losses which were offset by a full valuation allowance. The Company anticipates that they will maintain a valuation allowance on the remaining deferred tax assets at the end of the year.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities were </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, and relate to the taxable temporary differences on the goodwill recognized in the PCT acquisition in 2011. The taxable temporary differences, which were tax deductible and were to be amortized over 15 years. The deferred tax liability was reversed during the three months ended June 30, 2017, as a result of the divestiture of PCT.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company applies ASC 740-10 for uncertain tax positions. The Company utilizes the two step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has both continuing and discontinued operations. ASC 740-20-45-7 addresses the income tax accounting treatment when there is a loss from continuing operations and income from discontinuing operations. The Company must consider the gain from discontinued operations for purposes of allocating a tax benefit to the current year loss from continuing operations. The Company has adopted a method in which the income from discontinued operations are recognized as a discrete item in the period in which it occurs and apply the concepts of the annual effective tax rate (AETR) during each period in computing the income tax provision from continuing operations. This method results in a tax expense for discontinued operations and an income tax benefit for the loss generated from continuing operations. The Company is forecasting losses from continuing operations for the remainder of 2017 against which an income tax benefit will be recorded.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company completed the audit of its federal tax returns for the years 2012 and 2013 during the fourth quarter of 2016. The audit resulted in an adjustment to the Company's NOL carryforward. For years prior to 2014, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from date of filing. The Company ceased doing business in China in 2012.&#160; After 2012, the Company had no foreign tax filing obligations.&#160; The foreign returns filed for 2012 and prior are subject to examination for five years.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:485px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less than one year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,273.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,244.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Greater than one year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,273.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,244.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:482px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:83px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:83px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,872.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,426.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,371.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,244.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,426.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Collaboration and License Agreement</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2016 Hitachi Transaction</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March&#160;11, 2016, PCT entered into a global collaboration with Hitachi. This collaboration consists of an equity investment in and a license agreement with PCT. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the equity investment agreement, Hitachi purchased a </font><font style="font-family:inherit;font-size:10pt;">19.9%</font><font style="font-family:inherit;font-size:10pt;"> membership interest in PCT for </font><font style="font-family:inherit;font-size:10pt;">$19.4 million</font><font style="font-family:inherit;font-size:10pt;"> of which </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> of proceeds was distributed to Caladrius from PCT and </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> remained at PCT to be used for the continued expansion and improvements at PCT in support of commercial product launch readiness as well as for general corporate purposes. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PCT and Hitachi also entered into an exclusive license agreement for the acceleration of the creation of a global commercial cell therapy development and manufacturing expertise in Asia pursuant to which PCT received </font><font style="font-family:inherit;font-size:10pt;">$5.6 million</font><font style="font-family:inherit;font-size:10pt;"> from Hitachi in 2016. PCT licensed certain cell therapy technology and know-how (including an exclusive license in Asia) and agreed to provide Hitachi Chemical with certain training and support.&#160; As additional consideration, Hitachi Chemical agreed to pay PCT royalties on contract revenue generated in Asia for a minimum of </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017 Hitachi Transaction</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">May&#160;18, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company sold its remaining </font><font style="font-family:inherit;font-size:10pt;">80.1%</font><font style="font-family:inherit;font-size:10pt;"> membership interest in PCT to Hitachi pursuant to the Purchase Agreement, dated as of March 16, 2017, by and among Caladrius PCT and Hitachi (the "2017 Hitachi Transaction"). The aggregate purchase price to the Company consisted of (i) </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, (ii) </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;">, representing Additional Consideration based on PCT&#8217;s cash and outstanding indebtedness as of the Closing Date, and (iii) a potential future milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> if PCT achieves </font><font style="font-family:inherit;font-size:10pt;">$125 million</font><font style="font-family:inherit;font-size:10pt;"> in Cumulative Revenue (excluding clinical service reimbursables) (the &#8220;Milestone&#8221;) for the period from January 1, 2017 through December 31, 2018 (the &#8220;Milestone Period&#8221;). </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hitachi paid the Company </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> in March 2017 as an advance payment pending shareholder approval of the transaction and other closing conditions. On the Closing Date, the Company received </font><font style="font-family:inherit;font-size:10pt;">$65.0 million</font><font style="font-family:inherit;font-size:10pt;">, with an additional </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against Caladrius. The Escrow Amount is classified as restricted cash on the balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. In June 2018, the escrow agent will disburse to the Company the Escrow Amount less (i) that portion of the Escrow Amount previously paid in satisfaction of claims for indemnification pursuant to the terms of the Purchase Agreement and (ii) that portion of the Escrow Amount that is determined, in the reasonable judgment of Hitachi, to be necessary to satisfy all unsatisfied or disputed claims for indemnification specified in any claim notice delivered to the Company. The Company also received the </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> Additional Consideration payment in July 2017. The Company incurred approximately </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> in transaction costs related to the 2017 Hitachi Transaction, including </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> in retention payments to PCT employees, of which </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> was paid in June 2017, and the other </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> payable on the one year anniversary of the Closing Date.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concurrent with the signing of the Purchase Agreement, on March&#160;16, 2017, Caladrius entered into a Retention and Incentive Agreement with Robert A. Preti, a former Caladrius director and a co-founder and the President of PCT, (the &#8220;Retention Agreement&#8221;). The Retention Agreement superseded all prior agreements and understandings between Dr. Preti and Caladrius regarding the subject matter of the Retention Agreement. Among other things, the Retention Agreement provided for:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Simultaneously with the closing of the 2017 Hitachi Transaction, Caladrius paid to Dr.</font><font style="font-family:inherit;font-size:9pt;"> </font><font style="font-family:inherit;font-size:10pt;">Preti </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;First Retention Payment&#8221;). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As an incentive to remain employed with PCT and to use commercially reasonable efforts to cause PCT to maximize its overall performance and in particular to achieve the Milestone (but not contingent upon achieving the Milestone), Dr. Preti will receive a lump-sum cash retention and incentive payment equal to </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the period from the Closing Date until the date one year after the date of the Closing Date (the &#8220;Anniversary Date&#8221;), subject to Dr. Preti&#8217;s continued employment with PCT through the Anniversary Date (the &#8220;Second Retention Payment&#8221;). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Preti will be entitled to </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of the Milestone Payment if it is successfully earned.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02,&#160;Leases (Topic 842). This ASU requires that a lessee recognize lease assets and lease liabilities for those leases classified as operating leases. The guidance is effective for interim and annual periods beginning after December 15, 2018, and will be applied at the beginning of the earliest period presented using a modified retrospective approach. This ASU may have a material impact on the Company&#8217;s financial statements. The impact on the Company&#8217;s results of operations is currently being evaluated. The impact of the ASU is non-cash in nature and will not affect the Company&#8217;s cash position.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09,&#160;Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting for forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance was effective for interim and annual periods beginning after December 15, 2016. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU&#160;2016-15&#160;is effective in first quarter of fiscal 2018 and earlier adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized as current period income tax expense or benefit at the transaction date and removes the option to defer and amortize the consolidated tax consequences of intra-entity transfers. The new standard will be effective on January 1, 2018 and will be adopted using a modified retrospective approach which requires a cumulative effect adjustment to retained earnings as of the beginning of the period of adoption. Early adoption is permitted at the beginning of a fiscal year. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard will be effective on January 1, 2018 and the Company has been early adopted, with all adjustments reflected as of the beginning of the fiscal years reported. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In May 2017, the FASB issued ASU&#160;2017-09,&#160;"Compensation &#8211; Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU&#160;2017-09&#160;also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. For all entities, including emerging growth companies, the standard is effective for annual periods beginning after December 15, 2017, and for interim periods therein. Early adoption is permitted. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Research Funding</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">California Institute of Regenerative Medicine Grant Award</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to </font><font style="font-family:inherit;font-size:10pt;">$12.2 million</font><font style="font-family:inherit;font-size:10pt;"> to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;"> in initial funding in May 2017, which will be amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses. As of September 30, 2017, </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> of the funding received is recorded in Accrued Liabilities, representing the amount expected to be recognized over the next 12 months, and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> of the funding received is recorded in Other Long-Term Liabilities. During the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company amortized and recognized a </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> credit to research and development related to CIRM funds received.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:675px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:420px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:118px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:106px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Salaries, employee benefits and related taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,169.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,406.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retention payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,233.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">367.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,075.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CIRM upfront funding - current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,745.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">544.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,028.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,135.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,659.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company excluded the following potentially dilutive securities:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,105,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">942,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">218,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,260</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td style="width:170px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:17px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:46px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Estimated Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certificate of deposits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">249.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">249.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49,345.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49,316.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,678.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,678.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,426.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,426.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,273.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,244.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,426.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,426.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized the following gain on the date of sale of its </font><font style="font-family:inherit;font-size:10pt;">80.1%</font><font style="font-family:inherit;font-size:10pt;"> interest in PCT (in thousands):</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of consideration received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction and retention costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,919</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Carrying value of segment non-controlling interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,193</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less carrying amount of assets and liabilities sold:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,727</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,090</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,278</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due from Caladrius</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unearned revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(342</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,449</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of PCT</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The operations and cash flows of the PCT Segment were eliminated from ongoing operations with the sale of the Company's PCT Interest. The operating results of the PCT Segment for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:678px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:400px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:95px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:67px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:67px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,482</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,321</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,168</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,251</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,587</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,608</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(147</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of segment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,330</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the components of share-based compensation expense for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,673.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,297.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">401.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">888.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">753.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,040.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,770.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,275.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">327.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">817.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">801.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021 and thereafter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">603.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,335.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company issued restricted stock for services as follows (in thousands, except share data):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:498px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:72px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:72px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of restricted stock issued</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132,726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value of restricted stock issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">469.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">651.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the activity for stock options and warrants for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Stock Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Weighted Average Remaining Contractual Term (Years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Aggregate Intrinsic Value (In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Weighted Average Remaining Contractual Term (Years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Aggregate Intrinsic Value (In Thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">952,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">39.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">388,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">76.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Changes during the period:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">447,757</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(244,413</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,691</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">700.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Expired</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(46,509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">41.20</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(167,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">104.50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding at September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,105,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">33.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">218,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">54.80</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Vested at September 30, 2017<br clear="none"/> or expected to vest in the future</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,105,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">33.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">218,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">54.80</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Vested at September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,097,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">32.70</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">218,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">54.80</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:505px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:71px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:71px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Options</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of shares vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,001.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,189.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average estimated fair value of shares granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company expenses all share-based payment awards to employees, directors, consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our 2016 Form 10-K. There were no changes to these policies during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risks</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to credit risk from our portfolio of cash, cash equivalents, restricted cash, and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company expenses all share-based payment awards to employees, directors, consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02,&#160;Leases (Topic 842). This ASU requires that a lessee recognize lease assets and lease liabilities for those leases classified as operating leases. The guidance is effective for interim and annual periods beginning after December 15, 2018, and will be applied at the beginning of the earliest period presented using a modified retrospective approach. This ASU may have a material impact on the Company&#8217;s financial statements. The impact on the Company&#8217;s results of operations is currently being evaluated. The impact of the ASU is non-cash in nature and will not affect the Company&#8217;s cash position.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09,&#160;Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting for forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance was effective for interim and annual periods beginning after December 15, 2016. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU&#160;2016-15&#160;is effective in first quarter of fiscal 2018 and earlier adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized as current period income tax expense or benefit at the transaction date and removes the option to defer and amortize the consolidated tax consequences of intra-entity transfers. The new standard will be effective on January 1, 2018 and will be adopted using a modified retrospective approach which requires a cumulative effect adjustment to retained earnings as of the beginning of the period of adoption. Early adoption is permitted at the beginning of a fiscal year. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard will be effective on January 1, 2018 and the Company has been early adopted, with all adjustments reflected as of the beginning of the fiscal years reported. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In May 2017, the FASB issued ASU&#160;2017-09,&#160;"Compensation &#8211; Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU&#160;2017-09&#160;also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. For all entities, including emerging growth companies, the standard is effective for annual periods beginning after December 15, 2017, and for interim periods therein. Early adoption is permitted. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Shareholders' Equity</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">July&#160;28, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on June 22, 2016 and unanimously approved by the Company&#8217;s board of directors on </font><font style="font-family:inherit;font-size:10pt;">July&#160;22, 2016</font><font style="font-family:inherit;font-size:10pt;">. The Reverse Stock Split became effective on July 27, 2016 at 5:00 pm and the common stock of the Company began trading on The NASDAQ Capital Market on a post-split basis at the open of business on </font><font style="font-family:inherit;font-size:10pt;">July&#160;28, 2016</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">July&#160;28, 2016</font><font style="font-family:inherit;font-size:10pt;">, every ten shares of the Company&#8217;s issued and outstanding common stock were combined into one share of its common stock, except to the extent that the Reverse Stock Split resulted in any of the Company&#8217;s stockholders owning a fractional share, which was rounded up to the next highest whole share. In connection with the Reverse Stock Split, there was no change in the nominal par value per share of </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;Additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Issuances</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">September 2016 Registered Direct Offering and Concurrent Private Placement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 14, 2016, the Company entered into a securities purchase agreement (the &#8220;RD Purchase Agreement&#8221;) with a single institutional investor (the &#8220;Purchaser&#8221;), pursuant to which the Company issued and sold to the Purchaser, in a registered direct offering, an aggregate of </font><font style="font-family:inherit;font-size:10pt;">847,458</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$4.72</font><font style="font-family:inherit;font-size:10pt;"> per share. The gross proceeds to the Company from the registered direct offering of the shares of common stock were </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In concurrent private placements, on September 14, 2016, the Company entered into Securities Purchase Agreements (each a &#8220;Private Placement Purchase Agreement&#8221; and, collectively, the &#8220;Private Placement Purchase Agreements&#8221;) with certain accredited investors (the &#8220;Investors&#8221;) with whom it had a substantive, pre-existing relationship, including certain existing stockholders, for the sale by the Company of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">4,449,153</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock, at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$4.72</font><font style="font-family:inherit;font-size:10pt;"> per share. The investments were placed in two tranches: (i) </font><font style="font-family:inherit;font-size:10pt;">$12.6 million</font><font style="font-family:inherit;font-size:10pt;"> upon an initial closing (the &#8220;Initial Closing&#8221;), and (ii) </font><font style="font-family:inherit;font-size:10pt;">$8.4 million</font><font style="font-family:inherit;font-size:10pt;">, subject to certain conditions, including the enrollment of </font><font style="font-family:inherit;font-size:10pt;">70</font><font style="font-family:inherit;font-size:10pt;"> subjects in the Company&#8217;s Phase 2 CLBS03 clinical trial, in a second closing (the &#8220;Second Closing&#8221;). As of March 31, 2017, </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the Initial Closing tranche had not been received from a single investor, who was in breach of his obligations under the Private Placement Purchase Agreement.&#160;This investor had also committed to fund </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the Second Closing. As a result, the Company terminated the Private Placement Purchase Agreement with this investor in the first quarter of 2017. In 2017, the Company met the conditions of the Second Closing, and received the remaining </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> in proceeds in accordance with the terms of the Second Closing tranche and issued </font><font style="font-family:inherit;font-size:10pt;">932,204</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Aspire Purchase Agreements </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with Aspire Capital Fund, LLC, an Illinois limited liability company (&#8220;Aspire Capital&#8221;), which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$30 million</font><font style="font-family:inherit;font-size:10pt;"> of shares (limited to a maximum of approximately </font><font style="font-family:inherit;font-size:10pt;">1.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares, unless stockholder approval is obtained or certain minimum sale price levels are reached) of the Company's common stock over a </font><font style="font-family:inherit;font-size:10pt;">24</font><font style="font-family:inherit;font-size:10pt;">-month term.&#160;As consideration for entering into the Purchase Agreement, the Company issued </font><font style="font-family:inherit;font-size:10pt;">84,270</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock to Aspire Capital. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company issued </font><font style="font-family:inherit;font-size:10pt;">210,506</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the Purchase Agreement for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">. Overall, as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has issued </font><font style="font-family:inherit;font-size:10pt;">319,776</font><font style="font-family:inherit;font-size:10pt;"> shares under the Purchase Agreement for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Purchase Agreement, at the Company&#8217;s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company&#8217;s common stock, provided certain price, trading volume and conditions, including NASDAQ's trading requirements, are met. The purchase price for the shares of common stock is based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company&#8217;s common stock (in the case of regular purchases) or a discount of </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreements. We have filed a registration statement with the SEC and a related prospectus supplement that covers the offering of shares of our common stock subject to the Purchase Agreement, and therefore can initiate sales to Aspire Capital at any time, subject to the limitation discussed above.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options and Warrants</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the activity for stock options and warrants for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Stock Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Weighted Average Remaining Contractual Term (Years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Aggregate Intrinsic Value (In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Weighted Average Remaining Contractual Term (Years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Aggregate Intrinsic Value (In Thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">952,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">39.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">388,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">76.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Changes during the period:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">447,757</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(244,413</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,691</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">700.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Expired</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(46,509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">41.20</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(167,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">104.50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding at September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,105,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">33.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">218,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">54.80</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Vested at September 30, 2017<br clear="none"/> or expected to vest in the future</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,105,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">33.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">218,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">54.80</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Vested at September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,097,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">32.70</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">218,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">54.80</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock</font></div><div style="line-height:120%;text-align:justify;text-indent:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company issued restricted stock for services as follows (in thousands, except share data):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:498px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:72px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:72px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of restricted stock issued</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132,726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value of restricted stock issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">469.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">651.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> EX-101.SCH 7 clbs-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2112100 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Available-for-Sale-Securities link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Available-for-Sale-Securities Available-for-Sale Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Available-for-Sale-Securities Classification of Available-for-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Available-for-Sale-Securities Schedule of Available-for-Sale Securities Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Available-for-Sale-Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - The Business link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - The Business Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - The Business Immunomodulation (Treg Technology) (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Collaboration and License Agreement link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Collaboration and License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2155100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2455402 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2355301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Equity link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2154100 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 2454403 - Disclosure - Discontinued Operations Gain on Sale of Discontinued Operation (Details) link:presentationLink link:calculationLink link:definitionLink 2454404 - Disclosure - Discontinued Operations Operating Results of PCT Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2454402 - Disclosure - Discontinued Operations PCT Segment Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2354301 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Fair Value Measurements Assets Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2152100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2452401 - Disclosure - Income Taxes Net Operating Loss Carry Forward (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Redeemable Securities link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - Redeemable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2151100 - Disclosure - Research Funding link:presentationLink link:calculationLink link:definitionLink 2451401 - Disclosure - Research Funding (Details) link:presentationLink link:calculationLink link:definitionLink 2150100 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2450402 - Disclosure - Share-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2350301 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Shareholders' Equity - Equity Issuances (Details) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Shareholders' Equity - Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Shareholders' Equity - Reverse Stock Split (Details) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Shareholders' Equity - Stock options and warrants (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 clbs-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 clbs-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 clbs-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt Disclosure [Abstract] Debt Debt Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Discontinued Operations and Disposal Groups [Abstract] Schedule of Disposal Groups, Including Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Accrued Liabilities [Abstract] Accrued Liabilities Accrued Liabilities [Text Block] Accrued Liabilities [Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Discontinued Operations [Member] Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] PCT Segment [Member] PCT Segment [Member] PCT Segment [Member] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Director [Member] Director [Member] Statement, Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Forecast [Member] Scenario, Forecast [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] PCT Allendale, LLC [Member] PCT Allendale, LLC [Member] PCT Allendale, LLC [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Hitachi Chemical Co., LTD [Member] Hitachi Chemical Co., LTD [Member] Hitachi Chemical Co., LTD [Member] Robert A. Preti [Member] Robert A. Preti [Member] Robert A. Preti [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Equity Method Investment, Ownership Percentage Equity Method Investment, Ownership Percentage Recorded Unconditional Purchase Obligation Recorded Unconditional Purchase Obligation Unrecorded Unconditional Purchase Obligation, Maximum Quantity Unrecorded Unconditional Purchase Obligation, Maximum Quantity Purchase Obligation Purchase Obligation Contract Receivable Contract Receivable Length of Contract for Royalty Payments from Revenue Generated in Asia Length of Contract for Royalty Payments from Revenue Generated in Asia Length of Contract for Royalty Payments from Revenue Generated in Asia Subsidiary, Ownership Interest by Parent Subsidiary, Ownership Interest by Parent Subsidiary, Ownership Interest by Parent Purchase Agreement, Aggregate Purchase Price Purchase Agreement, Aggregate Purchase Price Purchase Agreement, Aggregate Purchase Price Purchase Agreement, Additional Consideration Purchase Agreement, Additional Consideration Purchase Agreement, Additional Consideration Purchase Agreement, Potential Future Milestone Payment Purchase Agreement, Potential Future Milestone Payment Purchase Agreement, Potential Future Milestone Payment Cumulative Revenue Threshold for Receiving Milestone Payment Cumulative Revenue Threshold for Receiving Milestone Payment Cumulative Revenue Threshold for Receiving Milestone Payment Proceeds From Licensing Agreements, Initial Payment Proceeds From Licensing Agreements, Initial Payment Proceeds From Licensing Agreements, Initial Payment Proceeds From Licensing Agreements, Closing Payments Proceeds From Licensing Agreements, Closing Payments Proceeds From Licensing Agreements, Closing Payments Proceeds From Licensing Agreements, Escrow Amount Proceeds From Licensing Agreements, Escrow Amount Proceeds From Licensing Agreements, Escrow Amount Transaction Costs Related to Sale Disposal Group, Including Discontinued Operation, Transaction Costs Disposal Group, Including Discontinued Operation, Transaction Costs Payments to Employees Payments to Employees Retention Payments, First Retention Payment, Percent Payment for Retention Agreement in Connection with Sale, First Retention Payment, Percent Payment for Retention Agreement in Connection with Sale, First Retention Payment, Percent Retention Payments, Second Retention Payment, Percent Payment for Retention Agreement in Connection with Sale, Second Retention Payment, Percent Payment for Retention Agreement in Connection with Sale, Second Retention Payment, Percent Related Party Transaction, Payment for Retention Agreement in Connection with Sale, First Retention Payment Related Party Transaction, Payment for Retention Agreement in Connection with Sale, First Retention Payment Related Party Transaction, Payment for Retention Agreement in Connection with Sale, First Retention Payment Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Second Retention Payment Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Second Retention Payment Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Second Retention Payment Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Third Retention Payment, Percentage of Milestone Payment Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Third Retention Payment, Percentage of Milestone Payment Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Third Retention Payment, Percentage of Milestone Payment Available-for-sale Securities [Abstract] Amortized Cost Available-for-sale Securities, Debt Maturities, Amortized Cost Basis, Fiscal Year Maturity [Abstract] Less than one year Available-for-sale Securities, Debt Maturities, Remainder of Fiscal Year, Amortized Cost Basis Greater than one year Available-for-sale Securities, Debt Maturities, Rolling Year Two Through Five, Amortized Cost Basis Amortized Cost, Total Available-for-sale Debt Securities, Amortized Cost Basis Estimated Fair Value Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract] Less than one year Available-for-sale Securities, Debt Maturities, Remainder of Fiscal Year, Fair Value Greater than one year Available-for-sale Securities, Debt Maturities, Rolling Year Two Through Five, Fair Value Estimated Fair Value, Total Available-for-sale Securities, Debt Securities Share-based Compensation [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Disclosure of Share-based Compensation Arrangements by Share-based Payment Award Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Income Statement [Abstract] Operating Expenses: Operating Expenses [Abstract] Research and development Research and Development Expense General and administrative Selling, General and Administrative Expense Total operating expenses Operating Expenses Operating loss Operating Income (Loss) Other income (expense): Nonoperating Income (Expense) [Abstract] Other income (expense), net Other Nonoperating Income (Expense) Interest expense Interest Expense Other income (expense) Nonoperating Income (Expense) Loss from continuing operations before benefit from income taxes and noncontrolling interests Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Benefit from income taxes Income Tax Expense (Benefit) Net loss from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Discontinued operations - net of taxes Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net (loss) income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Less - net loss from continuing operations attributable to noncontrolling interests Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Less - net loss from discontinued operations attributable to noncontrolling interests Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders Net Income (Loss) Available to Common Stockholders, Basic Amounts Attributable to Caladrius Inc. common stockholders: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Loss from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Income (loss) from discontinued operations - net of taxes Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Basic and diluted income (loss) per share Earnings Per Share, Basic and Diluted [Abstract] Continuing operations (in usd per share) Income (Loss) from Continuing Operations, Per Basic and Diluted Share Discontinued operations (in usd per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share Caladrius Biosciences, Inc. common stockholders (in usd per share) Earnings Per Share, Basic and Diluted Weighted average common shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Basic and diluted shares Weighted Average Number of Shares Outstanding, Basic and Diluted Organization, Consolidation and Presentation of Financial Statements [Abstract] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Income Statement Location [Axis] Income Statement Location [Axis] Total share-based compensation expense Income Statement Location [Domain] Research and Development [Member] Research and Development Expense [Member] General and Administrative [Member] Selling, General and Administrative Expenses [Member] Discontinued Operations [Member] Discontinued Operations1 [Member] Discontinued Operations1 [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock Option [Member] Employee Stock Option [Member] Restricted Stock [Member] Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Allocated Share-based Compensation Expense Allocated Share-based Compensation Expense Accelerated equity compensation cost Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost Modification incremental compensation cost Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Expected weighted-average period in years of compensation cost to be recognized Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term Total fair value of shares vested Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Weighted average estimated fair value of shares granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Revenue Disposal Group, Including Discontinued Operation, Revenue Cost of revenues Disposal Group, Including Discontinued Operation, Costs of Goods Sold Research and development Disposal Group, Including Discontinued Operation, Research and Development Expense Disposal Group, Including Discontinued Operation, Research and Development Expense Selling, general, and administrative Disposal Group, Including Discontinued Operation, General and Administrative Expense Other expense Disposal Group, Including Discontinued Operation, Other Expense Provision for income taxes Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period Gain on sale of segment Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Income (loss) from discontinued operations Statement of Financial Position [Abstract] Allowance for doubtful accounts on accounts receivable Allowance for Doubtful Accounts Receivable, Current Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock Convertible Preferred Stock, Shares Issued upon Conversion Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares designated Preferred stock, shares designated Preferred stock, shares designated Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares, outstanding Common Stock, Shares, Outstanding Treasury stock (shares) Treasury Stock, Shares Fair Value Disclosures [Abstract] Fair Value, Assets Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Research Funding [Abstract] Research Funding [Abstract] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accrued Liabilities [Member] Accounts Payable and Accrued Liabilities [Member] Other Long-Term Liabilities [Member] Other Noncurrent Liabilities [Member] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Grants Receivable Grants Receivable Grants Receivable, Current Grants Receivable, Current Deferred Grant Revenue Deferred Grant Revenue Deferred Grant Revenue Grant Revenue Recognized Deferred Revenue, Revenue Recognized Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] The Business The Business [Text Block] The Business [Text Block] Equity [Abstract] Share-based Compensation, Stock Options, Activity Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Restricted Stock Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of Available-for-sale Securities Reconciliation Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of Marketable Securities Marketable Securities [Table Text Block] Investments Classified by Contractual Maturity Date Investments Classified by Contractual Maturity Date [Table Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Redeemable Securities Redeemable Securities [Text Block] Redeemable Securities [Text Block] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Aspire Capital Purchase Agreement [Member] Aspire Capital Purchase Agreement [Member] Aspire Capital Purchase Agreement [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Sale of Stock [Domain] RD Purchase Agreement [Member] RD Purchase Agreement [Member] RD Purchase Agreement [Member] Private Purchase Agreement [Member] Private Purchase Agreement [Member] Private Purchase Agreement [Member] Class of Stock [Line Items] Class of Stock [Line Items] Common Stock Warrants, Shares Common Stock Warrants, Shares Common Stock Warrants, Shares Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Shares Issued, Price Per Share Shares Issued, Price Per Share Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock, Second Closing, Receivable Proceeds from Issuance of Common Stock, Second Closing, Receivable Proceeds from Issuance of Common Stock, Second Closing, Receivable Purchase Commitment, Maximum Amount Committed, Shares Purchase Commitment, Maximum Amount Committed, Shares Purchase Commitment, Maximum Amount Committed, Shares Proceeds from Issuance of Common Stock, Initial Closing Proceeds from Issuance of Common Stock, Initial Closing Proceeds from Issuance of Common Stock, Initial Closing Proceeds from Issuance of Common Stock, Second Closing Proceeds from Issuance of Common Stock, Second Closing Proceeds from Issuance of Common Stock, Second Closing Number of Subjects, Phase 2 CLBS03 Clinical Trial, Second Closing Number of Subjects, Phase 2 CLBS03 Clinical Trial, Second Closing Number of Subjects, Phase 2 CLBS03 Clinical Trial, Second Closing Purchase Commitment, Remaining Minimum Amount Committed Purchase Commitment, Remaining Minimum Amount Committed Term of agreement in months Term Of Agreement In Months Term Of Agreement In Months Stock Issued During Period, Shares, Other Stock Issued During Period, Shares, Other Shares, Issued Shares, Issued Common Stock, Value, Issued Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Fair Value of Shares Discount Applied To Weighted Average Price Discount Applied To Weighted Average Price Discount Applied To Weighted Average Price Cash and cash equivalents Cash Marketable securities Marketable Securities Total Cash, Cash Equivalents, and Short-term Investments 2017 Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2018 Operating Leases, Future Minimum Payments, Due in Two Years 2019 Operating Leases, Future Minimum Payments, Due in Three Years 2020 Operating Leases, Future Minimum Payments, Due in Four Years 2021 and thereafter Operating Leases, Future Minimum Payments, Due in Five Years Total minimum lease payments Operating Leases, Future Minimum Payments Due Operating lease expense Operating Leases, Rent Expense Operating Leases, Future Minimum Payments Due [Abstract] Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Business Combination, Consideration Transfered, Interest Rate Business Combination, Consideration Transfered, Interest Rate Business Combination, Consideration Transfered, Interest Rate Redeemable Securities Agreement, Required Purchase Based on Equity Event, Maximum Redeemable Securities Agreement, Required Purchase Based on Equity Event, Maximum Redeemable Securities Agreement, Required Purchase Based on Equity Event, Maximum Redeemable Securities, Classified to Additional Paid In Capital Redeemable Securities, Classified to Additional Paid In Capital Redeemable Securities, Classified to Additional Paid In Capital Redeemable Securities, Classified to Non-Controlling Interests Redeemable Securities, Classified to Non-Controlling Interests Redeemable Securities, Classified to Non-Controlling Interests Concentration of Risks Concentration Risk, Credit Risk, Policy [Policy Text Block] Share-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Recently Issued Accounting Pronouncement New Accounting Pronouncements, Policy [Policy Text Block] Earnings Per Share [Abstract] Loss Per Share Earnings Per Share [Text Block] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards Operating Loss Carryforwards Deferred Tax Liabilities, Net, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Salaries, employee benefits and related taxes Employee-related Liabilities Retention payments Retention Payable Professional fees Accrued Professional Fees Income tax payable Taxes Payable, Current CIRM upfront funding - current Customer Advances, Current Other Other Accrued Liabilities Total accrued liabilities Accrued Liabilities Available-for-Sale Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Certificates of Deposit [Member] Certificates of Deposit [Member] Corporate Debt Securities [Member] Corporate Debt Securities [Member] Money Market Funds [Member] Money Market Funds [Member] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Amortized Cost Available-for-sale Securities, Amortized Cost Basis Gross Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Estimated Fair Value Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Total NeoStem, Inc. Shareholders' Equity [Member] Parent [Member] Series B Convertible Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Additional Paid in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Treasury Stock Treasury Stock [Member] Non- Controlling Interest in Subsidiary Noncontrolling Interest [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series B Convertible Preferred Stock Series B Preferred Stock [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning Balance (shares) Shares, Outstanding Beginning Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Net income (loss) Unrealized gain/loss on marketable securities Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Share-based compensation (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Share-based compensation Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Net proceeds from issuance of common stock (in shares) Net proceeds from issuance of common stock Stock Issued During Period, Value, New Issues Proceeds from option exercises (in shares) Stock Issued During Period, Shares, Share-based Compensation, Gross Proceeds from option exercises Stock Issued During Period, Value, Stock Options Exercised Elimination of non-controlling interests associated with PCT sale Temporary Equity, Elimination as Part of Reorganization Reclassification of redeemable securities Debt Conversion, Original Debt, Amount Change in Ownership in Subsidiary Change in Ownership in Subsidiary Change in Ownership in Subsidiary Ending Balance Ending Balance (shares) Fair Value Measurements Fair Value Disclosures [Text Block] Assets [Abstract] Current Assets Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash Restricted Cash, Current Accounts receivable, net of allowances of $0 at September 30, 2017 and December 31, 2016, respectively Accounts Receivable, Net, Current Prepaid and other current assets Prepaid Expense and Other Assets, Current Current assets related to discontinued operations Disposal Group, Including Discontinued Operation, Assets, Current Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Other assets Other Assets, Noncurrent Other assets related to discontinued operations Disposal Group, Including Discontinued Operation, Assets, Noncurrent Total assets Assets LIABILITIES, REDEEMABLE SECURITIES - NON-CONTROLLING INTERESTS AND EQUITY Liabilities and Equity [Abstract] Current Liabilities Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Accrued Liabilities, Current Long-term debt, current Long-term Debt, Current Maturities Notes payable, current Notes Payable, Current Due to PCT Due to Related Parties, Current Current liabilities related to discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Current Total current liabilities Liabilities, Current Notes payable Notes Payable, Noncurrent Long-term debt Long-term Debt, Excluding Current Maturities Other long-term liabilities Other Liabilities, Noncurrent Liabilities related to discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent Total liabilities Liabilities Commitments and Contingencies Commitments and Contingencies Redeemable Securities - Non-Controlling Interests Redeemable Noncontrolling Interest, Equity, Carrying Amount EQUITY Stockholders' Equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2017 and December 31, 2016 Preferred Stock, Value, Issued Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 9,427,001 and 8,205,790 shares, at September 30, 2017 and December 31, 2016, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury stock, at cost; 11,080 shares at September 30, 2017 and December 31, 2016, respectively Treasury Stock, Value Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total Caladrius Biosciences, Inc. stockholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total equity Liabilities and Equity, Total Liabilities and Equity Fair value of consideration received Disposal Group, Including Discontinued Operation, Consideration Transaction and retention costs Carrying value of segment non-controlling interest Disposal Group, Including Discontinued Operation, Value Of Segment Non-Controlling Interest Disposal Group, Including Discontinued Operation, Value Of Segment Non-Controlling Interest Total consideration net of transaction costs and adjustments Disposal Group, Including Discontinued Operation, Total Consideration Net Of Transaction Costs And Adjustments Disposal Group, Including Discontinued Operation, Total Consideration Net Of Transaction Costs And Adjustments Less carrying amount of assets and liabilities sold: Disposal Group, Including Discontinued Operation, Unclassified Balance Sheet Disclosures [Abstract] Cash Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Accounts receivable Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Deferred costs Disposal Group, Including Discontinued Operation, Deferred Costs Disposal Group, Including Discontinued Operation, Deferred Costs Prepaid expenses and other current assets Disposal Group, Including Discontinued Operation, Prepaid and Other Assets Property, plant and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Goodwill Disposal Group, Including Discontinued Operation, Goodwill Intangibles, net Disposal Group, Including Discontinued Operation, Intangible Assets Other assets Disposal Group, Including Discontinued Operation, Other Assets Accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable Accrued liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities Due from Caladrius Disposal Group, Including Discontinued Operation, Other Receivable Disposal Group, Including Discontinued Operation, Other Receivable Unearned revenues Disposal Group, Including Discontinued Operation, Deferred Revenue Notes payable Disposal Group Including Discontinued Operation, Notes Payable Disposal Group Including Discontinued Operation, Notes Payable Disposal group, including discontinued operation, net assets Disposal Group, Including Discontinued Operation, Net Assets Disposal Group, Including Discontinued Operation, Net Assets Gain on sale of PCT Stock Issued During Period, Shares, Restricted Stock Award, Gross Stock Issued During Period, Shares, Restricted Stock Award, Gross Stock Issued During Period, Value, Restricted Stock Award, Gross Stock Issued During Period, Value, Restricted Stock Award, Gross Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Project [Axis] Project [Axis] Project [Domain] Project [Domain] The Sanford Project: T-Rex Study [Member] The Sanford Project: T-Rex Study [Member] The Sanford Project: T-Rex Study [Member] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Number of Cohorts Number of Cohorts Number of Cohorts Interim Efficacy Analysis, Percentage Threshold Interim Efficacy Analysis, Percentage Threshold Interim Efficacy Analysis, Percentage Threshold Interim Efficacy Analysis, Follow-up Milestone Period Interim Efficacy Analysis, Follow-up Milestone Period Interim Efficacy Analysis, Follow-up Milestone Period Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Collaboration and License Agreement Mergers, Acquisitions and Dispositions Disclosures [Text Block] Reverse Stock Split, Conversion Ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Schedule of Future Minimum Rental Payments for Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Warrant [Member] Warrant [Member] Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Oxford Finance LLC [Member] Oxford Finance LLC [Member] Oxford Finance LLC [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Notes Payable, Other Payables [Member] Notes Payable, Other Payables [Member] Loans Payable [Member] Loans Payable [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Loan and Security Agreement [Member] Loan and Security Agreement [Member] Loan and Security Agreement [Member] Maximum [Member] Maximum [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Notes Payable Notes Payable Debt Instrument, Payment Terms Debt Instrument, Term Long-term Debt, Gross Long-term Debt, Gross Repayments of Debt Repayments of Debt Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Percent Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Percent Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Percent Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Amount Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Amount Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Amount Long-term Debt Long-term Debt Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Interest Expense Share-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Marketable securities - available for sale Investments, Fair Value Disclosure Assets, fair value disclosure Assets, Fair Value Disclosure Statement of Comprehensive Income [Abstract] Available for sale securities - net unrealized loss Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Total other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive (loss) income attributable to Caladrius Biosciences, Inc. common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] (Income) loss from discontinued operations Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-based compensation Issuance of Stock and Warrants for Services or Claims Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Loss on disposal of assets Impairment of Long-Lived Assets to be Disposed of Accretion on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Prepaid and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts receivable Increase (Decrease) in Accounts Receivable Other assets Increase (Decrease) in Other Operating Assets Due to/from PCT Increase (Decrease) in Due from Affiliates, Current Accounts payable, accrued liabilities and other liabilities Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities Net cash used in operating activities - continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of marketable securities Payments to Acquire Marketable Securities Sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Net proceeds from PCT sale Proceeds from Divestiture of Businesses Net cash sold in PCT sale Cash Divested from Deconsolidation Acquisition of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Net cash provided by (used in) investing activities - continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities - discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of options Proceeds from Stock Options Exercised Tax withholding payments on net share settlement equity awards Payments Related to Tax Withholding for Share-based Compensation Net proceeds from issuance of common stock Proceeds from Issuance or Sale of Equity Repayment of long-term debt Repayments of Long-term Debt Proceeds from notes payable Proceeds from Notes Payable Repayment of notes payable Repayments of Notes Payable PCT dividend to Caladrius Proceeds from Divestiture of Interest in Consolidated Subsidiaries Net cash (used in) provided by financing activities - continuing operations Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash (used in) provided by financing activities - discontinued operations Cash Provided by (Used in) Financing Activities, Discontinued Operations Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period - continuing operations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at beginning of period - discontinued operations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Less cash and cash equivalents of discontinued operations at end of period Cash, cash equivalents and restricted cash of continuing operations at end of period Supplemental Disclosure of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Cash paid during the period for: Interest Paid [Abstract] Interest Interest Paid Schedule of Stockholders' Equity Note, Stock Options and warrants [Table] Class of Warrant or Right [Table] Stock Options Activity [Axis] Stock Options Activity [Axis] Stock Options Activity [Axis] Stock Options Activity [Domain] Stock Options Activity [Domain] Stock Options Activity [Domain] US Equity Plan [Member] US Equity Plan [Member] US Equity Plan [Member] Stock Options and Warrants [Line Items] Class of Warrant or Right [Line Items] Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options, Outstanding, Beginning of Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options, Grants in Period, Net of Forfeitures Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Options, Outstanding, End of Period Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Options, Outstanding, Weighted Average Exercise Price, Beginning of Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options, Forfeitures in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options, Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Options, Outstanding, Weighted Average Exercise Price, End of Period Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Options, Vested and Expected to Vest, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Options, Vested, Weighted Average Remaining Contractual Term Options, Vested, weighted Average Remaining Contractual Term Options, Vested, weighted Average Remaining Contractual Term Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Warrants Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Warrants, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Warrants, Shares, Beginning of Period Warrants Granted Warrants Granted Warrants Granted Warrants Exercised Warrants Exercised Warrants Exercised Warrants Canceled Warrants Canceled Warrants Canceled Warrants Expired Warrants Expired Warrants Expired Warrants, Shares, End of Period Warrants Weighted Average Exercise Price [Roll Forward] Warrants Weighted Average Exercise Price [Roll Forward] Warrants Weighted Average Exercise Price [Roll Forward] Weighted Average Exercise Price, Warrants Outstanding, Beginning of Period Weighted Average Exercise Price, Warrants Outstanding Weighted Average Exercise Price, Warrants Outstanding Weighted Average Exercise Price, Warrants Granted Weighted Average Exercise Price, Warrants Granted Weighted Average Exercise Price, Warrants Granted Weighted Average Exercise Price, Warrants Exercised Weighted Average Exercise Price, Warrants Exercised Weighted Average Exercise Price, Warrants Exercised Weighted Average Exercise Price, Warrants Canceled Weighted Average Exercise Price, Warrants Canceled Weighted Average Exercise Price, Warrants Canceled Weighted Average Exercise Price, Warrants Expired Weighted Average Exercise Price, Warrants Expired Weighted Average Exercise Price, Warrants Expired Weighted Average Exercise Price, Warrants Outstanding, End of Period Weighted Average Remaining Contractual Term, Warrant outstanding Weighted Average Remaining Contractual Term warrant outstanding Weighted Average Remaining Contractual Term warrant outstanding Aggregate Intrinsic Value, Warrants Outstanding Aggregate Intrinsic Value, Warrants Outstanding Aggregate Intrinsic Value, Warrants Outstanding Warrants, vested and expected to vest shares, vested and expected to vest shares, vested and expected to vest Weighted Average Exercise Price, Warrants vested & expected to vest Weighted Average Exercise Price, Warrants vested & expected to vest Weighted Average Exercise Price, Warrants vested & expected to vest Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest Aggregate Intrinsic Value, Warrants vested and expected to vest Aggregate Intrinsic Value, Warrants vested and expected to vest Aggregate Intrinsic Value, Warrants vested and expected to vest Warrants, Vested. Number Warrants, Vested Warrants, Vested Warrants, Vested, Weighted Average Exercise Price Weighted Average Exercise Price, Warrants Exercisable Weighted Average Exercise Price, Warrants Exercisable Warrants, Vested, Weighted Average Remaining Contractual Term weighted Average Remaining Contractual Term, warrants vested weighted Average Remaining Contractual Term, warrants vested Warrants, Vested, Aggregate Intrinsic Value Aggregate Intrinsic Value, Warrants vested Aggregate Intrinsic Value, Warrants vested Research Funding Research, Development, and Computer Software Disclosure [Text Block] Payments to Employees Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] EX-101.PRE 11 clbs-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2017
Nov. 09, 2017
Document and Entity Information [Abstract]    
Entity Registrant Name Caladrius Biosciences, Inc.  
Entity Central Index Key 0000320017  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Document Type 10-Q  
Document Period End Date Sep. 30, 2017  
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   9,470,860
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Current Assets    
Cash and cash equivalents $ 15,077,872 $ 7,076,651
Restricted cash 5,002,649 0
Marketable securities 44,371,615 0
Accounts receivable, net of allowances of $0 at September 30, 2017 and December 31, 2016, respectively 401,558 138,774
Prepaid and other current assets 920,008 1,900,493
Current assets related to discontinued operations 0 15,533,043
Total current assets 65,773,702 24,648,961
Property, plant and equipment, net 364,118 705,438
Other assets 1,417,439 1,582,209
Other assets related to discontinued operations 0 26,577,834
Total assets 67,555,259 53,514,442
Current Liabilities    
Accounts payable 879,625 2,226,580
Accrued liabilities 10,135,600 2,659,433
Long-term debt, current 0 3,126,457
Notes payable, current 359,553 563,777
Due to PCT 0 1,681,594
Current liabilities related to discontinued operations 0 10,925,052
Total current liabilities 11,374,778 21,182,893
Notes payable 0 159,180
Long-term debt 0 2,524,897
Other long-term liabilities 3,200,154 389,858
Liabilities related to discontinued operations 0 5,791,134
Total liabilities 14,574,932 30,047,962
Commitments and Contingencies
Redeemable Securities - Non-Controlling Interests 0 19,400,000
Stockholders' Equity    
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2017 and December 31, 2016 100 100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 9,427,001 and 8,205,790 shares, at September 30, 2017 and December 31, 2016, respectively 9,427 8,206
Additional paid-in capital 433,006,780 410,372,049
Treasury stock, at cost; 11,080 shares at September 30, 2017 and December 31, 2016, respectively (707,637) (707,637)
Accumulated deficit (378,947,243) (404,788,809)
Accumulated other comprehensive loss (28,717) 0
Total Caladrius Biosciences, Inc. stockholders' equity 53,332,710 4,883,909
Noncontrolling interests (352,383) (817,429)
Total equity 52,980,327 4,066,480
Liabilities and Equity, Total $ 67,555,259 $ 53,514,442
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts on accounts receivable $ 0 $ 0
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock 1 1
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, shares designated 825,000 825,000
Preferred stock, shares issued 10,000 10,000
Preferred stock, shares outstanding 10,000 10,000
Common stock, par value (in usd per share) $ 0.001 $ 0.001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 9,427,001 8,205,791
Common stock, shares, outstanding 9,427,001 8,205,791
Treasury stock (shares) 11,080 11,080
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Operating Expenses:        
Research and development $ 3,187,024 $ 2,958,593 $ 11,190,939 $ 13,496,045
General and administrative 2,942,877 2,768,927 9,081,806 10,513,570
Total operating expenses 6,129,901 5,727,520 20,272,745 24,009,615
Operating loss (6,129,901) (5,727,520) (20,272,745) (24,009,615)
Other income (expense):        
Other income (expense), net 176,855 5,117 137,288 19,559
Interest expense (8,687) (368,364) (372,099) (1,601,421)
Other income (expense) 168,168 (363,247) (234,811) (1,581,862)
Loss from continuing operations before benefit from income taxes and noncontrolling interests (5,961,733) (6,090,767) (20,507,556) (25,591,477)
Benefit from income taxes (2,413,951) 0 (8,301,494) 0
Net loss from continuing operations (3,547,782) (6,090,767) (12,206,062) (25,591,477)
Discontinued operations - net of taxes 0 (1,196,838) 37,329,963 (1,628,694)
Net (loss) income (3,547,782) (7,287,605) 25,123,901 (27,220,171)
Less - net loss from continuing operations attributable to noncontrolling interests (119,342) (59,423) (149,509) (187,126)
Less - net loss from discontinued operations attributable to noncontrolling interests 0 (345,649) (568,156) (334,879)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders (3,428,440) (6,882,533) 25,841,566 (26,698,166)
Amounts Attributable to Caladrius Inc. common stockholders:        
Loss from continuing operations (3,428,440) (6,031,344) (12,056,553) (25,404,351)
Income (loss) from discontinued operations - net of taxes 0 (851,189) 37,898,119 (1,293,815)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders $ (3,428,440) $ (6,882,533) $ 25,841,566 $ (26,698,166)
Basic and diluted income (loss) per share        
Continuing operations (in usd per share) $ (0.38) $ (0.95) $ (1.37) $ (4.23)
Discontinued operations (in usd per share) 0.00 (0.13) 4.30 (0.22)
Caladrius Biosciences, Inc. common stockholders (in usd per share) $ (0.38) $ (1.09) $ 2.94 $ (4.45)
Weighted average common shares outstanding:        
Basic and diluted shares 9,093,880 6,323,427 8,803,784 6,001,572
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Statement of Comprehensive Income [Abstract]        
Net income (loss) $ (3,547,782) $ (7,287,605) $ 25,123,901 $ (27,220,171)
Available for sale securities - net unrealized loss (28,717) (486) (28,717) (486)
Total other comprehensive loss (28,717) (486) (28,717) (486)
Comprehensive (loss) income (3,576,499) (7,288,091) 25,095,184 (27,220,657)
Comprehensive loss attributable to noncontrolling interests (119,342) (405,072) (717,665) (522,005)
Comprehensive (loss) income attributable to Caladrius Biosciences, Inc. common stockholders $ (3,457,157) $ (6,883,019) $ 25,812,849 $ (26,698,652)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Equity - USD ($)
Total
Total NeoStem, Inc. Shareholders' Equity [Member]
Series B Convertible Preferred Stock
Series B Convertible Preferred Stock
Common Stock
Additional Paid in Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2015     10,000 5,673,302          
Beginning Balance at Dec. 31, 2015 $ 23,283,824 $ 23,713,533 $ 100 $ 5,673 $ 396,547,401 $ 486 $ (372,132,490) $ (707,637) $ (429,709)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income (loss) (27,220,171) (26,698,166)         (26,698,166)   (522,005)
Unrealized gain/loss on marketable securities (486) (486)       (486)      
Share-based compensation (in shares)       104,754          
Share-based compensation 2,275,616 2,275,616   $ 105 2,275,511        
Net proceeds from issuance of common stock (in shares)       2,403,865          
Net proceeds from issuance of common stock 11,650,712 11,650,712   $ 2,404 11,648,308        
Change in Ownership in Subsidiary 0 (195,219)     (195,219)       195,219
Ending Balance at Sep. 30, 2016 9,989,495 10,745,990 $ 100 $ 8,182 410,276,001 0 (398,830,656) (707,637) (756,495)
Ending Balance (shares) at Sep. 30, 2016     10,000 8,181,921          
Beginning Balance (shares) at Dec. 31, 2016     10,000 8,205,790          
Beginning Balance at Dec. 31, 2016 4,066,480 4,883,909 $ 100 $ 8,206 410,372,049 0 (404,788,809) (707,637) (817,429)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income (loss) 25,123,901 25,841,566         25,841,566   (717,665)
Unrealized gain/loss on marketable securities (28,717) (28,717)       (28,717)      
Share-based compensation (in shares)       54,545          
Share-based compensation 2,412,981 2,412,981   $ 55 2,412,926        
Net proceeds from issuance of common stock (in shares)       1,162,831          
Net proceeds from issuance of common stock 5,678,632 5,678,632   $ 1,162 5,677,470        
Proceeds from option exercises (in shares)       3,835          
Proceeds from option exercises 13,576 13,576   $ 4 13,572        
Elimination of non-controlling interests associated with PCT sale (3,686,526)               (3,686,526)
Reclassification of redeemable securities 19,400,000 14,733,908     14,733,908       4,666,092
Change in Ownership in Subsidiary 0 (203,145)     (203,145)       203,145
Ending Balance at Sep. 30, 2017 $ 52,980,327 $ 53,332,710 $ 100 $ 9,427 $ 433,006,780 $ (28,717) $ (378,947,243) $ (707,637) $ (352,383)
Ending Balance (shares) at Sep. 30, 2017     10,000 9,427,001          
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash flows from operating activities:    
Net income (loss) $ 25,123,901 $ (27,220,171)
(Income) loss from discontinued operations (37,329,963) 1,628,694
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 1,881,712 2,275,616
Depreciation and amortization 284,005 351,226
Loss on disposal of assets 175,793 591,307
Accretion on marketable securities 218,755 0
Changes in operating assets and liabilities:    
Prepaid and other current assets 980,495 871,417
Accounts receivable (262,784) 14,424
Other assets 164,788 191,717
Due to/from PCT (1,681,593) 1,605,550
Accounts payable, accrued liabilities and other liabilities (5,823,272) (3,210,626)
Net cash used in operating activities - continuing operations (16,268,163) (22,900,846)
Net cash used in operating activities (638,069) 2,608,615
Net cash used in operating activities (16,906,232) (20,292,231)
Cash flows from investing activities:    
Purchase of marketable securities 51,724,691 0
Sale of marketable securities 7,105,603 0
Net proceeds from PCT sale 74,689,814 0
Net cash sold in PCT sale (6,727,263) 0
Acquisition of property, plant and equipment (118,478) (1,068,130)
Net cash provided by (used in) investing activities - continuing operations 23,224,985 (1,068,130)
Net cash used in investing activities - discontinued operations (188,794) (1,247,623)
Net cash provided by (used in) investing activities 23,036,191 (2,315,753)
Cash flows from financing activities:    
Proceeds from exercise of options 13,576 0
Tax withholding payments on net share settlement equity awards (357,665) 0
Net proceeds from issuance of common stock 5,678,632 11,650,712
Repayment of long-term debt (5,651,354) (9,348,646)
Proceeds from notes payable 400,998 368,615
Repayment of notes payable (764,402) (715,610)
PCT dividend to Caladrius 0 15,000,000
Net cash (used in) provided by financing activities - continuing operations (680,215) 16,955,071
Net cash (used in) provided by financing activities - discontinued operations (74,231) 3,941,244
Net cash (used in) provided by financing activities (754,446) 20,896,315
Net increase (decrease) in cash, cash equivalents and restricted cash 5,375,513 (1,711,669)
Cash, cash equivalents and restricted cash at beginning of period - continuing operations 7,076,651 18,657,971
Cash and cash equivalents at beginning of period - discontinued operations 7,628,357 1,660,440
Cash, cash equivalents and restricted cash at end of period 20,080,521 18,606,742
Less cash and cash equivalents of discontinued operations at end of period 0 6,962,677
Cash, cash equivalents and restricted cash of continuing operations at end of period 20,080,521 11,644,065
Cash paid during the period for:    
Interest $ 706,231 $ 973,729
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
The Business
 9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Business
The Business
 
Overview
 
Caladrius Biosciences, Inc. (“we,” “us,” "our," “Caladrius” or the “Company”), is a company developing cellular therapeutics to treat certain diseases. We leverage specialized clinical development expertise to select and develop early-stage cell therapy candidates with the intention of developing such candidates to their next significant clinical milestone and, if appropriate, partnering such candidates. Our current lead product candidate, CLBS03, is an autologous polyclonal regulatory T cell ("Treg") clinical phase 2 therapy targeting children aged 8-17 with recent-onset type 1 diabetes mellitus ("T1D").

Immunomodulation (Treg Technology)

We are developing strategically, through the utilization of our core clinical development expertise, a product candidate (CLBS03) that has the potential to be an innovative therapy for T1D. This therapy is based on a proprietary platform technology for immunomodulation. We have selected as an initial target the unmet medical need of patients who are newly diagnosed with T1D, most of whom will be under the age of 18. This program is based on the use of Tregs to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg number and function. Tregs are a natural part of the human immune system and regulate the activity of effector T cells, the cells that are responsible for protecting the body from pathogens and foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by effector T cells. In autoimmune disease, however, it is thought that deficient Treg activity and numbers permit the effector T cells to attack the body's own beneficial cells. In the case of T1D, the beta cells in the pancreas are attacked thereby reducing and/or eliminating over time the patient's ability to produce insulin. Insulin is necessary to regulate sugar metabolism and maintain proper sugar levels in the blood. Inconsistent or unnatural insulin levels can lead to many complications, including blindness, vascular disease and, if no insulin supplement is provided, even death. There are currently no curative treatments for TID, only lifelong insulin therapy, which often does not prevent serious co-morbidities. Two Phase 1 clinical trials of Treg technology in T1D demonstrated safety and tolerance, feasibility of manufacturing, an implied durability of effect as well as an early indication of potential therapeutic effect through the preservation of beta cell function. In the first quarter of 2016, we commenced patient enrollment in the first of two cohorts in The Sanford Project: T-Rex Study, a Phase 2 prospective, randomized, placebo-controlled, double-blind clinical trial (the "TRex Study") to evaluate the safety and efficacy of CLBS03 in adolescents with recent onset TID. In October 2016, we received a satisfactory safety evaluation by our independent Data Safety Monitoring Board based on safety data then available from the first 19 patients enrolled in the trial. A subsequent interim analysis is planned after approximately 50% of patients reach the six-month follow-up milestone, the results of which are expected to be publicly available by the mid to late first quarter of 2018. We entered into a strategic collaboration with Sanford Research to support the execution of this trial. Sanford Research is a U.S.-based non-profit research organization that supports an emerging translational research center focused on finding a cure for T1D. On February 23, 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received $5.7 million in initial funding on May 4, 2017. CLBS03 has been granted Fast Track and orphan drug designations from the U.S. Food and Drug Administration ("FDA") as well as Advanced Therapeutic Medicinal Product ("ATMP") classification from the European Medicines Agency ("EMA").

Ischemic Repair (CD34 Cell Technology)
Our CD34 cell technology has led to the development of therapeutic candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Through the administration of CD34 cells, we seek to promote the development and formation of new blood vessels and thereby increase blood flow to the impacted area. We believe that conditions caused by underlying ischemic injury can be improved through our CD34 cell technology, including critical limb ischemia ("CLI"). Published reports in Circulation Cardiovascular Interventions, Atherosclerosis, Stem Cells and Circulation Journal, provide preliminary evidence that CD34 cell therapy is safe and can exert significant therapeutic effects in patients with CLI, a condition in which blood flow to the legs is severely impaired, causing pain and non-healing ulcers and, ultimately, potentially resulting in the need for amputation. Our Clinical Trial Notification for a pivotal Phase 2 trial investigating our product candidate in CLI CLBS12 was submitted to the Japanese Pharmaceutical and Medical Device Agency ("PMDA") and was cleared to proceed. The protocol design was agreed to with PMDA and, we intend to begin enrolling patients in late 2017 or early 2018. Under our agreement with the PMDA, a successful outcome of this trial would make CLBS12 eligible for early conditional approval in Japan. We are seeking to collaborate on CLBS12 with development and/or manufacturing partners. Furthermore, we submitted grant applications in an effort to seek non-dilutive financing to investigate the CD34 technology for additional clinical indications in the United States and on October 2, 2017 we announced receipt of a $1.9M grant award from the National Institutes of Health to support a clinical study of CD34 cells in patients with coronary microvascular dysfunction.
We intend to develop this platform if capital becomes available through grants, partnerships or licensing, as well as potentially using reasonable amounts of our own capital.
Additional Out-licensing Opportunities
    
Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. These include additional indications for our Treg product, additional indications for our CD34 cell technology and a platform using tumor cell/dendritic cell technology for immuno-oncology application. The immuno-oncology program has the benefit of promising Phase 2 clinical data and applicability to multiple indications. In 2016, we completed multiple out-licensing agreements for this and other technology platforms in an effort to monetize non-core assets.

Our current long-term strategy focuses on advancing our therapies through development toward the market and assisting patients suffering from life-threatening medical conditions. We believe that we are positioned to realize potentially meaningful value increases within our own proprietary pipeline based on the realization of advancing our product candidates to their next significant development milestone.

Discontinued Operations
On May 18, 2017 (the "Closing Date"), we completed the previously announced sale of our remaining 80.1% membership interest in PCT, LLC, a Caladrius company ("PCT") to Hitachi Chemical Co. America, Ltd. ("Hitachi"), pursuant to the Interest Purchase Agreement (the "Purchase Agreement"), dated as of March 16, 2017, by and among us, PCT and Hitachi (the "2017 Hitachi Transaction"), for $75.0 million in cash, plus an additional cash adjustment based on PCT’s cash and outstanding indebtedness as of the Closing Date ("Additional Consideration") and a potential future milestone payment (see Note 3). The sale of PCT represents a strategic shift that has a major effect on our operations, and therefore, PCT is accounted for as discontinued operations. All periods presented were adjusted to reflect PCT as discontinued operations.

Basis of Presentation

The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of September 30, 2017 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2016 and 2015 included in our 2016 Form 10-K. Operating results for the nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.
    
Use of Estimates
 
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining useful lives of our long-lived assets, allowances for doubtful accounts, and stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.

An accounting policy is considered to be critical if it is important to the Company’s financial condition and results of operations and if it requires management’s most difficult, subjective and complex judgments in its application.
 
Principles of Consolidation
 
The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly-owned and partially-owned subsidiaries and affiliates, as well as the operations of our former subsidiaries PCT, LLC, a Caladrius company, NeoStem Family Storage, LLC, and PCT Allendale, LLC entities (collectively the "PCT Segment") through May 18, 2017, representing the date which these entities were sold to Hitachi (see Note 3). The PCT Segment is reported in discontinued operations. All intercompany activities have been eliminated in consolidation, except for intercompany activities between Caladrius and the PCT Segment, which are reported without intercompany eliminations in continuing operations and discontinued operations, respectively.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies
 
In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our 2016 Form 10-K. There were no changes to these policies during the three and nine months ended September 30, 2017.

Concentration of Risks
We are subject to credit risk from our portfolio of cash, cash equivalents, restricted cash, and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.

Share-Based Compensation  

The Company expenses all share-based payment awards to employees, directors, consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.


Recently Issued Accounting Pronouncement

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires that a lessee recognize lease assets and lease liabilities for those leases classified as operating leases. The guidance is effective for interim and annual periods beginning after December 15, 2018, and will be applied at the beginning of the earliest period presented using a modified retrospective approach. This ASU may have a material impact on the Company’s financial statements. The impact on the Company’s results of operations is currently being evaluated. The impact of the ASU is non-cash in nature and will not affect the Company’s cash position.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting for forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance was effective for interim and annual periods beginning after December 15, 2016. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU 2016-15 is effective in first quarter of fiscal 2018 and earlier adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.

In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized as current period income tax expense or benefit at the transaction date and removes the option to defer and amortize the consolidated tax consequences of intra-entity transfers. The new standard will be effective on January 1, 2018 and will be adopted using a modified retrospective approach which requires a cumulative effect adjustment to retained earnings as of the beginning of the period of adoption. Early adoption is permitted at the beginning of a fiscal year. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard will be effective on January 1, 2018 and the Company has been early adopted, with all adjustments reflected as of the beginning of the fiscal years reported.

In May 2017, the FASB issued ASU 2017-09, "Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU 2017-09 also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. For all entities, including emerging growth companies, the standard is effective for annual periods beginning after December 15, 2017, and for interim periods therein. Early adoption is permitted. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration and License Agreement
 9 Months Ended
Sep. 30, 2017
Business Combinations [Abstract]  
Collaboration and License Agreement
Collaboration and License Agreement

2016 Hitachi Transaction

On March 11, 2016, PCT entered into a global collaboration with Hitachi. This collaboration consists of an equity investment in and a license agreement with PCT.

Under the equity investment agreement, Hitachi purchased a 19.9% membership interest in PCT for $19.4 million of which $15.0 million of proceeds was distributed to Caladrius from PCT and $4.4 million remained at PCT to be used for the continued expansion and improvements at PCT in support of commercial product launch readiness as well as for general corporate purposes.

PCT and Hitachi also entered into an exclusive license agreement for the acceleration of the creation of a global commercial cell therapy development and manufacturing expertise in Asia pursuant to which PCT received $5.6 million from Hitachi in 2016. PCT licensed certain cell therapy technology and know-how (including an exclusive license in Asia) and agreed to provide Hitachi Chemical with certain training and support.  As additional consideration, Hitachi Chemical agreed to pay PCT royalties on contract revenue generated in Asia for a minimum of ten years.

2017 Hitachi Transaction

On May 18, 2017, the Company sold its remaining 80.1% membership interest in PCT to Hitachi pursuant to the Purchase Agreement, dated as of March 16, 2017, by and among Caladrius PCT and Hitachi (the "2017 Hitachi Transaction"). The aggregate purchase price to the Company consisted of (i) $75.0 million in cash, (ii) $4.4 million, representing Additional Consideration based on PCT’s cash and outstanding indebtedness as of the Closing Date, and (iii) a potential future milestone payment of $5.0 million if PCT achieves $125 million in Cumulative Revenue (excluding clinical service reimbursables) (the “Milestone”) for the period from January 1, 2017 through December 31, 2018 (the “Milestone Period”).
Hitachi paid the Company $5.0 million in March 2017 as an advance payment pending shareholder approval of the transaction and other closing conditions. On the Closing Date, the Company received $65.0 million, with an additional $5.0 million of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against Caladrius. The Escrow Amount is classified as restricted cash on the balance sheet as of September 30, 2017. In June 2018, the escrow agent will disburse to the Company the Escrow Amount less (i) that portion of the Escrow Amount previously paid in satisfaction of claims for indemnification pursuant to the terms of the Purchase Agreement and (ii) that portion of the Escrow Amount that is determined, in the reasonable judgment of Hitachi, to be necessary to satisfy all unsatisfied or disputed claims for indemnification specified in any claim notice delivered to the Company. The Company also received the $4.4 million Additional Consideration payment in July 2017. The Company incurred approximately $6.9 million in transaction costs related to the 2017 Hitachi Transaction, including $4.3 million in retention payments to PCT employees, of which 50% was paid in June 2017, and the other 50% payable on the one year anniversary of the Closing Date.

Concurrent with the signing of the Purchase Agreement, on March 16, 2017, Caladrius entered into a Retention and Incentive Agreement with Robert A. Preti, a former Caladrius director and a co-founder and the President of PCT, (the “Retention Agreement”). The Retention Agreement superseded all prior agreements and understandings between Dr. Preti and Caladrius regarding the subject matter of the Retention Agreement. Among other things, the Retention Agreement provided for:

•
Simultaneously with the closing of the 2017 Hitachi Transaction, Caladrius paid to Dr. Preti $1.9 million (the “First Retention Payment”).
•
As an incentive to remain employed with PCT and to use commercially reasonable efforts to cause PCT to maximize its overall performance and in particular to achieve the Milestone (but not contingent upon achieving the Milestone), Dr. Preti will receive a lump-sum cash retention and incentive payment equal to $1.9 million for the period from the Closing Date until the date one year after the date of the Closing Date (the “Anniversary Date”), subject to Dr. Preti’s continued employment with PCT through the Anniversary Date (the “Second Retention Payment”).
•
Dr. Preti will be entitled to 5% of the Milestone Payment if it is successfully earned.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Available-for-Sale-Securities
 9 Months Ended
Sep. 30, 2017
Available-for-sale Securities [Abstract]  
Available-for-Sale Securities
Available-for-Sale-Securities
 
The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):

 
September 30, 2017
 
December 31, 2016
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
Certificate of deposits
$
249.0

 
$
—

 
$
—

 
$
249.0

 
$
—

 
$
—

 
$
—

 
$
—

Corporate debt securities
49,345.6

 
—

 
(28.8
)
 
49,316.8

 
—

 
—

 
—

 
—

Money market funds
6,678.6

 
0.1

 
—

 
6,678.7

 
4,426.8

 
—

 
—

 
4,426.8

Total
$
56,273.2

 
$
0.1

 
$
(28.8
)
 
$
56,244.5

 
$
4,426.8

 
$
—

 
$
—

 
$
4,426.8



Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):

 
September 30, 2017
 
December 31, 2016
Cash and cash equivalents
$
11,872.9

 
$
4,426.8

Marketable securities
44,371.6

 
—

Total
$
56,244.5

 
$
4,426.8



The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):
 
 
September 30, 2017
 
Amortized Cost
 
Estimated Fair Value
Less than one year
$
56,273.2

 
$
56,244.5

Greater than one year
—

 
—

Total
$
56,273.2

 
$
56,244.5
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Loss Per Share
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Loss Per Share
Loss Per Share
 
For the three and nine months ended September 30, 2017 and 2016, the Company incurred net losses from continuing operations and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At September 30, 2017 and 2016, the Company excluded the following potentially dilutive securities:
 
September 30,
 
2017
 
2016
Stock Options
1,105,790

 
942,129

Warrants
218,978

 
362,650

Restricted Stock Awards
8,000

 
61,456

Restricted Stock Units
10,260

 
—
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
 
The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:
 
Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
 
Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.
 
Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
 
The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of September 30, 2017, and December 31, 2016 (in thousands).

 
 
September 30, 2017
 
December 31, 2016
 
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketable securities - available for sale
 
$
—

 
$
44,371.6

 
$
—

 
$
44,371.6

 
$
—

 
$
—

 
$
—

 
$
—

 
 
$
—

 
$
44,371.6

 
$
—

 
$
44,371.6

 
$
—

 
$
—

 
$
—

 
$
—
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Liabilities
 9 Months Ended
Sep. 30, 2017
Accrued Liabilities [Abstract]  
Accrued Liabilities
Accrued Liabilities

Accrued liabilities as of September 30, 2017 and December 31, 2016 were as follows (in thousands):
 
September 30, 2017
 
December 31, 2016
Salaries, employee benefits and related taxes
$
1,169.6

 
$
1,406.3

Retention payments
2,233.0

 
—

Professional fees
367.3

 
224.5

Income tax payable
4,075.6

 
—

CIRM upfront funding - current
1,745.5

 
—

Other
544.7

 
1,028.6

Total
$
10,135.7

 
$
2,659.4
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt
 9 Months Ended
Sep. 30, 2017
Debt Disclosure [Abstract]  
Debt
Debt
 
Notes Payable
 
As of September 30, 2017 and December 31, 2016, the Company had notes payable of approximately $0.4 million and $0.7 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years.
 
Long-Term Debt

On September 26, 2014, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (together with its successors and assigns, the “Lender”) pursuant to which the Lender disbursed $15.0 million (the “Loan”). The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and will be amortized to interest expense throughout the life of the Loan using the effective interest rate method.

In March 2016, concurrent with the 2016 Hitachi Transaction (see Note 3), the Company and the Lender entered into an amendment to the Loan and Security Agreement whereby (i) the Company paid $7.0 million to Lender, comprising principal, interest and early termination fees, (ii) the Company's subsidiaries PCT, PCT Allendale, LLC, and NeoStem Family Storage, LLC (collectively the "Removed Borrowers") were removed as borrowers under the Loan, (iii) Lender's security interests in any and all assets of the Removed Borrowers were released, (iv) the interest only period on the remaining outstanding Loan balance was extended until January 1, 2017, and (v) in the event the Company received gross proceeds from the sale or issuance of any equity securities or subordinated debt, or any partnership, licenses, collaboration, dividend, grant or asset sale through March 31, 2017, 20% of such proceeds will be paid to Lender, up to a $3.0 million maximum as additional partial repayment of Loan. On September 14, 2016, concurrent with the Company's September 2016 Registered Direct Offering and Concurrent Private Placement (see Note 10), the Company repaid $3.0 million of such proceeds to the Lender. The outstanding balance was approximately $5.7 million at December 31, 2016.

In May 2017, concurrent with the 2017 Hitachi Transaction (see Note 3), the Company retired the Loan in full, and paid $4.9 million to Lender, comprising principal, interest and early termination fees. The Company was making interest-only payments on the outstanding amount of the Loan on a monthly basis at a rate of 8.50% per annum. During the nine months ended September 30, 2017, the Company recognized $0.4 million of interest expense related to the Loan and Security Agreement. During the three and nine months ended September 30, 2016, the Company recognized $0.2 million and $0.7 million of interest expense, respectively, related to the Loan and Security Agreement.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Redeemable Securities
 9 Months Ended
Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Redeemable Securities
Redeemable Securities

Under the 2016 Hitachi Transaction (see Note 3), Hitachi had the right, at any time following the tenth anniversary of the 2016 Hitachi Transaction to require Caladrius or PCT to purchase all or some of the equity securities in PCT then held by Hitachi ("Hitachi Put Right") for an amount equal to the lesser of (i) the fair market value of the Hitachi equity holdings and (ii) the original purchase price paid of $19.4 million on March 11, 2016 for its 19.9% ownership interest, plus interest at a rate of 2.0% per annum compounded annually; provided, however, that if Hitachi ownership interests increased subsequent to its initial ownership interest, and it offers to sell its equity holdings in excess of 21% of PCT’s outstanding equity securities, then the Company would be required to purchase all such equity holdings of Hitachi but in no event would the aggregate purchase price of such Hitachi equity holdings exceed $20.5 million plus interest at the rate of 2.0% per annum compounded annually.

As of December 31, 2016, since Hitachi had the right to deliver the equity interests in PCT it held in exchange for cash from Caladrius or PCT, the initial $19.4 million value of the non-controlling interest was considered redeemable equity, requiring it to be treated as mezzanine equity. Redeemable non-controlling interest is required to be initially measured at the initial carrying amount. If the non-controlling interest is not currently redeemable and also not probable of becoming redeemable (e.g., it is not probable a contingency that triggers redemption will be met), the non-controlling interest should be classified in mezzanine equity.

Concurrent with 2017 Hitachi Transaction (see Note 3), the Hitachi Put Right was eliminated, and $14.7 million previously classified as Redeemable Securities was classified to Additional Paid in Capital. In addition, the remaining portion classified as Redeemable Securities of $4.7 million was classified to Non-Controlling Interests, representing Hitachi's ownership interest in PCT at the time of the 2016 Hitachi Transaction, which was subsequently eliminated upon the 2017 Hitachi transaction and included the PCT gain on sale.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Shareholders' Equity
 9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Shareholders' Equity
Shareholders' Equity

Reverse Stock Split

On July 28, 2016, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on June 22, 2016 and unanimously approved by the Company’s board of directors on July 22, 2016. The Reverse Stock Split became effective on July 27, 2016 at 5:00 pm and the common stock of the Company began trading on The NASDAQ Capital Market on a post-split basis at the open of business on July 28, 2016. As of July 28, 2016, every ten shares of the Company’s issued and outstanding common stock were combined into one share of its common stock, except to the extent that the Reverse Stock Split resulted in any of the Company’s stockholders owning a fractional share, which was rounded up to the next highest whole share. In connection with the Reverse Stock Split, there was no change in the nominal par value per share of $0.001.

All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “Additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.

Equity Issuances

September 2016 Registered Direct Offering and Concurrent Private Placement

On September 14, 2016, the Company entered into a securities purchase agreement (the “RD Purchase Agreement”) with a single institutional investor (the “Purchaser”), pursuant to which the Company issued and sold to the Purchaser, in a registered direct offering, an aggregate of 847,458 shares of the Company’s common stock at a purchase price of $4.72 per share. The gross proceeds to the Company from the registered direct offering of the shares of common stock were $4.0 million.

In concurrent private placements, on September 14, 2016, the Company entered into Securities Purchase Agreements (each a “Private Placement Purchase Agreement” and, collectively, the “Private Placement Purchase Agreements”) with certain accredited investors (the “Investors”) with whom it had a substantive, pre-existing relationship, including certain existing stockholders, for the sale by the Company of an aggregate of 4,449,153 shares of Common Stock, at a purchase price of $4.72 per share. The investments were placed in two tranches: (i) $12.6 million upon an initial closing (the “Initial Closing”), and (ii) $8.4 million, subject to certain conditions, including the enrollment of 70 subjects in the Company’s Phase 2 CLBS03 clinical trial, in a second closing (the “Second Closing”). As of March 31, 2017, $6.0 million of the Initial Closing tranche had not been received from a single investor, who was in breach of his obligations under the Private Placement Purchase Agreement. This investor had also committed to fund $4.0 million in the Second Closing. As a result, the Company terminated the Private Placement Purchase Agreement with this investor in the first quarter of 2017. In 2017, the Company met the conditions of the Second Closing, and received the remaining $4.4 million in proceeds in accordance with the terms of the Second Closing tranche and issued 932,204 shares of common stock.

Aspire Purchase Agreements

In November 2015, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30 million of shares (limited to a maximum of approximately 1.1 million shares, unless stockholder approval is obtained or certain minimum sale price levels are reached) of the Company's common stock over a 24-month term. As consideration for entering into the Purchase Agreement, the Company issued 84,270 shares of its common stock to Aspire Capital. During the nine months ended September 30, 2017, the Company issued 210,506 shares of common stock under the Purchase Agreement for gross proceeds of $1.2 million. Overall, as of September 30, 2017, the Company has issued 319,776 shares under the Purchase Agreement for gross proceeds of $1.5 million.

Under the Purchase Agreement, at the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price, trading volume and conditions, including NASDAQ's trading requirements, are met. The purchase price for the shares of common stock is based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreements. We have filed a registration statement with the SEC and a related prospectus supplement that covers the offering of shares of our common stock subject to the Purchase Agreement, and therefore can initiate sales to Aspire Capital at any time, subject to the limitation discussed above.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2017:

 
 
Stock Options
 
Warrants
 
 
Shares
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term (Years)
 
Aggregate Intrinsic Value (In Thousands)
 
Shares
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term (Years)
 
Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2016
 
952,790

 
$
39.90

 
7.60
 
$
—

 
388,062

 
$
76.50

 
1.24
 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Changes during the period:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Granted
 
447,757

 
11.70

 
 
 
 
 
—

 
—

 
 
 
 
Exercised
 
(3,835
)
 
4.70

 
 
 
 
 
—

 
—

 
 
 
 
Forfeited
 
(244,413
)
 
18.70

 
 
 
 
 
(1,691
)
 
700.00

 
 
 
 
Expired
 
(46,509
)
 
41.20

 
 
 
 
 
(167,393
)
 
104.50

 
 
 
 
Outstanding at September 30, 2017
 
1,105,790

 
$
33.30

 
5.11
 
$
8.2

 
218,978

 
$
54.80

 
1.15
 
$
—

Vested at September 30, 2017
or expected to vest in the future
 
1,105,336

 
$
33.30

 
5.11
 
$
8.2

 
218,978

 
$
54.80

 
1.15
 
$
—

Vested at September 30, 2017
 
1,097,350

 
$
32.70

 
5.12
 
$
8.2

 
218,978

 
$
54.80

 
1.15
 
$
—




Restricted Stock

During the nine months ended September 30, 2017 and 2016, the Company issued restricted stock for services as follows (in thousands, except share data):

 
 
Nine Months Ended September 30,
  
 
2017
 
2016
Number of restricted stock issued
 
132,726

 
107,719

Value of restricted stock issued
 
$
469.9

 
$
651.7
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation
 9 Months Ended
Sep. 30, 2017
Share-based Compensation [Abstract]  
Share-Based Compensation
Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants, restricted stock, and restricted stock units.  The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2017 and 2016 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Research and development
$
—

 
$
154.0

 
$
208.2

 
$
225.0

General and administrative
62.4

 
485.6

 
1,673.6

 
1,297.6

Discontinued operations
—

 
401.0

 
888.9

 
753.0

Total share-based compensation expense
$
62.4

 
$
1,040.6

 
$
2,770.7

 
$
2,275.6

 
 
 
 
 
 
 
 


The approval of the 2017 Hitachi Transaction (see Note 3) by our stockholders resulted in a change in control under our equity compensation plans (as defined in the 2009 Plan and the 2015 Equity Plan, and, together with the 2009 Plan, the “Equity Compensation Plans”). Accordingly, all outstanding unvested equity awards were accelerated upon the Closing Date, resulting in an acceleration of $1.9 million of equity compensation in the second quarter of 2017. In addition, in connection with the 2017 Hitachi Transaction, the Company agreed to extend the post-termination option exercise period for all PCT employees transitioning to Hitachi from 90 days to the earlier of (i) two years (May 18, 2019) or (ii) the date of the employees' termination from PCT. The post-termination option exercise period modification resulted in an additional expense of $0.3 million, which was recorded entirely during the three months ended June 30, 2017 and recorded in discontinued operations, since there were no future service requirements to receive the extended benefit.
 
Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2017 were as follows (in thousands):
 
Stock Options
 
Restricted Stock
Unrecognized compensation cost
$
39.7

 
$
4.2

Expected weighted-average period in years of compensation cost to be recognized
0.67

 
0.13



Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2017 and 2016 were as follows (in thousands):
 
Stock Options
 
Nine Months Ended September 30,
 
2017
 
2016
Total fair value of shares vested
$
5,001.7

 
$
2,189.4

Weighted average estimated fair value of shares granted
$
1.72

 
$
3.25



Valuation Assumptions

The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Research Funding
 9 Months Ended
Sep. 30, 2017
Research Funding [Abstract]  
Research Funding
Research Funding

California Institute of Regenerative Medicine Grant Award
In February 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received $5.7 million in initial funding in May 2017, which will be amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses. As of September 30, 2017, $1.7 million of the funding received is recorded in Accrued Liabilities, representing the amount expected to be recognized over the next 12 months, and $3.2 million of the funding received is recorded in Other Long-Term Liabilities. During the three and nine months ended September 30, 2017, the Company amortized and recognized a $0.4 million and $0.7 million credit to research and development related to CIRM funds received.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
 9 Months Ended
Sep. 30, 2017
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
 
As of December 31, 2016, the Company had approximately $232.7 million of federal net operating loss carryforwards ("NOLs") available to offset future taxable income expiring from 2027 through 2036. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  If a change of ownership did occur, there would be an annual limitation on the usage of the Company’s losses, which are available through 2036.

In assessing the ability to realize deferred tax assets, including the NOLs, the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  During the quarter ended June 30, 2017, the Company generated a gain from the sale of 80.1% of their ownership in PCT. The gain from the sale of PCT is included in discontinued operations. The Company for the nine months ended September 30, 2017 has generated losses from continuing operations and has forecasted losses for the remainder of the year. Based on generating taxable income for the 2017 year, the Company will utilize net operating losses which were offset by a full valuation allowance. The Company anticipates that they will maintain a valuation allowance on the remaining deferred tax assets at the end of the year.

Deferred tax liabilities were $0 and $1.1 million as of September 30, 2017 and December 31, 2016, respectively, and relate to the taxable temporary differences on the goodwill recognized in the PCT acquisition in 2011. The taxable temporary differences, which were tax deductible and were to be amortized over 15 years. The deferred tax liability was reversed during the three months ended June 30, 2017, as a result of the divestiture of PCT.

The Company applies ASC 740-10 for uncertain tax positions. The Company utilizes the two step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.

As of September 30, 2017, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

During the nine months ended September 30, 2017, the Company has both continuing and discontinued operations. ASC 740-20-45-7 addresses the income tax accounting treatment when there is a loss from continuing operations and income from discontinuing operations. The Company must consider the gain from discontinued operations for purposes of allocating a tax benefit to the current year loss from continuing operations. The Company has adopted a method in which the income from discontinued operations are recognized as a discrete item in the period in which it occurs and apply the concepts of the annual effective tax rate (AETR) during each period in computing the income tax provision from continuing operations. This method results in a tax expense for discontinued operations and an income tax benefit for the loss generated from continuing operations. The Company is forecasting losses from continuing operations for the remainder of 2017 against which an income tax benefit will be recorded.

The Company completed the audit of its federal tax returns for the years 2012 and 2013 during the fourth quarter of 2016. The audit resulted in an adjustment to the Company's NOL carryforward. For years prior to 2014, the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from date of filing. The Company ceased doing business in China in 2012.  After 2012, the Company had no foreign tax filing obligations.  The foreign returns filed for 2012 and prior are subject to examination for five years.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Discontinued Operations
 9 Months Ended
Sep. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations
Discontinued Operations
 
PCT Segment

On May 18, 2017, the Company completed the previously announced Sale of its remaining 80.1% membership interest in PCT to Hitachi. Pursuant to the Purchase Agreement, by and among Caladrius, PCT and Hitachi, the aggregate purchase price to the Company consisted of (i) $75.0 million in cash, (ii) a $4.4 million cash adjustment, based on PCT’s cash and outstanding indebtedness as of the Closing Date, and (iii) a potential future milestone payment of $5.0 million if PCT achieves $125 million in Cumulative Revenue (excluding clinical service reimbursables) (the “Milestone”) for the period from January 1, 2017 through December 31, 2018 (the “Milestone Period”). The Company has determined that the fair value of the milestone payment as of the closing date was valued at zero. 
Pursuant to the terms of the Purchase Agreement, Hitachi paid the Company $5.0 million in March 2017 as an advance payment pending shareholder approval of the transaction and other closing conditions included in the Purchase Agreement. On the Closing Date, the Company received $65.0 million, with an additional $5.0 million of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against Caladrius. In June 2018, the escrow agent will disburse to the Company the Escrow Amount less (i) that portion of the Escrow Amount previously paid in satisfaction of claims for indemnification pursuant to the terms of the Purchase Agreement and (ii) that portion of the Escrow Amount that is determined, in the reasonable judgment of Hitachi, to be necessary to satisfy all unsatisfied or disputed claims for indemnification specified in any claim notice delivered to the Company. The Company also received the additional $4.4 million cash adjustment payment in July 2017. The Company incurred approximately $6.9 million in transaction costs related to the Sale, including $4.3 million in retention payments to PCT employees, of which 50% was paid in June 2017, and the other 50% payable on the one year anniversary of the Closing Date.

The Company recognized the following gain on the date of sale of its 80.1% interest in PCT (in thousands):
Fair value of consideration received
$
79,425

Transaction and retention costs
(6,919
)
Carrying value of segment non-controlling interest
3,687

 
$
76,193

Less carrying amount of assets and liabilities sold:
 
Cash
$
6,727

Accounts receivable
3,702

Deferred costs
4,685

Prepaid expenses and other current assets
743

Property, plant and equipment, net
14,900

Goodwill
7,013

Intangibles, net
2,090

Other assets
215

Accounts payable
(2,278
)
Accrued liabilities
(2,927
)
Due from Caladrius
450

Unearned revenues
(10,529
)
Notes payable
(342
)
 
$
24,449

 
 
Gain on sale of PCT
$
51,744



The operations and cash flows of the PCT Segment were eliminated from ongoing operations with the sale of the Company's PCT Interest. The operating results of the PCT Segment for the nine months ended September 30, 2017 and three and nine months ended September 30, 2016 were as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2017
 
2016
Revenue
$
10,794

 
$
16,039

 
$
29,910

Cost of revenues
(9,482
)
 
(15,321
)
 
(25,122
)
Research and development
(277
)
 
(257
)
 
(610
)
Selling, general, and administrative
(2,168
)
 
(3,251
)
 
(5,587
)
Other expense
(17
)
 
(16
)
 
(72
)
Provision for income taxes
(47
)
 
(11,608
)
 
(147
)
Gain on sale of segment
—

 
51,744

 
—

Income (loss) from discontinued operations
$
(1,197
)
 
$
37,330

 
$
(1,629
)
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
 
Lease Commitments
 
We lease facilities under various operating lease agreements in Basking Ridge, NJ, New York, NY, and Irvine, CA, of which certain leases have escalation clauses and renewal options. We also lease equipment under certain noncancelable operating leases. Our leases expire from time to time through 2021.
A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2017 are as follows (in thousands):  
Years ended
 
Operating Leases
2017
 
$
327.5

2018
 
817.4

2019
 
786.2

2020
 
801.6

2021 and thereafter
 
603.0

Total minimum lease payments
 
$
3,335.7


 
Expense incurred under operating leases was approximately $0.3 million and $1.1 million for the three and nine months ended September 30, 2017, respectively. Expense incurred under operating leases was approximately $0.3 million and $1.0 million for the three and nine months ended September 30, 2016, respectively.
 
Contingencies
 
We have entered into a strategic collaboration with Sanford Research with the goal of developing a therapy for the treatment of T1D. The initial focus of the collaboration will be the execution of a prospective, randomized, placebo-controlled, double-blind clinical trial (The Sanford Project: T-Rex Study) to evaluate the safety and efficacy of the Company’s T regulatory cell product candidate, CLBS03, in adolescents with recent onset T1D. The Phase 2 study has an open and active IND in place and subject enrollment commenced in the first quarter of 2016. We were initially responsible for the supply of all study drug to the first 19 enrolled patients while Sanford assumed all patient and clinical site costs for subjects enrolled in their two centers as well as the expense associated with general clinical monitoring services. For the remaining 92 patients in the study, we will continue to be responsible for the supply of all study drug and the costs of study enrollment for sites outside of the Sanford centers.

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Concentration of Risks
Concentration of Risks
We are subject to credit risk from our portfolio of cash, cash equivalents, restricted cash, and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.
Share-Based Compensation
Share-Based Compensation  

The Company expenses all share-based payment awards to employees, directors, consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Recently Issued Accounting Pronouncement
Recently Issued Accounting Pronouncement

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires that a lessee recognize lease assets and lease liabilities for those leases classified as operating leases. The guidance is effective for interim and annual periods beginning after December 15, 2018, and will be applied at the beginning of the earliest period presented using a modified retrospective approach. This ASU may have a material impact on the Company’s financial statements. The impact on the Company’s results of operations is currently being evaluated. The impact of the ASU is non-cash in nature and will not affect the Company’s cash position.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting for forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance was effective for interim and annual periods beginning after December 15, 2016. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU 2016-15 is effective in first quarter of fiscal 2018 and earlier adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.

In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized as current period income tax expense or benefit at the transaction date and removes the option to defer and amortize the consolidated tax consequences of intra-entity transfers. The new standard will be effective on January 1, 2018 and will be adopted using a modified retrospective approach which requires a cumulative effect adjustment to retained earnings as of the beginning of the period of adoption. Early adoption is permitted at the beginning of a fiscal year. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard will be effective on January 1, 2018 and the Company has been early adopted, with all adjustments reflected as of the beginning of the fiscal years reported.

In May 2017, the FASB issued ASU 2017-09, "Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU 2017-09 also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. For all entities, including emerging growth companies, the standard is effective for annual periods beginning after December 15, 2017, and for interim periods therein. Early adoption is permitted. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Available-for-Sale-Securities (Tables)
 9 Months Ended
Sep. 30, 2017
Available-for-sale Securities [Abstract]  
Schedule of Available-for-sale Securities Reconciliation
The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):

 
September 30, 2017
 
December 31, 2016
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
Certificate of deposits
$
249.0

 
$
—

 
$
—

 
$
249.0

 
$
—

 
$
—

 
$
—

 
$
—

Corporate debt securities
49,345.6

 
—

 
(28.8
)
 
49,316.8

 
—

 
—

 
—

 
—

Money market funds
6,678.6

 
0.1

 
—

 
6,678.7

 
4,426.8

 
—

 
—

 
4,426.8

Total
$
56,273.2

 
$
0.1

 
$
(28.8
)
 
$
56,244.5

 
$
4,426.8

 
$
—

 
$
—

 
$
4,426.8
Schedule of Marketable Securities
Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):

 
September 30, 2017
 
December 31, 2016
Cash and cash equivalents
$
11,872.9

 
$
4,426.8

Marketable securities
44,371.6

 
—

Total
$
56,244.5

 
$
4,426.8
Investments Classified by Contractual Maturity Date
The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):
 
 
September 30, 2017
 
Amortized Cost
 
Estimated Fair Value
Less than one year
$
56,273.2

 
$
56,244.5

Greater than one year
—

 
—

Total
$
56,273.2

 
$
56,244.5
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
At September 30, 2017 and 2016, the Company excluded the following potentially dilutive securities:
 
September 30,
 
2017
 
2016
Stock Options
1,105,790

 
942,129

Warrants
218,978

 
362,650

Restricted Stock Awards
8,000

 
61,456

Restricted Stock Units
10,260

 
—
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Fair Value, Assets Measured on Recurring Basis
The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of September 30, 2017, and December 31, 2016 (in thousands).

 
 
September 30, 2017
 
December 31, 2016
 
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketable securities - available for sale
 
$
—

 
$
44,371.6

 
$
—

 
$
44,371.6

 
$
—

 
$
—

 
$
—

 
$
—

 
 
$
—

 
$
44,371.6

 
$
—

 
$
44,371.6

 
$
—

 
$
—

 
$
—

 
$
—
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Liabilities (Tables)
 9 Months Ended
Sep. 30, 2017
Accrued Liabilities [Abstract]  
Schedule of Accrued Liabilities
Accrued liabilities as of September 30, 2017 and December 31, 2016 were as follows (in thousands):
 
September 30, 2017
 
December 31, 2016
Salaries, employee benefits and related taxes
$
1,169.6

 
$
1,406.3

Retention payments
2,233.0

 
—

Professional fees
367.3

 
224.5

Income tax payable
4,075.6

 
—

CIRM upfront funding - current
1,745.5

 
—

Other
544.7

 
1,028.6

Total
$
10,135.7

 
$
2,659.4
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Shareholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Share-based Compensation, Stock Options, Activity
The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2017:

 
 
Stock Options
 
Warrants
 
 
Shares
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term (Years)
 
Aggregate Intrinsic Value (In Thousands)
 
Shares
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term (Years)
 
Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2016
 
952,790

 
$
39.90

 
7.60
 
$
—

 
388,062

 
$
76.50

 
1.24
 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Changes during the period:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Granted
 
447,757

 
11.70

 
 
 
 
 
—

 
—

 
 
 
 
Exercised
 
(3,835
)
 
4.70

 
 
 
 
 
—

 
—

 
 
 
 
Forfeited
 
(244,413
)
 
18.70

 
 
 
 
 
(1,691
)
 
700.00

 
 
 
 
Expired
 
(46,509
)
 
41.20

 
 
 
 
 
(167,393
)
 
104.50

 
 
 
 
Outstanding at September 30, 2017
 
1,105,790

 
$
33.30

 
5.11
 
$
8.2

 
218,978

 
$
54.80

 
1.15
 
$
—

Vested at September 30, 2017
or expected to vest in the future
 
1,105,336

 
$
33.30

 
5.11
 
$
8.2

 
218,978

 
$
54.80

 
1.15
 
$
—

Vested at September 30, 2017
 
1,097,350

 
$
32.70

 
5.12
 
$
8.2

 
218,978

 
$
54.80

 
1.15
 
$
—
Schedule of Restricted Stock
During the nine months ended September 30, 2017 and 2016, the Company issued restricted stock for services as follows (in thousands, except share data):

 
 
Nine Months Ended September 30,
  
 
2017
 
2016
Number of restricted stock issued
 
132,726

 
107,719

Value of restricted stock issued
 
$
469.9

 
$
651.7
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2017
Share-based Compensation [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs
The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2017 and 2016 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Research and development
$
—

 
$
154.0

 
$
208.2

 
$
225.0

General and administrative
62.4

 
485.6

 
1,673.6

 
1,297.6

Discontinued operations
—

 
401.0

 
888.9

 
753.0

Total share-based compensation expense
$
62.4

 
$
1,040.6

 
$
2,770.7

 
$
2,275.6

 
 
 
 
 
 
 
 
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award
Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2017 were as follows (in thousands):
 
Stock Options
 
Restricted Stock
Unrecognized compensation cost
$
39.7

 
$
4.2

Expected weighted-average period in years of compensation cost to be recognized
0.67

 
0.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2017 and 2016 were as follows (in thousands):
 
Stock Options
 
Nine Months Ended September 30,
 
2017
 
2016
Total fair value of shares vested
$
5,001.7

 
$
2,189.4

Weighted average estimated fair value of shares granted
$
1.72

 
$
3.25
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Discontinued Operations (Tables)
 9 Months Ended
Sep. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Disposal Groups, Including Discontinued Operations
The Company recognized the following gain on the date of sale of its 80.1% interest in PCT (in thousands):
Fair value of consideration received
$
79,425

Transaction and retention costs
(6,919
)
Carrying value of segment non-controlling interest
3,687

 
$
76,193

Less carrying amount of assets and liabilities sold:
 
Cash
$
6,727

Accounts receivable
3,702

Deferred costs
4,685

Prepaid expenses and other current assets
743

Property, plant and equipment, net
14,900

Goodwill
7,013

Intangibles, net
2,090

Other assets
215

Accounts payable
(2,278
)
Accrued liabilities
(2,927
)
Due from Caladrius
450

Unearned revenues
(10,529
)
Notes payable
(342
)
 
$
24,449

 
 
Gain on sale of PCT
$
51,744



The operations and cash flows of the PCT Segment were eliminated from ongoing operations with the sale of the Company's PCT Interest. The operating results of the PCT Segment for the nine months ended September 30, 2017 and three and nine months ended September 30, 2016 were as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2017
 
2016
Revenue
$
10,794

 
$
16,039

 
$
29,910

Cost of revenues
(9,482
)
 
(15,321
)
 
(25,122
)
Research and development
(277
)
 
(257
)
 
(610
)
Selling, general, and administrative
(2,168
)
 
(3,251
)
 
(5,587
)
Other expense
(17
)
 
(16
)
 
(72
)
Provision for income taxes
(47
)
 
(11,608
)
 
(147
)
Gain on sale of segment
—

 
51,744

 
—

Income (loss) from discontinued operations
$
(1,197
)
 
$
37,330

 
$
(1,629
)
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases
A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2017 are as follows (in thousands):  
Years ended
 
Operating Leases
2017
 
$
327.5

2018
 
817.4

2019
 
786.2

2020
 
801.6

2021 and thereafter
 
603.0

Total minimum lease payments
 
$
3,335.7
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
The Business Immunomodulation (Treg Technology) (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2016
cohort
May 04, 2017
USD ($)
Feb. 23, 2017
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Interim Efficacy Analysis, Percentage Threshold 50.00%    
Interim Efficacy Analysis, Follow-up Milestone Period 6 years    
Grants Receivable     $ 12.2
Grants Receivable, Current   $ 5.7  
The Sanford Project: T-Rex Study [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Number of Cohorts | cohort 2    
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration and License Agreement (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 18, 2017
Jul. 31, 2017
Mar. 31, 2017
Sep. 30, 2017
Sep. 30, 2016
May 18, 2018
Mar. 11, 2016
Business Acquisition [Line Items]              
Equity Method Investment, Ownership Percentage             19.90%
Hitachi Chemical Co., LTD [Member]              
Business Acquisition [Line Items]              
Equity Method Investment, Ownership Percentage             21.00%
Recorded Unconditional Purchase Obligation             $ 19,400
Unrecorded Unconditional Purchase Obligation, Maximum Quantity             15,000
PCT Allendale, LLC [Member]              
Business Acquisition [Line Items]              
Contract Receivable             $ 5,600
PCT Allendale, LLC [Member]              
Business Acquisition [Line Items]              
Purchase Obligation             $ 4,400
Minimum [Member] | PCT Allendale, LLC [Member]              
Business Acquisition [Line Items]              
Length of Contract for Royalty Payments from Revenue Generated in Asia         10 years    
Director [Member] | Robert A. Preti [Member]              
Business Acquisition [Line Items]              
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, First Retention Payment $ 1,900            
Director [Member] | Scenario, Forecast [Member] | Robert A. Preti [Member]              
Business Acquisition [Line Items]              
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Second Retention Payment           $ 1,900  
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Third Retention Payment, Percentage of Milestone Payment           5.00%  
Discontinued Operations [Member] | PCT Segment [Member]              
Business Acquisition [Line Items]              
Subsidiary, Ownership Interest by Parent 80.10%            
Transaction Costs Related to Sale $ 6,919            
Payments to Employees       $ (4,300)      
Retention Payments, First Retention Payment, Percent       50.00%      
Retention Payments, Second Retention Payment, Percent       50.00%      
Discontinued Operations [Member] | PCT Segment [Member] | Hitachi Chemical Co., LTD [Member]              
Business Acquisition [Line Items]              
Purchase Agreement, Additional Consideration 4,400            
Purchase Agreement, Potential Future Milestone Payment 5,000            
Cumulative Revenue Threshold for Receiving Milestone Payment 125,000            
Proceeds From Licensing Agreements, Initial Payment     $ 5,000        
Proceeds From Licensing Agreements, Closing Payments 65,000 $ 4,400          
Proceeds From Licensing Agreements, Escrow Amount 5,000            
Discontinued Operations [Member] | PCT Segment [Member] | PCT Allendale, LLC [Member] | Hitachi Chemical Co., LTD [Member]              
Business Acquisition [Line Items]              
Purchase Agreement, Aggregate Purchase Price $ 75,000            
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Available-for-Sale-Securities Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 56,273,200 $ 4,426,800
Gross Unrealized Gains 100 0
Gross Unrealized Losses (28,800) 0
Estimated Fair Value 56,244,500 4,426,800
Certificates of Deposit [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 249,000 0
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value 249,000 0
Corporate Debt Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 49,345,600 0
Gross Unrealized Gains 0 0
Gross Unrealized Losses (28,800) 0
Estimated Fair Value 49,316,800 0
Money Market Funds [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 6,678,600 4,426,800
Gross Unrealized Gains 100 0
Gross Unrealized Losses 0 0
Estimated Fair Value $ 6,678,700 $ 4,426,800
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Available-for-Sale-Securities Classification of Available-for-Sale Securities (Details) - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Available-for-sale Securities [Abstract]    
Cash and cash equivalents $ 11,872,900 $ 4,426,800
Marketable securities 44,371,615 0
Total $ 56,244,500 $ 4,426,800
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Available-for-Sale-Securities Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Amortized Cost    
Less than one year $ 56,273,200  
Greater than one year 0  
Amortized Cost, Total 56,273,200  
Estimated Fair Value    
Less than one year 56,244,500  
Greater than one year 0  
Estimated Fair Value, Total $ 56,244,500 $ 4,426,800
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Loss Per Share (Details) - shares
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Stock Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share 1,105,790 942,129
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share 218,978 362,650
Restricted Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share 8,000 61,456
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share 10,260 0
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities - available for sale $ 44,371,600 $ 0
Assets, fair value disclosure 44,371,600 0
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities - available for sale 0 0
Assets, fair value disclosure 0 0
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities - available for sale 44,371,600 0
Assets, fair value disclosure 44,371,600 0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities - available for sale 0 0
Assets, fair value disclosure $ 0 $ 0
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Liabilities (Details) - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Accrued Liabilities [Abstract]    
Salaries, employee benefits and related taxes $ 1,169,600 $ 1,406,300
Retention payments 2,233,000 0
Professional fees 367,300 224,500
Income tax payable 4,075,600 0
CIRM upfront funding - current 1,745,500 0
Other 544,700 1,028,600
Total accrued liabilities $ 10,135,700 $ 2,659,400
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
May 18, 2017
Sep. 14, 2016
Mar. 31, 2016
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Sep. 26, 2014
Debt Instrument [Line Items]                  
Notes Payable       $ 400,000   $ 400,000   $ 700,000  
Interest Expense       $ 8,687 $ 368,364 $ 372,099 $ 1,601,421    
Notes Payable, Other Payables [Member] | Minimum [Member]                  
Debt Instrument [Line Items]                  
Debt Instrument, Payment Terms           1 year      
Notes Payable, Other Payables [Member] | Maximum [Member]                  
Debt Instrument [Line Items]                  
Debt Instrument, Payment Terms           3 years      
Oxford Finance LLC [Member] | Loan and Security Agreement [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt, Gross                 $ 15,000,000
Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Percent     20.00%            
Oxford Finance LLC [Member] | Loan and Security Agreement [Member] | Maximum [Member]                  
Debt Instrument [Line Items]                  
Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Amount     $ 3,000,000            
Oxford Finance LLC [Member] | Loans Payable [Member] | Loan and Security Agreement [Member]                  
Debt Instrument [Line Items]                  
Repayments of Debt $ 4,900,000 $ 3,000,000 $ 7,000,000            
Long-term Debt               $ 5,700,000  
Debt Instrument, Interest Rate, Effective Percentage       8.50%   8.50%      
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Redeemable Securities (Details) - USD ($)
$ in Millions
May 18, 2017
Mar. 11, 2016
Business Acquisition [Line Items]    
Equity Method Investment, Ownership Percentage   19.90%
Hitachi Chemical Co., LTD [Member]    
Business Acquisition [Line Items]    
Recorded Unconditional Purchase Obligation   $ 19.4
Equity Method Investment, Ownership Percentage   21.00%
Business Combination, Consideration Transfered, Interest Rate   2.00%
Redeemable Securities Agreement, Required Purchase Based on Equity Event, Maximum   $ 20.5
Redeemable Securities, Classified to Additional Paid In Capital $ 14.7  
Redeemable Securities, Classified to Non-Controlling Interests $ 4.7  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Shareholders' Equity - Reverse Stock Split (Details)
Jul. 28, 2016
$ / shares
Sep. 30, 2017
$ / shares
Dec. 31, 2016
$ / shares
Equity [Abstract]      
Common stock, par value (in usd per share) $ 0.001 $ 0.001 $ 0.001
Reverse Stock Split, Conversion Ratio 0.1    
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Shareholders' Equity - Equity Issuances (Details)
$ / shares in Units, $ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 14, 2016
USD ($)
clinical_trial_subject
$ / shares
shares
Nov. 30, 2015
USD ($)
shares
Mar. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
shares
Dec. 31, 2016
shares
Class of Stock [Line Items]          
Common Stock Warrants, Shares | shares       218,978 388,062
Shares Issued, Price Per Share | $ / shares $ 4.72        
Common stock, shares issued | shares       9,427,001 8,205,791
RD Purchase Agreement [Member]          
Class of Stock [Line Items]          
Stock Issued During Period, Shares, New Issues | shares 847,458        
Proceeds from Issuance of Common Stock $ 4.0        
Private Purchase Agreement [Member]          
Class of Stock [Line Items]          
Proceeds from Issuance of Common Stock     $ 6.0    
Proceeds from Issuance of Common Stock, Second Closing, Receivable     $ 4.0    
Purchase Commitment, Maximum Amount Committed, Shares | shares 4,449,153        
Proceeds from Issuance of Common Stock, Initial Closing $ 12.6        
Proceeds from Issuance of Common Stock, Second Closing $ 8.4        
Number of Subjects, Phase 2 CLBS03 Clinical Trial, Second Closing | clinical_trial_subject 70        
Aspire Capital Purchase Agreement [Member]          
Class of Stock [Line Items]          
Proceeds from Issuance of Common Stock       $ 1.2  
Purchase Commitment, Maximum Amount Committed, Shares | shares   1,101,927.6      
Purchase Commitment, Remaining Minimum Amount Committed   $ 30.0      
Term of agreement in months   24 months      
Stock Issued During Period, Shares, Other | shares   84,269.6   210,506  
Shares, Issued | shares       319,776  
Common Stock, Value, Issued       $ 1.5  
Discount Applied To Weighted Average Price   5.00%      
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Shareholders' Equity - Stock options and warrants (Details)
 9 Months Ended 12 Months Ended
Sep. 30, 2017
USD ($)
$ / shares
$ / warrant
shares
Dec. 31, 2016
USD ($)
$ / shares
$ / warrant
shares
Warrants, Number of Shares [Roll Forward]    
Warrants, Shares, Beginning of Period 388,062  
Warrants Granted 0  
Warrants Exercised 0  
Warrants Canceled (1,691)  
Warrants Expired (167,393)  
Warrants, Shares, End of Period 218,978 388,062
Warrants Weighted Average Exercise Price [Roll Forward]    
Weighted Average Exercise Price, Warrants Outstanding, Beginning of Period | $ / warrant 76.50  
Weighted Average Exercise Price, Warrants Granted | $ / shares $ 0.00  
Weighted Average Exercise Price, Warrants Exercised | $ / shares 0.00  
Weighted Average Exercise Price, Warrants Canceled | $ / shares 700.00  
Weighted Average Exercise Price, Warrants Expired | $ / shares $ 104.50  
Weighted Average Exercise Price, Warrants Outstanding, End of Period | $ / warrant 54.80 76.50
Weighted Average Remaining Contractual Term, Warrant outstanding 1 year 1 month 24 days 1 year 2 months 27 days
Aggregate Intrinsic Value, Warrants Outstanding | $ $ 0 $ 0
Warrants, vested and expected to vest 218,978  
Weighted Average Exercise Price, Warrants vested & expected to vest | $ / warrant 54.80  
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest 1 year 1 month 24 days  
Aggregate Intrinsic Value, Warrants vested and expected to vest | $ $ 0  
Warrants, Vested. Number 218,978  
Warrants, Vested, Weighted Average Exercise Price | $ / warrant 54.80  
Warrants, Vested, Weighted Average Remaining Contractual Term 1 year 1 month 24 days  
Warrants, Vested, Aggregate Intrinsic Value | $ $ 0  
US Equity Plan [Member]    
Options, Outstanding [Roll Forward]    
Options, Outstanding, Beginning of Period 952,790  
Options, Grants in Period, Net of Forfeitures 447,757  
Options, Exercises in Period (3,835)  
Options, Forfeitures in Period (244,413)  
Options, Expirations in Period (46,509)  
Options, Outstanding, End of Period 1,105,790 952,790
Options, Outstanding, Weighted Average Exercise Price [Abstract]    
Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ / shares $ 39.90  
Options, Grants in Period, Weighted Average Exercise Price | $ / shares 11.70  
Options, Exercises in Period, Weighted Average Exercise Price | $ / shares 4.70  
Options, Forfeitures in Period, Weighted Average Exercise Price | $ / shares 18.70  
Options, Expirations in Period, Weighted Average Exercise Price | $ / shares 41.20  
Options, Outstanding, Weighted Average Exercise Price, End of Period | $ / shares $ 33.30 $ 39.90
Options, Outstanding, Weighted Average Remaining Contractual Term 5 years 1 month 10 days 7 years 7 months 6 days
Options, Outstanding, Intrinsic Value | $ $ 8,200 $ 0
Options, Vested and Expected to Vest, Outstanding, Number 1,105,336  
Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares $ 33.30  
Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 5 years 1 month 10 days  
Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | $ $ 8,200  
Options, Vested and Expected to Vest, Exercisable, Number 1,097,350  
Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | $ / shares $ 32.70  
Options, Vested, Weighted Average Remaining Contractual Term 5 years 1 month 13 days  
Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | $ $ 8,200  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Shareholders' Equity - Restricted Stock (Details) - USD ($)
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Equity [Abstract]    
Stock Issued During Period, Shares, Restricted Stock Award, Gross 132,726 107,719
Stock Issued During Period, Value, Restricted Stock Award, Gross $ 469,900 $ 651,700
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Allocated Share-based Compensation Expense $ 62,400 $ 1,040,600 $ 2,770,700 $ 2,275,600  
Accelerated equity compensation cost 1,900,000   1,900,000    
Modification incremental compensation cost 300,000        
Stock Option [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Unrecognized compensation cost $ 39,700   $ 39,700    
Expected weighted-average period in years of compensation cost to be recognized     8 months 1 day    
Total fair value of shares vested     $ 5,001,700 2,189,400  
Weighted average estimated fair value of shares granted $ 1.72   $ 1.72   $ 3.25
Restricted Stock [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Unrecognized compensation cost $ 4,200   $ 4,200    
Expected weighted-average period in years of compensation cost to be recognized     1 month 17 days    
Research and Development [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Allocated Share-based Compensation Expense 0 154,000 $ 208,200 225,000  
General and Administrative [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Allocated Share-based Compensation Expense 62,400 485,600 1,673,600 1,297,600  
Discontinued Operations [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Allocated Share-based Compensation Expense $ 0 $ 401,000 $ 888,900 $ 753,000  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Research Funding (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2017
May 04, 2017
Feb. 23, 2017
Deferred Revenue Arrangement [Line Items]      
Grants Receivable     $ 12.2
Grants Receivable, Current   $ 5.7  
Grant Revenue Recognized $ 0.7    
Accrued Liabilities [Member]      
Deferred Revenue Arrangement [Line Items]      
Deferred Grant Revenue 1.7    
Other Long-Term Liabilities [Member]      
Deferred Revenue Arrangement [Line Items]      
Deferred Grant Revenue $ 3.2    
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes Net Operating Loss Carry Forward (Details) - USD ($)
$ in Millions
Sep. 30, 2017
Dec. 31, 2016
Operating Loss Carryforwards [Line Items]    
Operating Loss Carryforwards   $ 232.7
Deferred Tax Liabilities, Net, Noncurrent $ 0.0 $ 1.1
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1
Discontinued Operations PCT Segment Narrative (Details) - PCT Segment [Member] - Discontinued Operations [Member] - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
May 18, 2017
Jul. 31, 2017
Mar. 31, 2017
Sep. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Subsidiary, Ownership Interest by Parent 80.10%      
Transaction Costs Related to Sale $ 6,919      
Payments to Employees       $ 4,300
Retention Payments, First Retention Payment, Percent       50.00%
Retention Payments, Second Retention Payment, Percent       50.00%
Hitachi Chemical Co., LTD [Member]        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Purchase Agreement, Additional Consideration 4,400      
Purchase Agreement, Potential Future Milestone Payment 5,000      
Cumulative Revenue Threshold for Receiving Milestone Payment 125,000      
Proceeds From Licensing Agreements, Initial Payment     $ 5,000  
Proceeds From Licensing Agreements, Closing Payments 65,000 $ 4,400    
Proceeds From Licensing Agreements, Escrow Amount 5,000      
PCT Allendale, LLC [Member] | Hitachi Chemical Co., LTD [Member]        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Purchase Agreement, Aggregate Purchase Price $ 75,000      
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1
Discontinued Operations Gain on Sale of Discontinued Operation (Details) - PCT Segment [Member] - Discontinued Operations [Member] - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
May 18, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Fair value of consideration received $ 79,425      
Transaction and retention costs 6,919      
Carrying value of segment non-controlling interest 3,687      
Total consideration net of transaction costs and adjustments 76,193      
Less carrying amount of assets and liabilities sold:        
Cash 6,727      
Accounts receivable 3,702      
Deferred costs 4,685      
Prepaid expenses and other current assets 743      
Property, plant and equipment, net 14,900      
Goodwill 7,013      
Intangibles, net 2,090      
Other assets 215      
Accounts payable 2,278      
Accrued liabilities 2,927      
Due from Caladrius 450      
Unearned revenues 10,529      
Notes payable 342      
Disposal group, including discontinued operation, net assets 24,449      
Gain on sale of PCT $ 51,744 $ 0 $ 51,744 $ 0
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1
Discontinued Operations Operating Results of PCT Segment (Details) - USD ($)
 3 Months Ended 9 Months Ended
May 18, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Income (loss) from discontinued operations   $ 0 $ (1,196,838) $ 37,329,963 $ (1,628,694)
PCT Segment [Member] | Discontinued Operations [Member]          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Revenue     10,794,000 16,039,000 29,910,000
Cost of revenues     (9,482,000) (15,321,000) (25,122,000)
Research and development     (277,000) (257,000) (610,000)
Selling, general, and administrative     (2,168,000) (3,251,000) (5,587,000)
Other expense     (17,000) (16,000) (72,000)
Provision for income taxes     (47,000) (11,608,000) (147,000)
Gain on sale of segment $ 51,744,000   0 51,744,000 0
Income (loss) from discontinued operations     $ (1,197,000) $ 37,330,000 $ (1,629,000)
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]        
2017 $ 327,500   $ 327,500  
2018 817,400   817,400  
2019 786,200   786,200  
2020 801,600   801,600  
2021 and thereafter 603,000   603,000  
Total minimum lease payments 3,335,700   3,335,700  
Operating lease expense $ 300,000 $ 300,000 $ 1,100,000 $ 1,000,000
EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 145 316 1 false 46 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.caladrius.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.caladrius.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 1003000 - Statement - Consolidated Statements of Operations Sheet http://www.caladrius.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 1004000 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.caladrius.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 5 false false R6.htm 1005000 - Statement - Consolidated Statements of Equity Sheet http://www.caladrius.com/role/ConsolidatedStatementsOfEquity Consolidated Statements of Equity Statements 6 false false R7.htm 1006000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.caladrius.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101100 - Disclosure - The Business Sheet http://www.caladrius.com/role/Business The Business Notes 8 false false R9.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.caladrius.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2104100 - Disclosure - Collaboration and License Agreement Sheet http://www.caladrius.com/role/CollaborationAndLicenseAgreement Collaboration and License Agreement Notes 10 false false R11.htm 2105100 - Disclosure - Available-for-Sale-Securities Sheet http://www.caladrius.com/role/AvailableForSaleSecurities Available-for-Sale-Securities Notes 11 false false R12.htm 2109100 - Disclosure - Loss Per Share Sheet http://www.caladrius.com/role/LossPerShare Loss Per Share Notes 12 false false R13.htm 2110100 - Disclosure - Fair Value Measurements Sheet http://www.caladrius.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2112100 - Disclosure - Accrued Liabilities Sheet http://www.caladrius.com/role/AccruedLiabilities Accrued Liabilities Notes 14 false false R15.htm 2113100 - Disclosure - Debt Sheet http://www.caladrius.com/role/Debt Debt Notes 15 false false R16.htm 2115100 - Disclosure - Redeemable Securities Sheet http://www.caladrius.com/role/RedeemableSecurities Redeemable Securities Notes 16 false false R17.htm 2116100 - Disclosure - Shareholders' Equity Sheet http://www.caladrius.com/role/ShareholdersEquity Shareholders' Equity Notes 17 false false R18.htm 2150100 - Disclosure - Share-Based Compensation Sheet http://www.caladrius.com/role/ShareBasedCompensation Share-Based Compensation Notes 18 false false R19.htm 2151100 - Disclosure - Research Funding Sheet http://www.caladrius.com/role/ResearchFunding Research Funding Notes 19 false false R20.htm 2152100 - Disclosure - Income Taxes Sheet http://www.caladrius.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2154100 - Disclosure - Discontinued Operations Sheet http://www.caladrius.com/role/DiscontinuedOperations Discontinued Operations Notes 21 false false R22.htm 2155100 - Disclosure - Commitments and Contingencies Sheet http://www.caladrius.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 22 false false R23.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.caladrius.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.caladrius.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 2305301 - Disclosure - Available-for-Sale-Securities (Tables) Sheet http://www.caladrius.com/role/AvailableForSaleSecuritiesTables Available-for-Sale-Securities (Tables) Tables http://www.caladrius.com/role/AvailableForSaleSecurities 24 false false R25.htm 2309301 - Disclosure - Loss Per Share (Tables) Sheet http://www.caladrius.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.caladrius.com/role/LossPerShare 25 false false R26.htm 2310301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.caladrius.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.caladrius.com/role/FairValueMeasurements 26 false false R27.htm 2312301 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.caladrius.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.caladrius.com/role/AccruedLiabilities 27 false false R28.htm 2316301 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.caladrius.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.caladrius.com/role/ShareholdersEquity 28 false false R29.htm 2350301 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.caladrius.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.caladrius.com/role/ShareBasedCompensation 29 false false R30.htm 2354301 - Disclosure - Discontinued Operations (Tables) Sheet http://www.caladrius.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.caladrius.com/role/DiscontinuedOperations 30 false false R31.htm 2355301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.caladrius.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.caladrius.com/role/CommitmentsAndContingencies 31 false false R32.htm 2401401 - Disclosure - The Business Immunomodulation (Treg Technology) (Details) Sheet http://www.caladrius.com/role/BusinessImmunomodulationTregTechnologyDetails The Business Immunomodulation (Treg Technology) (Details) Details 32 false false R33.htm 2404401 - Disclosure - Collaboration and License Agreement (Details) Sheet http://www.caladrius.com/role/CollaborationAndLicenseAgreementDetails Collaboration and License Agreement (Details) Details http://www.caladrius.com/role/CollaborationAndLicenseAgreement 33 false false R34.htm 2405402 - Disclosure - Available-for-Sale-Securities Schedule of Available-for-Sale Securities Reconciliation (Details) Sheet http://www.caladrius.com/role/AvailableForSaleSecuritiesScheduleOfAvailableForSaleSecuritiesReconciliationDetails Available-for-Sale-Securities Schedule of Available-for-Sale Securities Reconciliation (Details) Details 34 false false R35.htm 2405403 - Disclosure - Available-for-Sale-Securities Classification of Available-for-Sale Securities (Details) Sheet http://www.caladrius.com/role/AvailableForSaleSecuritiesClassificationOfAvailableForSaleSecuritiesDetails Available-for-Sale-Securities Classification of Available-for-Sale Securities (Details) Details 35 false false R36.htm 2405404 - Disclosure - Available-for-Sale-Securities Available-for-Sale Securities by Contractual Maturity (Details) Sheet http://www.caladrius.com/role/AvailableForSaleSecuritiesAvailableForSaleSecuritiesByContractualMaturityDetails Available-for-Sale-Securities Available-for-Sale Securities by Contractual Maturity (Details) Details 36 false false R37.htm 2409402 - Disclosure - Loss Per Share (Details) Sheet http://www.caladrius.com/role/LossPerShareDetails Loss Per Share (Details) Details http://www.caladrius.com/role/LossPerShareTables 37 false false R38.htm 2410402 - Disclosure - Fair Value Measurements Assets Measured at Fair Value on Recurring Basis (Details) Sheet http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements Assets Measured at Fair Value on Recurring Basis (Details) Details 38 false false R39.htm 2412402 - Disclosure - Accrued Liabilities (Details) Sheet http://www.caladrius.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.caladrius.com/role/AccruedLiabilitiesTables 39 false false R40.htm 2413401 - Disclosure - Debt (Details) Sheet http://www.caladrius.com/role/DebtDetails Debt (Details) Details http://www.caladrius.com/role/Debt 40 false false R41.htm 2415401 - Disclosure - Redeemable Securities (Details) Sheet http://www.caladrius.com/role/RedeemableSecuritiesDetails Redeemable Securities (Details) Details http://www.caladrius.com/role/RedeemableSecurities 41 false false R42.htm 2416402 - Disclosure - Shareholders' Equity - Reverse Stock Split (Details) Sheet http://www.caladrius.com/role/ShareholdersEquityReverseStockSplitDetails Shareholders' Equity - Reverse Stock Split (Details) Details 42 false false R43.htm 2416403 - Disclosure - Shareholders' Equity - Equity Issuances (Details) Sheet http://www.caladrius.com/role/ShareholdersEquityEquityIssuancesDetails Shareholders' Equity - Equity Issuances (Details) Details 43 false false R44.htm 2416404 - Disclosure - Shareholders' Equity - Stock options and warrants (Details) Sheet http://www.caladrius.com/role/ShareholdersEquityStockOptionsAndWarrantsDetails Shareholders' Equity - Stock options and warrants (Details) Details 44 false false R45.htm 2416405 - Disclosure - Shareholders' Equity - Restricted Stock (Details) Sheet http://www.caladrius.com/role/ShareholdersEquityRestrictedStockDetails Shareholders' Equity - Restricted Stock (Details) Details 45 false false R46.htm 2450402 - Disclosure - Share-Based Compensation (Details) Sheet http://www.caladrius.com/role/ShareBasedCompensationDetails Share-Based Compensation (Details) Details http://www.caladrius.com/role/ShareBasedCompensationTables 46 false false R47.htm 2451401 - Disclosure - Research Funding (Details) Sheet http://www.caladrius.com/role/ResearchFundingDetails Research Funding (Details) Details http://www.caladrius.com/role/ResearchFunding 47 false false R48.htm 2452401 - Disclosure - Income Taxes Net Operating Loss Carry Forward (Details) Sheet http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails Income Taxes Net Operating Loss Carry Forward (Details) Details 48 false false R49.htm 2454402 - Disclosure - Discontinued Operations PCT Segment Narrative (Details) Sheet http://www.caladrius.com/role/DiscontinuedOperationsPctSegmentNarrativeDetails Discontinued Operations PCT Segment Narrative (Details) Details 49 false false R50.htm 2454403 - Disclosure - Discontinued Operations Gain on Sale of Discontinued Operation (Details) Sheet http://www.caladrius.com/role/DiscontinuedOperationsGainOnSaleOfDiscontinuedOperationDetails Discontinued Operations Gain on Sale of Discontinued Operation (Details) Details 50 false false R51.htm 2454404 - Disclosure - Discontinued Operations Operating Results of PCT Segment (Details) Sheet http://www.caladrius.com/role/DiscontinuedOperationsOperatingResultsOfPctSegmentDetails Discontinued Operations Operating Results of PCT Segment (Details) Details 51 false false R52.htm 2455402 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.caladrius.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.caladrius.com/role/CommitmentsAndContingenciesTables 52 false false All Reports Book All Reports clbs-20170930.xml clbs-20170930.xsd clbs-20170930_cal.xml clbs-20170930_def.xml clbs-20170930_lab.xml clbs-20170930_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 70 0000320017-17-000093-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000320017-17-000093-xbrl.zip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�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Ð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end